var title_f42_10_43168="Stool sample 2 with answer";
var content_f42_10_43168=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F73134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F73134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Trichuris trichura ovum in stool",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A wet mount of stool (x400) shows ovum of Trichuris trichura (whipworm).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_10_43168=[""].join("\n");
var outline_f42_10_43168=null;
var title_f42_10_43169="Donor selection HCT";
var content_f42_10_43169=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F72917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F72917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 550px\">",
"   <div class=\"ttl\">",
"    Genetic basis for donor selection for hematopoietic cell transplantation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 530px; height: 499px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHzAhIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDhviB8RLPwV4j8LabqFo7wa3NJE10HwtrtMY3MMcgmUc5GKx/Cfxm0PXNN1nUbi3uLGysr9LG2O1ppb1pOYvLjRdxLjBCjPBz05rpPGPgTTPF2t6Pfaxma30+G7ga0I+SdbhFVtx6jGwEYrAPwh0yMaibLULqzll1SDVrN4UTFlNCmxAqkEMu0kEHsaALFz8W/Dqap4ctLUXt1HrMs8IkjtJd1u8QO5JI9m4NuGCuMr944XmoPCXxc0XV9SfTNULadqLahdWMCtHIYZPJYj/AFpUIGIUnbnj8Rl9t8Krezk0W7stavotW0/ULrUpL1o43NzLcjE25Cu0ZHAwOPrzTk+FWn/ZbG3lvriSG21m41gqUA8xpg4aM+i4c89aALlv8V/B80F7P/aU8UFram+MktlOiy24YIZYsp+8TcQMrmuo8P65p/iDTxfaTM81qXKB2iePJHXAcAke/Q15hZfArSbLRtS0q31HZaXVo9mjrptqlwiMynLzLGHkI245PPfOBXrtrCLe2ihBJEaBAT3wMUASUUUUAFFFFABRRRQAUUUUAFeR/Dv40QeMLeW7fSYrS0jtnuGSDUY7u7AVwmDaxjzeSRg7e49RXrlea6b8ItIsPhbJ4Lhupk8yJ4m1KONEuGDTebhjjlc4UqeCoxQAap8ZfDVpp1pd266hc+bqkelzw/YpkmtnfnLxlN3QghQMt0GSCKbpPxf0WXxJqOkauJbCSLU1061lMErJKXRWQu2zbGxLEbWOePrVO0+DFpa6bdQQa1PDdSapbatDPBaQRLBPAuE2xKoTb7Y+uec6k3wvtZ4L9JtUuXe91qDWpHMag+ZEE+XA4wdn60AaMPxN8KS381ouoSgxpcSLM1pMIZhACZvKk27ZCmDkKT071s+FPFGkeK9PN7oN091aAqPMMEkQOVDDG9Rnhh0+nUGuB034J6Rpl5evYXix2s6XSojadatNH58bowFx5fmlR5jYG7PQEkcH0bwxpKaB4b0nR4ZWmi0+0itFkcYLiNAgJHqcUAaVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUyaWOCGSWaRI4o1LO7nCqBySSegp9YHxC/5EHxL/2DLn/0U1AFzS/EGjatM0Olavp17Ko3FLa5SRgPUhSeK06+Xvgx4D1S6tfA/i6bT9E0zTNGtZbnztNRjfaluUgCX5QD07knkgdeD4U+N9Vv/id4PitdfvrvStZS8S5sr7UxeyoYomdS6iFFhYnB2qW49B1APqGivmTR9e8br+zyvjWHxHqd/qV0jQPG6RlbWIXTI8y4QsWCrjcd20EkDgVkzeNvEVn4S8TNpfjFbuMNYyWrRal/aFxal5lR8ymGMYYH7pGRjp1oA+rbieK2hea4lSKFBlndgqqPcnpT0ZXVWRgysMgg5BFfM/jZNaj0v4weF7nX9Y1az0+wtL2B7pkeUFwXkXKqBsOOQAMAcY5NZ3ifxVLpnhTwx/wj3jy41DTFtnlurdtVSzupHCJ+7jn8rbhP+ef3stznsAfVVFeUeC/EC6h4h8GpP4g1eK6u9C+0f2ReW4JnGT++kkAA3j6DPXAzXq9ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBHPJ5UEkhGdilseuBXin/C/7X/oX5v/AAKH/wATXt554PSoPsdr/wA+0P8A3wKxrQqSt7OVvlc9PL8TgqHN9boe0va3vONu+29zxf8A4X/a/wDQvzf+BQ/+Jo/4X/a/9C/N/wCBQ/8Aia9o+x2v/PtD/wB8Cj7Ha/8APtD/AN8CsfY4j/n5+CPR/tHJv+gJ/wDgyX+R4v8A8L/tf+hfm/8AAof/ABNH/C/7X/oX5v8AwKH/AMTXtH2O1/59of8AvgUfY7X/AJ9of++BR7HEf8/PwQf2jk3/AEBP/wAGS/yPF/8Ahf8Aa/8AQvzf+BQ/+Jo/4X/a/wDQvzf+BQ/+Jr2j7Ha/8+0P/fAo+x2v/PtD/wB8Cj2OI/5+fgg/tHJv+gJ/+DJf5Hnvw9+KcPjLXm0yLSpLRlhabzGnDjggYxtHrXpNRR28MTbo4Y0bplVANS10UozjG03d/cePjq2HrVebDU/Zxttdy/FhRRXjH7SY+w2Hh3WNFuJ4vGVtqEcekQwAs12WI3xMoPKY5Ofp/FWhxns9FeU/s3NY3nw+/taK9nvtZ1C5kl1ea44kW6z80ZX+ELkYHoc4GcV6tQAVjeKdcXQNPjungM4eURbQ23GQTnp7Vs010Vxh1DD0IzUzUnFqLsxSTa0OA/4WXD/0DJP+/wAP8KP+Flw/9AyT/v8AD/Cu98iH/nlH/wB8ijyIf+eUf/fIrl9jiP8An5+CMeSr/N+BwX/Cy4f+gZJ/3+H+FH/Cy4f+gZJ/3+H+Fd75EP8Azyj/AO+RR5EP/PKP/vkUexxH/Pz8EHJV/m/A4L/hZcP/AEDJP+/w/wAKP+Flw/8AQMk/7/D/AArvfIh/55R/98ijyIf+eUf/AHyKPY4j/n5+CDkq/wA34HBf8LLh/wCgZJ/3+H+FdZ4b1ddb0xbxYTCCxXaW3dPetHyIf+eUf/fIp6qqDCqFHoBitKVOrGV5zuvSxUIzT96V/kLRRRXQahRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAU1ERM7FVckscDGSepp1FABUcMMUKlYY0jUnJCKACfXipKKACoBaWwjVPs8OxTuVdgwD6getT0UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQA2QFo2CnDEEA1wv/AAjfij/oM/8Ak1L/AIV3lFb0MRKjflS17o48VgaeKtztq3Z2OD/4RvxR/wBBn/yal/wo/wCEb8Uf9Bn/AMmpf8K7yiuj+0KvZfcjk/sWh/NL/wACZwf/AAjfij/oM/8Ak1L/AIUf8I34o/6DP/k1L/hXeUUf2hV7L7kH9i0P5pf+BM4P/hG/FH/QZ/8AJqX/AAo/4RvxR/0Gf/JqX/Cu8rntb8YaPpN4LFp3vNVIyun2MZuLgj1KLkqP9psL70f2hV7L7kH9i0P5pf8AgTIPDeka1Y6gZdT1D7TBsK7PPd+eMHDDHrXUVx2fGGvHIEHhewb+9sur5h9OYYj0/wCetdJo2nDS9OjtBdXl2UJJnu5jLI5JJJJP16AAAcAAVy1qsqsuaR34bDRw0OSDdvN3LtUrjStOuNTttRuLC0l1C1DLBdPCrSwhhhgjkZUEE5weak1O/tdL0+4vtRnjtrO3QySyyHCoo6k1R8L6nd6xpYv7zTn09JnLW8MrZlMPG1pFx8jHrsyccZOcgZHQWdN0fTNLmu5tM06zs5buTzbl7eBY2mfn5nIA3Hk8n1q9RWH/AMJDFD4q/sO+ge1lnj82xmZgY7sADeqns69Sp6r8wz82ADcrkviZomu69oUFr4X1P+zb1LlZHl8+SHMYVgVygJ6lTjpxXW1z+vaLqN1fLf6Jrlzp12qBDDIgntJQCT88RwQefvIyngZJxWtCtKhUVWO676oTV1Y8n/4Vx8T/APocv/Kpdf8AxNH/AArj4n/9Dl/5VLr/AOJr0UeLr7RBs8aaQ9jEvXUrHdc2Z56tgb4u3312j+8a6ywvbXULSO6sLmC6tZRlJoJA6MPUMODXsf6w4n+WH/gKM/ZRPDv+FcfE/wD6HL/yqXX/AMTR/wAK4+J//Q5f+VS6/wDia94oo/1hxP8ALD/wFB7KJ4P/AMK4+J//AEOX/lUuv/iaP+FcfE//AKHL/wAql1/8TXvFFH+sOJ/lh/4Cg9lE8H/4Vx8T/wDocv8AyqXX/wATXqXw80nWdF8NpZ+I9Q/tC/EjsZvOeXKk8Dc4BrpqK5cZm1bF0/Z1FFLfRJFRpqLugooorzCwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKy9e8QaT4ft1n1m/gtEc7YxI3zyN/dRR8zn2UE1hf254k1z5fDmjDTbVs41DWlKHHqlspEjfRzHQB108scELyzyJHEg3M7sFVR6knpXJP44i1B2h8Iadc+IJASDcQERWaketw3yt/2zDn2p0PgazupkufFN5deIrpSGUXxAt4yOmy3UCMYOMFgzcferrUVUVVRQqqMAAYAFAHH/wDCOa5rYz4p1x4bc9dO0Ytbx49Hn/1r/VTGD3FdDoeiaZoNn9l0awtrKDOSkEYXcf7zY6n1J5NaFFABTJ5o7eGSaeRIoY1Lu7sFVVAySSegFPrgXJ+Il+0ac+C7WTDsOmrSqeVHrApHJ6SEY+6DuAH6dFJ471KDV71Hj8MWkgk021cFTeyKflupB/cHWNT1++f4QO7oAwMDpRQAVleJ9CtfEOlPZXhkjIYSwTxNtlt5V5SVG7Mp5H5HIJFatFAHL+EtdupbufQfEIjj8QWaB2ZBtS8hzhbiMdgTwy9UbjoVJ6isHxd4eGu2sEltcGy1eyczWF8i5aCTGOR/EjD5WU8EH1wQ3wj4hbWYbm2v7cWWt2DCK+s927y2PKuh/ijYcq3pwcEEAA6CuVv/AARYm7lv9BnuNA1OQlnn08hUlY95YSDHIfcru9GFdVRQBxo1vxFoHy+JdKGp2a/8xLRo2YgeslsSXH/bMyfQV0Oha5pev2Yu9Gv7e9gzgtC4O091YdVI7g4IrRrntd8H6Tq939u2S2OrAALqNhIYLgAdAWH31/2XDL7UAdDRXG/aPFvh4f6ZDH4n09RkzWqrb3qj3iJEcn1UofRTWx4f8UaRr7yxaddg3cPE9pMpiuIT/txOA6/iMHtQBtUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVDe3dtY2slze3ENtbRjc8szhEUepJ4FAE1FccfGcurEp4O0i41cHgX0xNtZD3ErAtIPeNXHuKT/hE9S1kbvF+uT3MTddO03daWuPRiD5snvlwp/ujpQBc1XxtpNlevp9mZ9X1ZOGsNNTz5UP/TQj5YvrIyiqn2bxfrpP2u5t/DVg2f3NmVubxh7ysPLjPXhVf2aum0rTLHSLJLPSrO3srRPuw28YjQfgOKt0AYWg+E9G0O4e6s7XzNQkGJb65dp7mQehlclse2cDsBW7RRQAUUUUAFFFcZ4i1K817VZfDHh24e3MYH9q6jH1s42BIijP/Pdh0/uKdx5KggEGrzzeNdUuNC0yWSHQLVzFqt7ExVp3GM2kTDn/AK6OOg+Uckle1tbeG0tore1ijht4UEcccahVRQMAADgADtUOkabZ6Ppltp+m26W9nboI4okHCgfzPck8k8mrdABRRRQAUUUUAFcz4v0C4vJrfWdBeO38RWCkQO/EdxGSC1vLjqjY4PVWww7g9NRQBkeFtet/EOli6hjkt543MN1azDEttMMbo3HqMjkcEEEZBBrXrkPFOkXthqf/AAk/hqHzNSjQJe2KkAajAv8AD6CZf4GPup4OR0GhatZ65pcGo6bL5ttMDgkFWUg4ZWB5VgQQQeQQQaAL9FFFABWP4h8NaR4hWL+1bNJZocmG4RjHNCT3jlUh0P0IrYooA437F4s8P4OnXieJNPXA+zX7LDdqv+zMo2SfR1U8cvV/RvGWlalfLp8zT6Zq5Gf7P1GPyJyPVAflkH+0hYe9dHVDWtH07XLJrPWLG3vbYnPlzxhgD2Iz0I9RyKAL9Fcb/wAI/r2g5bwtq5vLRcn+zNZkaVfpHccyJ/wPzB6AVNaeOLKK7isfElrc+H7+RgiLfACCZvSKdSY29lyG/wBkUAdZRQDkZHSigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKpaZqlnqn2o2E6zLa3D2srLyBIuNy/gTg+4NYV94500XMlnocVzr+oodrQaYokWNvSSUkRx/RmB9jQB1VY3iDxPo/h/y11a+jhnl/wBTbKDJPN7RxKC7n/dBrH/s3xVrjZ1bU4tBsj/y6aUfMnYej3DrgfREBHZ62PD3hjR/D/mNpVkkU82POuXJknm95JWJd/xJoAx/7T8V67xpGmRaDZN/y+asPMnIx1S2Q8fV3BHdTU1l4G037VHe65Lc6/qMZ3LPqbCRY29Y4QBFH9VUH1Jrq6KACiiigAooooAKKKKACiis7xJDe3Ph7U4NK8sahLbSR25lbagkKkKWIBIGSM4BoA868O/ExviD4b0yLwZti1u/izeSOPMTSQDtdnH8TEg+Wp+91OADXonh3RLPw/pMWn6cjCJCWZ5G3PK7HLSO38TMSST6mvI/hV+z5o3gyaHUdQ1PUL/WF532872sSH0AQhm/4EcH0Fe3UAFFFFABRRRQAUUUUAFFFFABXEa7aXHhLVrjxHo0Ek+mXB36xp8K5JwP+PqFR/y0A++B99Rn7yjPb0UAQWN3b39nBd2M8dxazoJIpY2DK6kZBBHUVPXBXIPw+1F7uIH/AIQ+8l3XMY6aXMxH71fSBiSWH8DHd90tjrYNYsZ9Zm0qG4WS+hgS5kjXnbG5YKSfcq35UAaFFFFABRRRQAVFd20F5bSW95BFcW8g2vFKgdWHoQeDUtFAHG/8IdcaMfM8F6rLpaDH/EuuQbmxPssZIaL/ALZsq99poHjSXSD5fjXS5dGA66hE32iwb3MoAMf/AG1VB7muypCAwIIBB4INADLeeG6gjntpY5oZBuSSNgysPUEcEVJXJXPge1t7iS78L3lx4evXYu4swDbTMe8lu3yHPcqFb/aqBvEus+H0b/hL9J8yzQZbVdJVpoQMctJDzJGO/HmKByWFAHaUV5p8Dvida/EXQrne8aavYytHcRAgb0ydkoHoR19CD2xXpdABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRSEhQSSABySaAForDsvF/hq/nngsfEOkXU8Cs8sUF7HI6BQSSVBJGAD+VS2fiXRL2TTY7TVbOZ9SjaWzVJQTcIv3mT1A74oA16KpXeq2FpqVjp91eQRX1/5n2WB3AebYu59o74ByaNG1Ww1vTYdR0i8gvbGbd5c8Dh0fDFTgjrggj8KALtFFFABRRRQAUUVi+MtZk8PeGb7VILb7VJbKGEO4jdlgOoB9aUpKKcn0NKVKVapGlDeTSXqzaorwj/heep/9Ct/5Hb/AOIo/wCF56n/ANCt/wCR2/8AiK5Pr9Dv+DPoP9Us1/59r/wKP+Z7vXLfEl/FH/CL3EPge2gk1mf92k08oRLcEHMnP3mHYdM8npg+Y/8AC89T/wChW/8AI7f/ABFH/C89T/6Fb/yO3/xFH1+h3/Bh/qlmv/Ptf+BR/wAzF+C3w58V6JcXGh/ELTLu60CeVriNoNRVrfzj97z40YNIGwPvZUEcjnI+irKztrC1jtbG3htraIbY4oUCIg9Ao4Arw/8A4Xnqf/Qrf+R2/wDiKP8Aheep/wDQrf8Akdv/AIij6/Q7/gw/1SzX/n2v/Ao/5nu9FeEf8Lz1P/oVv/I7f/EV3/ww8bXPjODUJLrTP7PNqyKo3lt+4H1A9Kuni6VSXLF6+jObGcPY/BUXXrwSiv70Xvp0Z3FFFFdJ4gUUUUAeHaT4C8N+M/il8QpPEum/bXtbq2WE+fLHtDQ8/cYZ6DrXT/8ACjfh1/0L3/k7c/8Axyj4cf8AJTfiZ/192n/ok16Hf3H2Sxubnbv8mNpNucZwCcZ/ChuxSTk0keef8KN+HX/Qvf8Ak7c//HKP+FG/Dr/oXv8Ayduf/jlcl/w0F/1LP/k//wDa6P8AhoL/AKln/wAn/wD7XXH/AGhh/wCb8H/kfR/6o5x/z5/8mj/8kdb/AMKN+HX/AEL3/k7c/wDxyj/hRvw6/wChe/8AJ25/+OVyX/DQX/Us/wDk/wD/AGuj/hoL/qWf/J//AO10f2hh/wCb8H/kH+qOcf8APn/yaP8A8kdb/wAKN+HX/Qvf+Ttz/wDHKP8AhRvw6/6F7/yduf8A45XJf8NBf9Sz/wCT/wD9ro/4aC/6ln/yf/8AtdH9oYf+b8H/AJB/qjnH/Pn/AMmj/wDJHW/8KN+HX/Qvf+Ttz/8AHKP+FG/Dr/oXv/J25/8Ajlcl/wANBf8AUs/+T/8A9rrqfhz8Vf8AhM/EDaZ/Y32LbA03m/avM6EDGNg9fWqhjaE5KMZavyZhiOGc0w1KVarStGOrfNH9GSf8KN+HX/Qvf+Ttz/8AHKz/AIMaNYeH/G3xD0vSIPs9hbXVqsUW9n2gxEnliSeSepr1qvNfhx/yU34mf9fdp/6JNdR4J6VRRRQAUUUUAFFZniLVP7H01rvyfOwwXbu29ffBrlv+Fhf9Qz/yY/8Asa6qODrV481ON16o4MTmeFws/Z1pWfo/0R0fi2z1e/0Se20C8sLS8kUrvvbU3EZUjBG0Mv5ncPY14V8D/BfjXwB8V7xPFEJvdO1SyMEd/bMZYVaLaY1PAMahFZQCAOgFepf8LC/6hn/kx/8AY0f8LC/6hn/kx/8AY1r/AGZif5fxX+Zz/wBu4D/n5+Ev8jvKK4P/AIWF/wBQz/yY/wDsaP8AhYX/AFDP/Jj/AOxo/szE/wAv4r/MP7dwH/Pz8Jf5HeUVwf8AwsL/AKhn/kx/9jR/wsL/AKhn/kx/9jR/ZmJ/l/Ff5h/buA/5+fhL/I7yisbwxrf9uWks/wBn8jy32bd+7PAOeg9a2a46lOVOThNao9KjWhXgqlN3TCiiioNQrD8Y+GrTxbosmk6nPeR2ExHnx20vlmZf7jMBnb6gEZ6HjityuV8ReLf7H1I2n2LzsKG3+bt6+201rRozrS5aauznxOKpYWHtKzsvn+hk+EPg/wCCfCGrQap4f0qa11GIMonF7O24HghlL7SPYjsD1Ga9Arg/+Fhf9Qz/AMmP/saP+Fhf9Qz/AMmP/sa6v7MxP8v4r/M4P7dwH/Pz8Jf5HeUVwf8AwsL/AKhn/kx/9jR/wsL/AKhn/kx/9jR/ZmJ/l/Ff5h/buA/5+fhL/I7yiuD/AOFhf9Qz/wAmP/saP+Fhf9Qz/wAmP/saP7MxP8v4r/MP7dwH/Pz8Jf5HeUVwf/Cwv+oZ/wCTH/2Nd1G2+NWxjIBxXPXwtWhb2itc68Lj8PjL+wle2+jX5odRRRWB2BRRRQAUUUUAFct8U4bK4+HXiCDVb2ewsJbR45rqGMu0KngttHLAZ5A6jNdTRQB8sfD7V7jTtettFs5PCvia0ttJupbfWtIs/KuNOVIWC+awUAbuF2nJJOSeOUOrRX1x8H9R8TeIbjSVn0i+NxqUUqQyKSAOHKkLngcDPpX1JDBFACIYkjBOSEUDJ/CnOiyIyOoZWGCCMgigD5l8Datqus+NvhDdavdXN6gvNejsr25XbLc2qwKI5G4GSRnnvin+EvEHiLXfB/whtD4h1Gyk1y41KG9ubQosrqjybcblKggDAOOOvWvpgAKAAAAOABS0AfMEfi7xDF4T0201jxJqdtosPie70vUdcj5uI7eLHlBpADt3MSC2Ow+hrTeM9bk8G69/Z3jOQW0HiY2lvdX9z9nluLRYtwiWfy8RseDuIGeeex+j/FXh638SafFa3V3qNp5UwnSbT7t7aVWAI+8hBxhjx0/IVB4T8IaN4W0iXTtKtmMM8zXFw9xI00k8rYy7sxJZjgflQB5N4I8WDUvD3g24u/EWvaY9zrcltFFdEXpv8EfujOqqGjznD4/PGa95pFUKoVQAoGAB0ApaACiis3xFpz6to9xZRzeQ8u3EmM4wwP8ASpk2k2ldibaWhpUV5z/wry7/AOgx/wCQz/8AFUf8K8u/+gx/5DP/AMVXL7ev/wA+vxRj7Sp/J+J6NRXnP/CvLv8A6DH/AJDP/wAVR/wry7/6DH/kM/8AxVHt6/8Az6/FB7Sp/J+J6NRXnP8Awry7/wCgx/5DP/xVH/CvLv8A6DH/AJDP/wAVR7ev/wA+vxQe0qfyfiejUV5z/wAK8u/+gx/5DP8A8VXUeEdCl0K2uIprv7SZXDA7SMcfU1dOrVlK0oWXqiozm3Zxsb1FFFdJqFFFFAHmvw4/5Kb8TP8Ar7tP/RJr0qvNfhx/yU34mf8AX3af+iTXoeoQG6sLm3V9jSxtGG9MgjNNWbswZPRXg/8AwovU/wDoaf8AyA3/AMXR/wAKL1P/AKGn/wAgN/8AF17n9nZd/wBBa/8AAJGXPP8AlPeKK8H/AOFF6n/0NP8A5Ab/AOLo/wCFF6n/ANDT/wCQG/8Ai6P7Oy7/AKC1/wCASDnn/Ke8UV4P/wAKL1P/AKGn/wAgN/8AF0f8KL1P/oaf/IDf/F0f2dl3/QWv/AJBzz/lPeKK8H/4UXqf/Q0/+QG/+Lrqfhx8M73wj4hbUbnW/tyGBofK8tl5JBzksfSsq+BwMKblTxKk1suVq/zGpSb1ien15r8OP+Sm/Ez/AK+7T/0Sa9KrzX4cf8lN+Jn/AF92n/ok145oelUUUUAFFFFABRWb4i059W0e4so5vIeXbiTGcYYH+lcX/wAK8u/+gx/5DP8A8VXPVq1IO0IXXrYznOSfuxuejUV5z/wry7/6DH/kM/8AxVH/AAry7/6DH/kM/wDxVZ+3r/8APr8UR7Sp/J+J6NRXnP8Awry7/wCgx/5DP/xVH/CvLv8A6DH/AJDP/wAVR7ev/wA+vxQe0qfyfiejUV5z/wAK8u/+gx/5DP8A8VR/wry7/wCgx/5DP/xVHt6//Pr8UHtKn8n4no1FYPhHQpdCtriKa7+0mVwwO0jHH1Nb1dMJSlFOSszWLbV2rBRRRVlBRRXlvxD+F974r8Rvqdtrv2KNo0j8ry2bGO+QwrqwlGjWqctepyLvZv5WRMm0tFc9Sorwf/hRep/9DT/5Ab/4uj/hRep/9DT/AOQG/wDi69P+zsu/6C1/4BIjnn/Ke8UV4P8A8KL1P/oaf/IDf/F0f8KL1P8A6Gn/AMgN/wDF0f2dl3/QWv8AwCQc8/5T3iivB/8AhRep/wDQ0/8AkBv/AIuj/hRep/8AQ0/+QG/+Lo/s7Lv+gtf+ASDnn/Ke8UV4P/wovU/+hp/8gN/8XXulvGYoI4yclFC59cCuHG4bDUOX2Fb2l99GrfeXFt7qxJRRRXAUFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5N4K1nTNK+J/xIGp6jZWbSXVoUFxOse7EPONxGetd9/wl3hv/AKGHR/8AwNi/+KqtqngXwrqt/Ne6l4f0y6u5iDJNLbqzOQMckj0Aqr/wrTwT/wBCto//AICr/hQBp/8ACXeG/wDoYdH/APA2L/4qj/hLvDf/AEMOj/8AgbF/8VXOWfgz4f3ur6jp1t4Y0p57AR/aGFmuxWcFgmcfeCgMR2Dr61h6jD8HtN8RS6Ff6foNvqcUkcUkUlkQqPIoZAz7do3AjGTQB3//AAl3hv8A6GHR/wDwNi/+Ko/4S7w3/wBDDo//AIGxf/FVkL8OvArStEvhrRDKoyyC3TcPqKytO8NfDfVItKn0vw1pt7aal5hgurfTi8ICA5LuFwnQgbsZPA5oA6z/AIS7w3/0MOj/APgbF/8AFUf8Jd4b/wChh0f/AMDYv/iqyU+HPgZ2dU8M6KzIcMBbIdp96pat4O+HGkWRu9S0LQbe2WVYTI1uuA7MFVeB1JIH40AdH/wl3hv/AKGHR/8AwNi/+Ko/4S7w3/0MOj/+BsX/AMVXKeK/B/grw9pP9pSeDdJns4pUF0y26gwQk4aXGDkJncRx8oJ7YOuvw28EMoZfC+jFSMgi2TBH5UAan/CXeG/+hh0f/wADYv8A4quK+Fl1b3vxE+JFxZzxXFvJdWhSWJw6t+5I4I4NdF/wrTwT/wBCto//AICr/hWzoHhzRvDyTJoemWmnrMQZBbxBN5GcZx16mgDVooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKx/Futp4e0G5vzE1xONsVtbKcNcTuQsca+7MQPbr2rYrirb/iqPHclyfm0jw67Qw+k18y4dvpEjbAf70j91oA2fBmiNoOhR29zKLjUJna5vbgDHnXDnLt9M8AdlCjtXnN58KLnX/iV4x1LXbyeHw5qc+mzx2ls8f+mG3ixiUlSyhXHRSMgn2x7FRQB4Jb/DHxDP8Vodc1PTtL+w/wBoXj3E1u0SCe1ljdVRkEQdyd3zb5G68DFM8B/CvXtEXwVA9jYafJo02o/bL21nDtcGa3aOOcDaDnJUYPIC179RQB8wR/BTxPD4Y1qwFtEdUuNNNkbpb+EQ3befHIGKLbo5b5WO+R2YdMnPHR+Kvg3cTr40t9D0vTV028udLvNNtHk2xmSHcJ+MHYWViM45zzXvlFAGfpNnHHoFnZSafBaQrapC1ihDxQrsAMQ4AKj7vQZA6VzvgiSTQ9QufCF47MLNPP0uRzkzWROAue7REiM99vlk/ersq5jx3pF1e2NtqWiop13SZDdWQJ2iXjDwMf7si5X2O1v4RQB09FZ/h/V7XXtFs9UsGY211GHUONrKe6sOzA5BHYgitCgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA53xzrNxpOjrFpYRta1CUWWno4yPOYH52H91FDO3+yhq/wCGtGt/D+hWel2hdo7dMGRzl5XJyzse7MxLE+pNc74Z/wCKl8U3niWT5tPs9+naSOzAN+/nHrvZQin+7HkcOa7WgAooooAKKKKACiiigAooooA4qD/ilPGjW5+XRPEEpkh/u299gl09hKoLD/bV+7iu1rL8T6LB4h0K70y5d4hMoMc0f34ZFIZJF9GVgrD3Aqj4H1ufV9Llh1NUi1vT5TZ6hEowBKoB3qP7jqVdfZh3BoA6KiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAGzSJDE8szrHEilmdjgKB1JPYVy3j6+uXtrPQNImaLVdaZoUmQ/NbQAZmnH+6pAH+26VteI/L/wCEe1Tz8mH7LLvx127Dn9K+bv2Zj8SL4wahc2lm+irax2UGoaqJPNW2QsQkAUjcMkZJGDtUbjtAAB9M6bY22mada2FhCsFpbRLDDEgwERRgAfQCrNFFABRRRQAUUUUAFFFFABRRRQAVxfi9f+Eb1y38XQDFnsW01hR/z75Oyf6xMTn/AGHf+6K7SsjxXLqMOh3LaRpFvrNwVKmynuRAJlIIK7irDnpg4HvQBrb1O3DD5unPX6UtfMfwE8ReJL34zzaH4rt7rT49J0We3sdPuckwp58RXLEfOdgC7+6qPqfpygAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorlfipb6ndfDjxJBoPmHU5LGVYBESHJ2nIXHO4jIHvigDQtvFfh261CSwtde0me/jzvtoryNpVwMnKA5GAPSr2kanZaxp0N/pV1Dd2UwJjnhYMjgHBwR15Brwn4aav8AC5/DXhvTdNtLBPFcVqU8sWRW7iuFhbzjI+3I6Pkk4PHtWB8Hp9X0KD4Qvba9qUthrgvbe406VkNuipvZdihQQc8kkk/hxQB9D2nivQbz7B9l1ixm+3ySRWmyYHz3j++q+pXHPpV3U9VsNK+yf2leQWv2u4S0t/NcL5sz52xrnqxwcD2r5w8H6re6zffB+81O4a4uW1fV0MjAAkKGAHHsBWAuvTeIX8DXuv8AiW/uPFL+NbVb3QpHCw2CrNIqhY9uQQAvzZ53HqRmgD67or560nVvGc/gnx74nsNe1K8vtLv9QtLLTvLjeJVVlAfG3cxRSSASRx0OTnmdA8a69Ho3iSez8XpeRnw7NdrA2qG+uYblNp80HyI/KGDjYe/r2APquivAvCGqa5p3jTT7XUfFOrX1lq3hD+1pzd7H+zTfL88Sqq4AGeO/ck16n8Lr2PUfAWkXcGs3GuRyxsRqFxCYpJ/nYZKnpjGPwoA6qiiigAooooAKKKKACiiigAryrx98Ur7wx4muNKt9C+2RxKjCbzWXO5QegU+teq1RudX021naG51CzhmXG5JJ1VhxnkE+lROlUqrlpOz9LndgK9ChVcsRS9orbXa173R4t/wvPU/+hW/8jt/8RR/wvPU/+hW/8jt/8RXsv9v6N/0FtP8A/AlP8aP7f0b/AKC2n/8AgSn+NZfUcX/O/wDwE9j+08s/6AP/ACeX+R4vP8bb+4gkhn8JJLDIpR0eVmVlIwQQU5BHanR/HDUY0VI/CgVFGFUTMAB6D5K9m/t/Rv8AoLaf/wCBKf40f2/o3/QW0/8A8CU/xo+o4v8Anf8A4CH9p5Z/0Af+Ty/yPGv+F56n/wBCt/5Hb/4ij/heep/9Ct/5Hb/4ivZf7f0b/oLaf/4Ep/jR/b+jf9BbT/8AwJT/ABo+o4v+d/8AgIf2nln/AEAf+Ty/yPHrf436nLPHGfC+0OwXPnNxk/7le51mprukOwVNVsGYnAAuEJJ/OtKtKdGrS/itu/lY8vMcThq7j9Xoeyte/vOV/v7BRRRWh5oUUUUAed/E7xh4h8NX9lDoGif2lFNGzyP5Mj7CDgD5a4v/AIWt47/6E/8A8lJ/8a9ynuYLfb9onii3dN7hc/TNRf2lY/8AP7bf9/V/xr06Ga4KhTVOrQjKS6ttMXsaktY3seJf8LW8d/8AQn/+Sk/+NH/C1vHf/Qn/APkpP/jXtv8AaVj/AM/tt/39X/Gj+0rH/n9tv+/q/wCNa/23l/8A0Dw/8CYvq9Xz+48Hm+Ini+bUbe/l8DRNfW6skU5sp96K33lBznBwOOnAq3/wtbx3/wBCf/5KT/417b/aVj/z+23/AH9X/Gj+0rH/AJ/bb/v6v+NH9t5f/wBA8P8AwJh9Xq+f3HiX/C1vHf8A0J//AJKT/wCNH/C1vHf/AEJ//kpP/jXtv9pWP/P7bf8Af1f8aP7Ssf8An9tv+/q/40f23l//AEDw/wDAmH1er5/cV/DN7c6l4f069v4Ps93PAsksO0rsYjJGDyPxrTpsciSoHjZXQ8hlOQfxp1eTKSnJyirJlWtowoooqQCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBiwxJK8ixosj/AHmCgE/U0+iigApqxoru6ood8bmA5bHTNOooAKZHDFEztHGiM5yxVQNx9T60+igAooooAKKKKACiiigAooooAKKKKACuC8T/AAy0zxDrlzqlze3kU0+3cke3aNqheMj0Wu9orfD4qrhpc9GVnsXCpKm7xdjy7/hTGjf9BHUPzT/4mj/hTGjf9BHUPzT/AOJr1Giu3+2sd/z8f4Gv1ut/MeXf8KY0b/oI6h+af/E0f8KY0b/oI6h+af8AxNeo0Uf21jv+fj/APrdb+Y8u/wCFMaN/0EdQ/NP/AImj/hTGjf8AQR1D80/+Jr1Gij+2sd/z8f4B9brfzHmdp8H9ItrqGdNQvy0ThwDswSDn+7XplFFcmJxlbFNOtK9jOpVnU+N3CiiiuYzCiiigDH8Q6DBrn2f7RLLH5O7GzHOcdc/Ssf8A4QKw/wCfq6/8d/wrsKK8+vlWDxFR1atNOT6nXSx2IpRUITskcf8A8IFYf8/V1/47/hR/wgVh/wA/V1/47/hXYUVj/YeA/wCfS/H/ADNP7TxX87OP/wCECsP+fq6/8d/wo/4QKw/5+rr/AMd/wrsKKP7DwH/Ppfj/AJh/aeK/nZx//CBWH/P1df8Ajv8AhR/wgVh/z9XX/jv+FdhRR/YeA/59L8f8w/tPFfzsrabaJYWMNrGzMkS7QW6mrNFFepCChFRjsjhlJybk92FFFFUIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACisvxSzJ4Y1dkYqy2cxBBwQdhrmPDfgTw5c+HdLnn08vLLaxO7G4lyzFASfvUAd3RXK/wDCvvDH/QM/8mJf/iqP+FfeGP8AoGf+TEv/AMVQB1VFcr/wr7wx/wBAz/yYl/8AiqP+FfeGP+gZ/wCTEv8A8VQB1VFcr/wr7wx/0DP/ACYl/wDiqP8AhX3hj/oGf+TEv/xVAHVUVyv/AAr7wx/0DP8AyYl/+Ko/4V94Y/6Bn/kxL/8AFUAdVRXK/wDCvvDH/QM/8mJf/iqP+FfeGP8AoGf+TEv/AMVQB1VFcr/wr7wx/wBAz/yYl/8AiqP+FfeGP+gZ/wCTEv8A8VQB1VFcr/wr7wx/0DP/ACYl/wDiqP8AhX3hj/oGf+TEv/xVAHVUVyv/AAr7wx/0DP8AyYl/+Ko/4V94Y/6Bn/kxL/8AFUAdVRXK/wDCvvDH/QM/8mJf/iqP+FfeGP8AoGf+TEv/AMVQB1VFcr/wr7wx/wBAz/yYl/8AiqP+FfeGP+gZ/wCTEv8A8VQB1VFcr/wr7wx/0DP/ACYl/wDiqP8AhX3hj/oGf+TEv/xVAHVUVyv/AAr7wx/0DP8AyYl/+Ko/4V94Y/6Bn/kxL/8AFUAdVRXK/wDCvvDH/QM/8mJf/iqP+FfeGP8AoGf+TEv/AMVQB1VFcr/wr7wx/wBAz/yYl/8AiqP+FfeGP+gZ/wCTEv8A8VQB1VFcr/wr7wx/0DP/ACYl/wDiqP8AhX3hj/oGf+TEv/xVAHVUVyv/AAr7wx/0DP8AyYl/+Ko/4V94Y/6Bn/kxL/8AFUAdVRXK/wDCvvDH/QM/8mJf/iqP+FfeGP8AoGf+TEv/AMVQB1VFcBJ4f0zQPHnhk6RbtbfaFullAmdg4EYIyCSOtd/QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBleLP+RV1n/rym/9ANHhP/kVdG/68of/AEAUeLP+RV1n/rym/wDQDR4T/wCRV0b/AK8of/QBQBq0UUUAFFFFABRRRQAUVg+P9SudH8B+JNTsHCXllptzcwsVDBXSJmU4PB5A4rxD4Y/EvxNr3ivwjY2/iGHxCdQt2n1iz/ssW/8AZqBQQwlGA3zHHft6igD6NorxrRfj3oureJNNsYLIf2dqN9/Z9rdC/gaZpC21We2DeYiMRwx9RxyKtWXxmF62k3kPhm+/4R3V9Yj0ew1RriMCaRnZN/l/eC5Vue+D0PFAHrdFea/8LZsf7F/tH+zLnZ/wkP8Awj2zeufM3bfM/wB3261mH4nQ6FY+LL+6j1XU0sfEP9liBjFlC20ARYA+UZ4DEn3oA9dorybxP8ZE8PzWNhe6A9prd1BJdmy1HUra0EUKuUVmlZthZyDhQSeD6VXPxvgvbPTZfDvhvUdVkvtKk1VY1nii8tIpGjkDFj/CUbpknjA5oA9horyvwt8YbfW9Z0i2utBv9L0/VrCW/s724ljYSCJcyAohJUDBwTgnA45ql4R+Ouk+I/E+laZHYCC11WSSOznF/BLLuUEjzoEYvFuwcZ9vwAPYaK8h8L/Gn+3Z/DTt4V1G00zX3mgsr2S4iYPNGWBTaDuAyuNxxz2IGaxvC3xm1i28Bat4h8W+H5zb2t5JbRXEEsKo7+aEWIjdldueXI28cZ4BAPd6K5X4deLW8Y6PNfNZQWojlMa+RfxXkcgwDkSRkjvgg4IIryix+JmvWXi7xzrXiaPUYPD2gSC0h0+A27I0rFUSM4+dnYtu3A7QAQewoA+gaK8suPi22lR69B4m8NXmlatpenDVRZ/aY5hPbl9m5XXgEMcEH9a7TwZ4gufEmmNfXGi3ukxMVMC3bIWmQqGDgITgc4weeOgoA36K8G8XfFfWNUg0q68L6Zd2OhP4jt9NGrvLFi6XzCsiiI5YKcHDe3Y5x0U3xjijmnvh4evm8KQaj/ZcmsiePAl37C3lZ3GPcR836dqAPV6K8i1j40Lpt7qhPhjUJtJ0rVf7KvdRWeIJG5YAMEzvbJPTGBxzzirfiH4uDTL3XpLPw3f6joegTi31TUYp408p+NwSNjufbuGen9aAPUqK8/sviR/aXjrUPDekaDqF8ti9p59/E8YhjjuIxIsh3ENgA9ACTg9K9AoAKKKKACiiigAooooA5XxF/wAj34R/7fP/AEUK6quV8Rf8j34R/wC3z/0UK6qgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDK8Wf8irrP8A15Tf+gGjwn/yKujf9eUP/oAo8Wf8irrP/XlN/wCgGjwn/wAiro3/AF5Q/wDoAoA1aKKKACiiigAooooAz/EOlQa9oGp6RdvKltqFrLaStEQHVJEKkqSCM4JxkGuOX4UaHDN4VubK71Oz1Dw5CttbXkEiCWaEDHlzZQq6nnjA6nGM16DRQB5vo3wmsdD1KF9H17W7PSobsXiaZG8XkqwffsDGPeIyeq7ucn1rm9Z+Dlxp0nheLwtqmoTaTp3iS21Q6ZdTIILSEO7yGPCBictwCTwT3JNe2UUAeWv8FtHfVJrj+2teSyfVl1pdPS4TyEuQ24nBQkgntnp3rTvPhVod3aatbyXWpBNT1hdbmKyJlZlIIVfk4TgcHJ967+igDi/Gnw+svEut2etRajf6TrNrCbZbuz8sl4Sd2x1kVlYZyRxwar6f8MtNtb+3vp9T1e8vItNn0sy3EsZLxzSNIzHCD5gWIGMAAAY4rvKKAOF0n4YaHpkvhh4576YeH7SeytkmdCsscow3mAIMnHTGPxqp4Y+Fdr4bv7NtN8Qa4ul2cplg01pIjGvU7C+zzCgyflLenWvRaKAOA0b4VaHpGk+EtOtrrUmh8M3Ut3ZtJIhaR5GZiJMIARlzjAXtVSz+E8On2mq2WmeJ/EFnp99O90trHJEUhkdgzY3Rncp6bWyMH15r0qigDkfh14D03wJY30GmzT3Et9P9puJpgi7nxjhUVVUYHQCqd98L9Bv7HxXaXb3skPiO4W6uv3igxSLjaYiF+XBUHnP5cV3VFAHmp+EWm3dvrf8Abmta1q1/qtkumyX1zLH5sVuG3bI8IFGWAJJByefWvQtOtEsNPtrOEs0dvEsSljyQoAGffirFFAHlyfBjSEkSJNa12PSYdTXVbfTEmi8iGYOX4zGW2knpnjnvzUs3wd0eW/lzqmsDQ5r/APtOTRRKn2Vp927P3d+zIzt3Yz+VemUUAcBqHwq0O+0nxDp811qQh1vU11W5ZZEDJKGVtqfJgLlBwQT15qr4g+EWlaxqOrSjV9ZstO1mVZtT021mRYLpxjk5UsucDdtIz7V6TRQBznh/whp2heJtf1yxe4FxrS2qzxMy+VGLeMxoIwACPlPOSfbFdHRRQAUUUUAFFFFABRRRQByviL/ke/CP/b5/6KFdVXK+Iv8Ake/CP/b5/wCihXVUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZXiz/kVdZ/68pv/AEA0eE/+RV0b/ryh/wDQBR4s/wCRV1n/AK8pv/QDR4T/AORV0b/ryh/9AFAGrRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcr4i/5Hvwj/2+f+ihXVVyviL/AJHvwj/2+f8AooV1VABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGV4s/5FXWf+vKb/wBANHhP/kVdG/68of8A0AUeLP8AkVdZ/wCvKb/0A0eE/wDkVdG/68of/QBQBq0UUUAFFFFABXOaB448L+Ir42Wha/puoXYQyGG2nV22jGTgduR+ddHXzp4W+EvifTPgZeWC3mpW/iie0lhTTGuofIhb7T5gKOgyGZVHJkI+c5x2APe9b1nT9Dt4Z9VuVt4pp47aNmBO6RztReAepo0TWdP1y3mn0q5W4ihnktpGUEbZEO115A6GvFNV8M+N/Ees6zqN9oMtjFdanolzBaPqEMwjS3Z/PIIbAIypOOvbNeifCTQtR0DQ9Wt9Wt/s80+sXt1Gu9X3RSSlkbKk9R26+tAG7aeK9Bu7bTLi11exlg1ORorKRJgRcOpIZUP8RBB6elXdH1Ww1qxW80m8gvLRmZBLC4ZSVOCMj0IIr558BfCjxXo1j8M5r46i02majPNf6fLdwNb2KFpNrxheSWBBOGbljwO214LsPiD4b+Fuq+GbXwhcR6psujaXv9o22wvLKcEASZBVXLZP9zHUgUAez6Fr2leILWW50PUbTUIIpTC8ltKJFVwASpI74I/OtKvGfgz4E8R/D3xXqFjPb2Uvh2+sIH+0WbbUiuogIzlGbdukUb2YDBOOlZvif4d+INW8a3+qfZr5o5PEdk8UkepmILp3lBLnaqyDbnkEABz2oA94qsL+zOpHThd2/wDaAhFwbXzF80RFtofZnO3IIzjGRivn/UvAPi//AIQ/TtDXRnurGDVdQOz7ZG00Fsx/0cxmSTZt5Od2WUdBnNTeE/h94qsvEeh6pqOn3B1E+Gf7Okv2v1c2V6rSBXkXf867CgG0MM8kd6APc9Y1nT9FWzbU7lbcXl1HZQbgTvmkOETgdSfXitCvnNfhxrV5o3hvT7jwneW15balYS6vqD6yr/bFRz50y4k3A4JbPyuN2ADjjq/CHhDWdClWzl0m9m0638VT3VjjVQotbExAI5BLGRN24eWSGycmgD2GiiigDh/ifrPijSINPbwjp3255GcTjyGl2gAbehGOprgP+E1+K3/Qtf8AkhJ/8VXtt/qFlp6K1/eW9qrnCmaVUBPoMmqf/CTaD/0G9M/8C4/8aylgq1V88HK3ke1g82oYaiqU8NCbXV3uzx7/AITX4rf9C1/5ISf/ABVH/Ca/Fb/oWv8AyQk/+Kr2H/hJtB/6Demf+Bcf+NH/AAk2g/8AQb0z/wAC4/8AGp/s3EfzS+46f7fwv/QHT/H/ADPHv+E1+K3/AELX/khJ/wDFUf8ACa/Fb/oWv/JCT/4qvYf+Em0H/oN6Z/4Fx/40f8JNoP8A0G9M/wDAuP8Axo/s3EfzS+4P7fwv/QHT/H/M8e/4TX4rf9C1/wCSEn/xVH/Ca/Fb/oWv/JCT/wCKr2H/AISbQf8AoN6Z/wCBcf8AjR/wk2g/9BvTP/AuP/Gj+zcR/NL7g/t/C/8AQHT/AB/zI/Bt5qd/4ZsbnXbf7NqcikzRbCm07iBweRxitqobO7t72BZ7O4huIWyBJE4dTjryKmrZRcFyvdHgVZqpUlNKybbstl5IKKKKZmFFFFABRRRQByviL/ke/CP/AG+f+ihXVVyviL/ke/CP/b5/6KFdVQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBleLP+RV1n/rym/wDQDR4T/wCRV0b/AK8of/QBR4s/5FXWf+vKb/0A0eE/+RV0b/ryh/8AQBQBq0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBynxA8E2XjaztLfULm5t0tpDIpg25JIxzkGuJ/4UHoP/AEFNU/OP/wCJr2GivRw+bYzDU1So1GoroQ6cZO7R49/woPQf+gpqn5x//E0f8KD0H/oKap+cf/xNew0Vv/b+Y/8AP1/h/kL2UOx49/woPQf+gpqn5x//ABNH/Cg9B/6CmqfnH/8AE17DRR/b+Y/8/X+H+Qeyh2PHv+FB6D/0FNU/OP8A+Jo/4UHoP/QU1T84/wD4mvYaKP7fzH/n6/w/yD2UOxh+DfDlv4V0CDSbOaaaGFmYPLjcdzEnOAB3rcooryqlSVWbqTd29WWlbRBRRRUDCiiigAooooA5XxF/yPfhH/t8/wDRQrqq5XxF/wAj34R/7fP/AEUK6qgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDK8Wf8irrP/XlN/6AaPCf/Iq6N/15Q/8AoAo8Wf8AIq6z/wBeU3/oBo8J/wDIq6N/15Q/+gCgDVooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOV8Rf8j34R/7fP8A0UK6quV8Rf8AI9+Ef+3z/wBFCuqoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAyvFn/Iq6z/15Tf+gGjwn/yKujf9eUP/AKAKPFn/ACKus/8AXlN/6AaPCf8AyKujf9eUP/oAoA1aKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDlfEX/I9+Ef+3z/ANFCuqrlfEX/ACPfhH/t8/8ARQrqqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMrxZ/yKus/9eU3/oBo8J/8iro3/XlD/wCgCjxZ/wAirrP/AF5Tf+gGjwn/AMiro3/XlD/6AKANWiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiuZ+IXjPTvAmgrq2rw3c1s0ywBbVVZ9zAkHDMox8p71zniH4xeH9C8MaFr13Z6q9nrKs1ukUUZkULjO8FwB17E0Aek0V574r+LOheGdV0Wwv7TU5JtWhjngMMcZVVdtoDZcYOeuM1PqHxP0Ww+IsHgya11FtUmZFWVY08kFl3DJ37un+zQB3dFcJonxP0XWPH954QtrXUU1K1aVXlkjQQkx9cEOT9OKq+E/i7oPif8At37BaapH/Y9u9zP50cY3KuchMOcng9cUAei0V5tovxi8P6v4O1rxLbWeqrY6UyLPHJFGJGLEAbQHIPXuRRJ8YvD8fgCLxebPVf7NkuvsYjEUfnb+ecb8Y49fwoA9JorK8La5beJfD1jrFik0dreR+bGswAcD3AJGfxNatABRRRQAUUUUAFFFFAHK+Iv+R78I/wDb5/6KFdVXK+Iv+R78I/8Ab5/6KFdVQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBleLP8AkVdZ/wCvKb/0A0eE/wDkVdG/68of/QBR4s/5FXWf+vKb/wBANHhP/kVdG/68of8A0AUAatFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAUtW0rTtZtRbavYWl/bBg4iuoVlTcOhwwIzyefeql34W8P3lla2d5oWlT2dqCLeCW0jaOEHrsUjC/hWd8RtH1vXPD62nhrUf7OvhOrmbz3h+QA5G5AT3HHtXmP8Awrn4nf8AQ5f+VS6/+Jrnq1pwlaMGz2MDluHxNL2lTExpu+zvc9hvvDWhahPbTX+i6ZczWyhIJJrWN2iUHICkj5QD0Ap03h7RZtXXVZtI06TVFIK3jWyGYEDAw+N3A46145/wrn4nf9Dl/wCVS6/+Jo/4Vz8Tv+hy/wDKpdf/ABNZ/Wan/PtnZ/YmD/6DYfcz2O28PaLa6rJqdtpGnQ6lIWL3cdsizMW65cDJz35plh4Y0HT/ALV9g0TS7X7Uhjn8m0jTzlPVXwPmHJ4NeP8A/Cufid/0OX/lUuv/AImj/hXPxO/6HL/yqXX/AMTR9Zqf8+2H9iYP/oNh9zPX7bwt4fttPuLC20LSobG5IM9tHaRrHKR03KBhuneg+FvD7aUumHQtKOmq/mi0NpH5If8AvbMYzz1xXkH/AArn4nf9Dl/5VLr/AOJo/wCFc/E7/ocv/Kpdf/E0fWan/Pth/YmD/wCg2H3M9wsbO2sLSK1sbeG2tYhtjhhQIiD0CjgCp65b4c6Preh+H2tPEuo/2jfGdnE3nvN8hAwNzgHsePeuprqhJyim1Y8HEUo0qsqcJKSXVbMKKKKoxCiiigAooooA5XxF/wAj34R/7fP/AEUK6quV8Rf8j34R/wC3z/0UK6qgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDK8Wf8irrP8A15Tf+gGjwn/yKujf9eUP/oAo8Wf8irrP/XlN/wCgGjwn/wAiro3/AF5Q/wDoAoA1aKKKACiiua8ceMLHwdFo0upRytHqepw6WjoVAieXcQ7kkYUbTmgDpaK4fT/ib4fum19pZZILbSLxbJ59vmrM7LuHlhNxI/DtVmX4l+D4tOtb59etfs90kjwkBiziM4f5QN2VzyMZFAHX0VxUXxF0dtfv7SSaCPS7TSodXOqGceU8UjMBjj/ZznPOcYqtq/xb8IabpllfnUGuba6v004mGMhoZG5zIrbWVQCCeM4PANAHfUVz6+M/DrMFGrW283kdgFyc/aJF3JHjGckcj2qtpfxB8KarfLaWGu2cs7RSTKNxVSsZIchiAPlwSRnIHPTmgDqaK5/wx4y8P+KJriLQdUhvJYFV5EUMp2t91wGA3KccMMg+tUNT+Jfg3S9Vl03UPENjb30LtHJE7EFGVdxUnGAcdB3PAyaAOvorkbj4keErfRrDVZNZiOn3yyPBNHFI4ZYyA5O1SVCkgHdjGaht/ib4Yn8Xy+HlvgLmOyS/FwceQ8TIZOHz2jG8kgDBHNAHaUV5xrfxh8L2Npp91ZXkd7a3GowWM8oLRLbrKkjLN8y/Mv7psY4PY10mi+N/DetppraXq9tcf2k8sVoFJDSvEu6RcEZBUckHHFAHR0UUUAFFFFABRRXDfFLxTfeHF0GDT57Gx/tS++yS6lfoXgtF2M2WUMuSSuBlgKAO5orxXw/8SfFfiKTwfaabbaJBc6xb3ss01xHK0TfZ5QgkiAcHa4yQDnqOeOfaqACiiigAooooAKKKKACiiigAooooA5XxF/yPfhH/ALfP/RQrqq5XxF/yPfhH/t8/9FCuqoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAyvFn/ACKus/8AXlN/6AaPCf8AyKujf9eUP/oAo8Wf8irrP/XlN/6AaPCf/Iq6N/15Q/8AoAoA1aKKKACuP+JXgiDx1a6Fa3k8Udtp2rQanLFLbiZLlIwwMLAkABg5BJz9DXYUUAeRz/BpYbPXbbRNZTSrfUdVh1JLaCy2wIiKVNu8aSLvjbOSAV5ArBtvhH4i0PXNEg0DVbdLeOLUzPqTWKFIDcMhCCAygngEAgkDHI7V71RQB5E3wR0/+zL3Tk1a4Szn0a10pP3QLo8EplWYtnDZfGVwBjIzzVi8+FF3exXl7c+I1bxHc6vZ6ub1bACAPbKFiTyPM+7jr8+Sa9VooA8nHw+u7j48ReJ7mFhpVvp8Uryb1CXWoKrxBxGCSu2Jjye+MetYngH4Q6lceHdJh8bXhgisYNTt4NNt40Dw/a2lR3adXYPmNyQABjcM5Ir3OigDzr4afDZvBd+1zLqNrfFbMWUbpYmGXYGBG9zI27p0AUck4qKf4Xebq7339sY3eJovEez7N/ciMfk539853/htr0qigDxjUPgncXOiWumR+JyLeJr0yRTWJkhf7RIXDiMSgB0yQGJb6CtKL4R7fKgbXGNhJ4ci8O30QtcPMkcbKssb7/3ZywbBDjjHevVaKAPNR8OtYuYPD0Gr+KIbuHQ9RtL21WPTFhJSBJU2MRIcswkXLdBs4Xk1e8NeA7vQNZN3b61G9rLrF/qs9ubBCZBcrhY1kLFk2HncuN3QgCu8ooAKKKKACiiigAqK5t4bqFobqGOaFvvJIoZT9QalooAhFrbiSKQQRCSJSkbBBlFPYHsOBwKmoooAKKKKACiiigAooooAKKKKACiiigDlfEX/ACPfhH/t8/8ARQrqq5XxF/yPfhH/ALfP/RQrqqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMrxZ/yKus/wDXlN/6AaPCf/Iq6N/15Q/+gCjxZ/yKus/9eU3/AKAaPCf/ACKujf8AXlD/AOgCgDVooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDH8X+IbTwr4bvdb1GOeS1tFDOkCguQWC8AkDqR3rjpPjF4fj8AReLzZ6r/AGbJdfYxGIo/O388434xx6/hXoOoWNpqVnJaajbQXdrKMSQzxiRHGc8qeDyBWefC3h9tKXTDoWlHTVfzRaG0j8kP/e2YxnnrigDjvEPxi8P6F4Y0LXruz1V7PWVZrdIoozIoXGd4LgDr2JqfxX8WdC8M6rothf2mpyTatDHPAYY4yqq7bQGy4wc9cZrqrvwt4fvLK1s7zQtKns7UEW8EtpG0cIPXYpGF/CnX3hrQtQntpr/RdMuZrZQkEk1rG7RKDkBSR8oB6AUAc1qHxP0Ww+IsHgya11FtUmZFWVY08kFl3DJ37un+zRonxP0XWPH954QtrXUU1K1aVXlkjQQkx9cEOT9OK6ebw9os2rrqs2kadJqikFbxrZDMCBgYfG7gcdaLbw9otrqsmp22kadDqUhYvdx2yLMxbrlwMnPfmgDjvCfxd0HxP/bv2C01SP8Ase3e5n86OMblXOQmHOTweuKj0X4xeH9X8Ha14ltrPVVsdKZFnjkijEjFiANoDkHr3IrsrDwxoOn/AGr7Boml2v2pDHP5NpGnnKeqvgfMOTwaS28LeH7bT7iwttC0qGxuSDPbR2kaxykdNygYbp3oAqeAfF9h438PJrGlQ3UNs0jRBblVV8r14ViMfjXR1T0rS7DSLQWulWNrY2oJYQ20SxICep2qAM1coAKKKKACiiigAooooA5XxF/yPfhH/t8/9FCuqrlfEX/I9+Ef+3z/ANFCuqoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAyvFn/Iq6z/15Tf8AoBo8J/8AIq6N/wBeUP8A6AKPFn/Iq6z/ANeU3/oBo8J/8iro3/XlD/6AKANWiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMjxbo3/CQeG9Q0rz/ALP9riMfm7N+z3xkZ/OvHv8Ahnz/AKmb/wAkP/tte8UV6ODzbF4GLhh58qeuyf5pkSpxlqzwf/hnz/qZv/JD/wC20f8ADPn/AFM3/kh/9tr3iiuz/WXM/wDn7/5LH/In2MOx4P8A8M+f9TN/5If/AG2j/hnz/qZv/JD/AO217xRR/rLmf/P3/wAlj/kHsYdjwf8A4Z8/6mb/AMkP/ttH/DPn/Uzf+SH/ANtr3iij/WXM/wDn7/5LH/IPYw7Hn/wv+HX/AAgs+oSf2p9v+1qi4+z+Vs2k/wC02etegUUV5WKxVXF1XWrO8n10Xl0NIxUVZBRRRXOMKKKKACiiigDlfEX/ACPfhH/t8/8ARQrqq5XxF/yPfhH/ALfP/RQrqqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMrxZ/yKus/wDXlN/6Aay/C3iHRU8MaQr6vpystnCCDcoCDsHvXUOqurK6hlYYIIyCKy/+Ec0P/oDab/4Cp/hQAf8ACR6H/wBBnTf/AAKT/Gj/AISPQ/8AoM6b/wCBSf40f8I5of8A0BtN/wDAVP8ACj/hHND/AOgNpv8A4Cp/hQAf8JHof/QZ03/wKT/Gj/hI9D/6DOm/+BSf40f8I5of/QG03/wFT/Cj/hHND/6A2m/+Aqf4UAH/AAkeh/8AQZ03/wACk/xo/wCEj0P/AKDOm/8AgUn+NH/COaH/ANAbTf8AwFT/AAo/4RzQ/wDoDab/AOAqf4UAH/CR6H/0GdN/8Ck/xo/4SPQ/+gzpv/gUn+NH/COaH/0BtN/8BU/wo/4RzQ/+gNpv/gKn+FAB/wAJHof/AEGdN/8AApP8aP8AhI9D/wCgzpv/AIFJ/jR/wjmh/wDQG03/AMBU/wAKP+Ec0P8A6A2m/wDgKn+FAB/wkeh/9BnTf/ApP8aP+Ej0P/oM6b/4FJ/jR/wjmh/9AbTf/AVP8KP+Ec0P/oDab/4Cp/hQAf8ACR6H/wBBnTf/AAKT/Gj/AISPQ/8AoM6b/wCBSf40f8I5of8A0BtN/wDAVP8ACj/hHND/AOgNpv8A4Cp/hQAf8JHof/QZ03/wKT/Gj/hI9D/6DOm/+BSf40f8I5of/QG03/wFT/Cj/hHND/6A2m/+Aqf4UAH/AAkeh/8AQZ03/wACk/xo/wCEj0P/AKDOm/8AgUn+NH/COaH/ANAbTf8AwFT/AAo/4RzQ/wDoDab/AOAqf4UAH/CR6H/0GdN/8Ck/xo/4SPQ/+gzpv/gUn+NH/COaH/0BtN/8BU/wo/4RzQ/+gNpv/gKn+FAB/wAJHof/AEGdN/8AApP8aP8AhI9D/wCgzpv/AIFJ/jR/wjmh/wDQG03/AMBU/wAKP+Ec0P8A6A2m/wDgKn+FAB/wkeh/9BnTf/ApP8aP+Ej0P/oM6b/4FJ/jR/wjmh/9AbTf/AVP8KP+Ec0P/oDab/4Cp/hQAf8ACR6H/wBBnTf/AAKT/Gj/AISPQ/8AoM6b/wCBSf40f8I5of8A0BtN/wDAVP8ACj/hHND/AOgNpv8A4Cp/hQAf8JHof/QZ03/wKT/Gj/hI9D/6DOm/+BSf40f8I5of/QG03/wFT/Cj/hHND/6A2m/+Aqf4UAH/AAkeh/8AQZ03/wACk/xo/wCEj0P/AKDOm/8AgUn+NH/COaH/ANAbTf8AwFT/AAo/4RzQ/wDoDab/AOAqf4UAH/CR6H/0GdN/8Ck/xo/4SPQ/+gzpv/gUn+NH/COaH/0BtN/8BU/wo/4RzQ/+gNpv/gKn+FAB/wAJHof/AEGdN/8AApP8aP8AhI9D/wCgzpv/AIFJ/jR/wjmh/wDQG03/AMBU/wAKP+Ec0P8A6A2m/wDgKn+FAHPapqmn3/j3wmtjfWtyyi7LCGZXIHlDrg121UbPR9MspvOs9Os7eUDG+KBUbH1Aq9QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The above figure represents the genetic basis for donor selection. Every person has two sets of HLA antigens (haplotypes) which are located on chromosome 6; one set is derived from the father and one from the mother. These are shown in different colors, reflecting the vast HLA diversity among human subjects.",
"    <br>",
"     &nbsp;",
"     <br>",
"      For any given mother and father there are four equally possible sets of HLA antigens in their children. On average, only one out of every four siblings (25 percent) will be fully HLA matched with the patient requiring the transplantation, here shown in the black box. Two out of every four siblings (50 percent) will be haplotype matches only.",
"      <br>",
"       &nbsp;",
"       <br>",
"        Note that all of the patient's children and both of the patient's parents will only be haplotype matches. It is unlikely that any of the patient's parents, children, or first cousins will be full HLA matches unless the involved families happen to have very common haplotypes or there has been intermarrying among their families.",
"        <div class=\"footnotes\">",
"        </div>",
"        <div class=\"reference\">",
"         Figure supplied by Dr. Robert S. Negrin, Stanford University School of Medicine.",
"        </div>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_10_43169=[""].join("\n");
var outline_f42_10_43169=null;
var title_f42_10_43170="Angina treatment — medical versus interventional therapy";
var content_f42_10_43170=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Angina treatment ��������� medical versus interventional therapy (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?42/10/43170/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/10/43170/contributors\" id=\"au6237\">",
"       Julian M Aroesty, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?42/10/43170/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/10/43170/contributors\" id=\"se3839\">",
"       Donald Cutlip, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?42/10/43170/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/10/43170/contributors\" id=\"de1101\">",
"       Gordon M Saperia, MD, FACC",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?42/10/43170?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      ANGINA TREATMENT OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Coronary heart disease causes narrowing of the arteries that supply blood and oxygen to the heart muscle (",
"     <a class=\"graphic graphic_figure graphicRef78029 \" href=\"mobipreview.htm?36/60/37826\">",
"      figure 1",
"     </a>",
"     ). The consequences of coronary heart disease include stable angina (intermittent but predictable chest pain), unstable angina (angina that is new in onset, occurs at rest, or has a worsening pattern), heart attack (myocardial infarction), or death.",
"    </p>",
"    <p>",
"     There are several treatment options for people with stable angina. These options are classified as medical treatment (which include medications and lifestyle modifications) or interventional treatment (surgical treatment with percutaneous coronary intervention, with or without a stent, or coronary artery bypass graft surgery). The choice among these treatment options depends upon many individual factors, including a person's age, the severity of the coronary heart disease, the relative risks and benefits of various treatments, the presence of other medical conditions, and personal preferences.",
"    </p>",
"    <p>",
"     Because coronary heart disease is typically a chronic disease requiring long-term treatment, it is very important to learn as much as possible about this disease and about the benefits and risks of the various treatment options. You should discuss all of these options with a healthcare provider to determine which treatment is best.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      GOALS OF ANGINA TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     All of the medical and interventional treatments for people with coronary heart disease have the same goals: to improve quality of life and to alleviate symptoms such as angina. In some people, these interventions may also delay or stop the progression of the disease and thereby prolong life.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      MEDICAL ANGINA TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Medical treatment for coronary heart disease includes drugs called antianginal drugs, which alleviate symptoms and support heart function. It also includes lifestyle modifications. Medical treatment is usually considered first for all people with coronary heart disease. Medical therapy is discussed in detail in a separate article. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/1/31766?source=see_link\">",
"      \"Patient information: Angina treatment &mdash; medical therapy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      INTERVENTIONAL ANGINA TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The interventional treatments for coronary heart disease include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Angioplasty, with or without stent placement",
"      </li>",
"      <li>",
"       Coronary artery bypass graft surgery (CABG).",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     These treatments effectively relieve symptoms of coronary heart disease, such as angina, but they do not significantly increase life expectancy for most people. Because these treatments actively restore blood flow to the heart muscle, they are often called revascularization procedures.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Angioplasty",
"     </span>",
"     &nbsp;&mdash;&nbsp;Angioplasty, also known as percutaneous coronary intervention, uses a balloon to dilate narrowed arteries in the heart and may include placement of a stent to hold the artery open. The procedure is discussed in detail in a separate article. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/38/18020?source=see_link\">",
"      \"Patient information: Heart stents and angioplasty (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Coronary artery bypass graft surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Coronary artery bypass graft surgery (CABG) involves sewing one end of an artery or vein above a blocked coronary artery and the other end below the blockage, thereby allowing blood an alternate pathway to the heart. The arteries or veins used for the bypass (which are known as \"grafts\") are usually obtained from the leg or the chest wall. CABG is discussed in detail in a separate article. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/62/31717?source=see_link\">",
"      \"Patient information: Coronary artery bypass graft surgery (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      MEDICAL VERSUS INTERVENTIONAL ANGINA TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Several factors can help determine whether medical or interventional treatment is a better choice. You should discuss all of these factors with your healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Results of studies",
"     </span>",
"     &nbsp;&mdash;&nbsp;As a result of studies that compared medical to interventional treatment, many experts do not recommend using interventional treatment initially unless you have certain characteristics (see below) or you cannot tolerate or do not improve with aggressive medical treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Results of tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Certain tests are used to determine the extent of coronary heart disease. These tests may determine if medical or interventional treatment is more appropriate and can help decide which interventional option (angioplasty or bypass surgery) is best. As examples:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Exercise ECG testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;An exercise test can often determine if you have a risk of a heart attack or cardiac death. The test involves running on a treadmill or bicycling while an electrocardiogram is continuously monitored. In some cases, a radioactive tracer such as thallium or sestamibi is used to identify the particular regions in the heart that are not getting enough blood.",
"    </p>",
"    <p>",
"     Exercise testing provides information about the effects of coronary heart disease on the heart's ability to function at different levels of exertion. Advantages of this test are that it is noninvasive and particularly useful for identifying the small percentage of people with stable angina who have a high risk of heart attack and death from their coronary heart disease.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Angiography",
"     </span>",
"     &nbsp;&mdash;&nbsp;Angiography (also known as cardiac catheterization) involves passing a small catheter into the coronary arteries. Dye is injected into the artery and an x-ray image is used to show the outline of any blockages. Angiography is usually recommended for people who are considered to have \"high risk\" disease based upon the results of other tests, such as the exercise tests described above. The results of angiography can then help determine if angioplasty or bypass surgery is a better choice.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Age",
"     </span>",
"     &nbsp;&mdash;&nbsp;Interventional treatments have more risks in older people. For example, the risk of dying from bypass surgery is about 3 times greater for people who are 79 years or older compared to people who are 50 years of age.",
"    </p>",
"    <p>",
"     On the other hand, older people often have the most to gain from bypass surgery; in older patients (&gt;75 years of age), bypass surgery has a greater life-prolonging benefit relative to medical treatment. Therefore, advancing age does not necessarily rule out angioplasty or bypass surgery as treatment options.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Severity of angina",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who have angina are usually managed with medical treatment initially unless testing indicates that the person could have severe disease. If medical treatment does not significantly improve symptoms of angina or if the person cannot tolerate medical treatment, arteriography followed by angioplasty or coronary artery bypass graft surgery may be recommended.",
"    </p>",
"    <p>",
"     Angioplasty has not been shown to prolong life compared with medical therapy. Angioplasty is used principally to improve angina symptoms when medications have failed. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/38/18020?source=see_link\">",
"      \"Patient information: Heart stents and angioplasty (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Advanced heart disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;Heart disease may lead to poor pumping function of the left ventricle (the heart chamber that pumps blood to the body), and it may even lead to a serious condition called heart failure. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33877?source=see_link\">",
"      \"Patient information: Heart failure (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     People with these advanced types of heart disease may benefit more from interventional treatments, primarily bypass surgery, than from medical treatment. In fact, interventional treatment may even reverse abnormal function of the left ventricle in some cases. However, interventional procedures are associated with greater risks in people with advanced heart disease. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33877?source=see_link\">",
"      \"Patient information: Heart failure (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Narrowing of coronary arteries",
"     </span>",
"     &nbsp;&mdash;&nbsp;Interventional treatment is usually more beneficial than medical treatment when the coronary arteries are severely narrowed, when many coronary arteries are narrowed, and when the left main coronary artery (the artery that supplies blood to the left side of the heart) is narrowed. These early patterns of arterial narrowing often predict how severe heart damage would be if a heart attack occurs.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       People who have at least three narrowed coronary arteries are usually advised to undergo interventional treatment, most often bypass surgery.",
"      </li>",
"      <li>",
"       People who have two narrowed coronary arteries are usually advised to have interventional treatment.",
"      </li>",
"      <li>",
"       People who have only one narrowed coronary artery are advised to use medical treatment. If angina persists with medical treatment, then angioplasty, with or without a stent, or coronary bypass graft surgery may be recommended.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Peripheral artery disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;Peripheral artery disease refers to narrowing of arteries in parts of the body other than the heart. For example, arteries that supply blood to the arms and legs or to the brain may be narrowed. Studies suggest that people with peripheral vascular disease have greater risks from angioplasty and bypass surgery, and medical treatment may therefore be a better choice. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/35/14900?source=see_link\">",
"      \"Patient information: Peripheral artery disease and claudication (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784890629\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12678492\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/10/27809?source=see_link\">",
"      Patient information: Coronary heart disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/34/21027?source=see_link\">",
"      Patient information: Chest pain (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/27/21940?source=see_link\">",
"      Patient information: Medicines after a heart attack (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/53/35667?source=see_link\">",
"      Patient information: Cardiac catheterization (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/35/1587?source=see_link\">",
"      Patient information: Medicines for angina (chest pain) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/24/39298?source=see_link\">",
"      Patient information: Angioplasty and stenting for the heart (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/14/30946?source=see_link\">",
"      Patient information: Treatment choices for angina (chest pain) (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12678547\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/1/31766?source=see_link\">",
"      Patient information: Angina treatment &mdash; medical therapy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/38/18020?source=see_link\">",
"      Patient information: Heart stents and angioplasty (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/62/31717?source=see_link\">",
"      Patient information: Coronary artery bypass graft surgery (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33877?source=see_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/35/14900?source=see_link\">",
"      Patient information: Peripheral artery disease and claudication (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/28/39368?source=see_link\">",
"      Early cardiac complications of coronary artery bypass graft surgery",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=see_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/2/37930?source=see_link\">",
"      Long-term outcome after coronary artery bypass graft surgery",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/51/9018?source=see_link\">",
"      Medical therapy versus revascularization in the management of stable angina pectoris",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/48/38666?source=see_link\">",
"      Periprocedural complications of percutaneous coronary intervention",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung, and Blood Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/\">",
"      www.nhlbi.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Heart Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.americanheart.org/\">",
"      www.americanheart.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?42/10/43170/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 11, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?42/10/43170?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43170/abstract/1\">",
"      Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003; 107:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43170/abstract/2\">",
"      Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004; 110:e340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43170/abstract/3\">",
"      Scanlon PJ, Faxon DP, Audet AM, et al. ACC/AHA guidelines for coronary angiography: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography) developed in collaboration with the Society for Cardiac Angiography and Interventions. Circulation 1999; 99:2345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43170/abstract/4\">",
"      Patel MR, Dehmer GJ, Hirshfeld JW, et al. ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization: a report by the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol 2009; 53:530.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f42_10_43170=[""].join("\n");
var outline_f42_10_43170=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           ANGINA TREATMENT OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           GOALS OF ANGINA TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           MEDICAL ANGINA TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           INTERVENTIONAL ANGINA TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           MEDICAL VERSUS INTERVENTIONAL ANGINA TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/60/37826\" title=\"figure 1\">",
"           Angina PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f42_10_43171="Topical tretinoin (topical all trans retinoic acid): Pediatric drug information";
var content_f42_10_43171=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Topical tretinoin (topical all trans retinoic acid): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1862?source=see_link\">",
"    see \"Topical tretinoin (topical all trans retinoic acid): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/42/30372?source=see_link\">",
"    see \"Topical tretinoin (topical all trans retinoic acid): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F230490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Atralin&trade;;",
"     </li>",
"     <li>",
"      Avita&reg;;",
"     </li>",
"     <li>",
"      Refissa&reg;;",
"     </li>",
"     <li>",
"      Renova&reg;;",
"     </li>",
"     <li>",
"      Retin-A Micro&reg;;",
"     </li>",
"     <li>",
"      Retin-A&reg;;",
"     </li>",
"     <li>",
"      Tretin-X&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F230491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Rejuva-A&reg;;",
"     </li>",
"     <li>",
"      Renova&reg;;",
"     </li>",
"     <li>",
"      Retin-A Micro&reg;;",
"     </li>",
"     <li>",
"      Retin-A&reg;;",
"     </li>",
"     <li>",
"      Retinova&reg;;",
"     </li>",
"     <li>",
"      Stieva-A;",
"     </li>",
"     <li>",
"      Vitamin A Acid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1050424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Acne Products",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Retinoic Acid Derivative",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vitamin, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1050419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1862?source=see_link\">",
"      see \"Topical tretinoin (topical all trans retinoic acid): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &gt;12 years and Adults: Topical: Begin therapy with a weaker formulation of tretinoin (0.025% cream or 0.01% gel) and increase the concentration as tolerated; apply once daily before retiring or on alternate days; if stinging or irritation develop, decrease frequency of application",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F230472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical: 0.025% (20 g, 45 g); 0.05% (20 g, 40 g, 45 g, 60 g); 0.1% (20 g, 45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avita&reg;: 0.025% (20 g, 45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Refissa&reg;: 0.05% (40 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renova&reg;: 0.02% (40 g, 44 g, 60 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Retin-A&reg;: 0.025% (20 g, 45 g); 0.05% (20 g, 45 g); 0.1% (20 g, 45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tretin-X&reg;: 0.025% (35 g) [kit includes cleanser and moisturizer]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tretin-X&reg;: 0.0375% (35 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tretin-X&reg;: 0.05% (35 g); 0.1% (35 g) [kit includes cleanser and moisturizer]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical: 0.01% (15 g, 45 g); 0.025% (15 g, 45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Atralin&trade;: 0.05% (45 g) [contains benzyl alcohol, fish collagen]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avita&reg;: 0.025% (20 g, 45 g) [contains ethanol 83%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Retin-A&reg;: 0.01% (15 g, 45 g); 0.025% (15 g, 45 g) [contains ethanol 90% w/w]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tretin-X&reg;: 0.01% (35 g); 0.025% (35 g) [contains ethanol 90% w/w; kit includes cleanser and moisturizer]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical [microsphere gel]: 0.04% (20 g, 45 g, 50 g); 0.1% (20 g, 45 g, 50 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Retin-A Micro&reg;: 0.04% (20 g, 45 g, 50 g); 0.1% (20 g, 45 g, 50 g) [contains benzyl alcohol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F230458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1050427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Apply to dry skin (wait at least 15-30 minutes to apply after cleansing); avoid contact with eyes, mucous membranes, mouth, or open wounds",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1050426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acne vulgaris, photodamaged skin, and some skin cancers",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F230514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Tretinoin may be confused with ISOtretinoin, Tenormin&reg;, triamcinolone, trientine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Renova [U.S., Canada] may be confused with Remov brand name for nimesulide [Italy]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F230512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: erythema, excessive dryness, hyper-/hypopigmentation, initial acne flare-up, photosensitivity, pruritus, scaling of the skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Blistering, edema, stinging",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1050431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tretinoin or any component; sunburn",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1050418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with eczema",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1050417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid contact with abraded skin, mucous membranes, eyes, mouth, angles of the nose; avoid excessive exposure to sunlight or sunlamps",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F230502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F230467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Retinoic Acid Derivatives may diminish the therapeutic effect of Contraceptives (Progestins). Retinoic Acid Derivatives may decrease the serum concentration of Contraceptives (Progestins).  Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives.  Particularly, microdosed progesterone-only preparations may be inadequately effective.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1050434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid excessive intake of vitamin A",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F230469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F230480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral tretinoin is teratogenic and fetotoxic in rats at doses 1000 and 500 times the topical human dose, respectively. Tretinoin does not appear to be teratogenic when used topically since it is rapidly metabolized by the skin; however, there are rare reports of fetal defects. Use for acne only if benefit to mother outweighs potential risk to fetus. During pregnancy, do not use for palliation of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1050416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Keratinocytes in the sebaceous follicle become less adherent which allows for easy removal; inhibits microcomedone formation and eliminates lesions already present",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1050429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 2-3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: May require 6 weeks or longer",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1050430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Topical: Minimum absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In bile and urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1050423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/42/30372?source=see_link\">",
"      see \"Topical tretinoin (topical all trans retinoic acid): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs. Avoid washing face more frequently than 2-3 times/day; avoid using topical preparations with high alcoholic content during treatment period.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1050432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liquid preparation generally is more irritating",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Winston MH, Shalita AR, &ldquo;Acne Vulgaris, Pathogenesis and Treatment,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1991, 38(4):889-903.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/10/43171/abstract-text/1831256/pubmed\" id=\"1831256\" target=\"_blank\">",
"        1831256",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12857 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-71122602D8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_10_43171=[""].join("\n");
var outline_f42_10_43171=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230490\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230491\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050424\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050419\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230472\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230458\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050427\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050426\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230514\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230512\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050431\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050418\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050417\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230502\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230467\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050434\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230469\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230480\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050416\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050429\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050430\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050423\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050432\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12857\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12857|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1862?source=related_link\">",
"      Topical tretinoin (topical all trans retinoic acid): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/42/30372?source=related_link\">",
"      Topical tretinoin (topical all trans retinoic acid): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_10_43172="Chlorpheniramine and acetaminophen: Patient drug information";
var content_f42_10_43172=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Chlorpheniramine and acetaminophen: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/43/17077?source=see_link\">",
"     see \"Chlorpheniramine and acetaminophen: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F150017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Coricidin HBP&reg; Cold and Flu [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701777",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to chlorpheniramine, acetaminophen, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696680",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid other sources of acetaminophen. An overdose may cause problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an enlarged prostate, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you use other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid or limit drinking wine, beer, or mixed drinks to less than 3 drinks a day. Drinking too much alcohol may raise your chance of liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful if you have G6PD deficiency. Anemia may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694768",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take more than what your doctor told you to take. Liver problems may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is most useful if started before contact with the allergen. Take at least 1 to 3 hours before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12019 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-AFBC45AB80-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_10_43172=[""].join("\n");
var outline_f42_10_43172=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150017\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026930\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026929\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026934\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026935\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026937\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026932\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026933\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026938\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026939\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?16/43/17077?source=related_link\">",
"      Chlorpheniramine and acetaminophen: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_10_43173="Calcitonin in the prevention and treatment of osteoporosis";
var content_f42_10_43173=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Calcitonin in the prevention and treatment of osteoporosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/10/43173/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/10/43173/contributors\">",
"     Harold N Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/10/43173/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/10/43173/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/10/43173/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/10/43173/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/10/43173/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/10/43173/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoporosis is a disorder of bone characterized by reduced mineral density and bone mass. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3929?source=see_link\">",
"     \"Pathogenesis of osteoporosis\"",
"    </a>",
"    .) Multiple therapeutic regimens have been designed to prevent and treat osteoporosis in men and women by inhibiting bone resorption",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increasing bone formation. The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/9/28821?source=see_link\">",
"     calcitonin",
"    </a>",
"    in the prevention and treatment of osteoporosis will be reviewed here. We do not use calcitonin as first-line therapy because more effective drugs are available for prevention of bone loss and reduction of fracture risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREPARATIONS AND ROUTE OF ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/9/28821?source=see_link\">",
"     Calcitonin",
"    </a>",
"    is a peptide composed of 32 amino acids that binds to osteoclasts and inhibits bone resorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43173/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Calcitonins from many species are effective in humans, but salmon calcitonin is the one most widely used. It is highly potent in humans because of its high affinity (40 times that of human calcitonin) for the human calcitonin receptor and its slow rate of clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43173/abstract/1\">",
"     1",
"    </a>",
"    ]. The only other calcitonin used clinically is human calcitonin, which is less potent but also less antigenic than salmon calcitonin. Most clinical trials of calcitonin have used salmon calcitonin, but human calcitonin is as effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43173/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/9/28821?source=see_link\">",
"     Calcitonin",
"    </a>",
"    is available in the United States for administration by the subcutaneous, intramuscular, and intranasal routes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43173/abstract/1,4-9\">",
"     1,4-9",
"    </a>",
"    ]. The bioavailability of nasal salmon calcitonin is only about 25 percent that of intramuscular calcitonin; thus, the biological effect of 50 int. units of intramuscular salmon calcitonin is equivalent to that of 200 int. units of nasal salmon calcitonin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43173/abstract/10\">",
"     10",
"    </a>",
"    ]. There are also several other differences between the different preparations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The absorption of the nasal dose is delayed compared with the parenteral route [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/10/43173/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The administration of salmon",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/9/28821?source=see_link\">",
"       calcitonin",
"      </a>",
"      frequently is associated with side effects such as nausea, vomiting, and flushing; these side effects are much less common with the nasal route [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/10/43173/abstract/1,11\">",
"       1,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nasal salmon",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/9/28821?source=see_link\">",
"       calcitonin",
"      </a>",
"      may provide more effective analgesia than parenteral salmon calcitonin (see below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the convenience and freedom from side effects make nasal salmon",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/9/28821?source=see_link\">",
"     calcitonin",
"    </a>",
"    the preferred route of administration in patients who can tolerate and cooperate with intranasal administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6679777\">",
"    <span class=\"h2\">",
"     Osteoporosis prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The perimenopausal acceleration of bone loss is due to increased bone resorption. This has led to extensive studies of the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/9/28821?source=see_link\">",
"     calcitonin",
"    </a>",
"    in preventing postmenopausal bone loss, since it inhibits bone resorption. In one study, for example, 52 postmenopausal women were randomly assigned to treatment with either 100 int. units nasal salmon calcitonin or placebo; all subjects received calcium supplementation. Over two years, mean spinal bone mineral density (BMD) increased by 2.5 percent in the calcitonin group and decreased by 5.7 percent in the placebo group (",
"    <a class=\"graphic graphic_figure graphicRef59085 \" href=\"mobipreview.htm?25/1/25629\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43173/abstract/5\">",
"     5",
"    </a>",
"    ]. In comparison, whole body and forearm BMD did not differ between the placebo group and the calcitonin group. Other studies have shown similar results using both human [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43173/abstract/3\">",
"     3",
"    </a>",
"    ] and salmon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43173/abstract/6,12\">",
"     6,12",
"    </a>",
"    ] calcitonin by both the subcutaneous and intranasal routes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43173/abstract/1\">",
"     1",
"    </a>",
"    ]. In a two-year extension study of a randomized trial, nasal calcitonin maintained efficacy in preventing perimenopausal bone loss at the lumbar spine after as long as five years of continuous use (",
"    <a class=\"graphic graphic_figure graphicRef80875 \" href=\"mobipreview.htm?21/43/22205\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43173/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Osteoporosis treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is also evidence that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/9/28821?source=see_link\">",
"     calcitonin",
"    </a>",
"    is effective in the treatment of established osteoporosis. In one study of calcitonin in osteoporosis, 208 elderly osteopenic women were treated with calcium and either intranasal placebo, 50, 100, or 200 int. units of salmon calcitonin daily for two years. Mean spine BMD was increased by salmon calcitonin in a dose-dependent fashion, with a maximum effect at 200 int. units daily. Salmon calcitonin was also associated with a significantly lower fracture rate than placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43173/abstract/7\">",
"     7",
"    </a>",
"    ], a finding that has been confirmed by others (",
"    <a class=\"graphic graphic_figure graphicRef73907 \" href=\"mobipreview.htm?18/36/19021\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43173/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/9/28821?source=see_link\">",
"     calcitonin",
"    </a>",
"    for treatment of osteoporosis was a five-year trial in 1255 women with a lumbar spine T score of &lt;-2 and at least one vertebral fracture who were randomly assigned to either placebo or 100, 200, or 400 units of intranasal calcitonin per day (",
"    <a class=\"graphic graphic_figure graphicRef79619 \" href=\"mobipreview.htm?24/55/25470\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43173/abstract/14\">",
"     14",
"    </a>",
"    ]. There was a small increase in spine BMD (1 to 1.5 percent) in all groups. The risk of vertebral fracture was significantly lower than placebo only in the group taking 200 int. units per day, and the risk of nonvertebral fractures was significantly lower than placebo only in the group taking 100 int. units per day. Thus, the beneficial effect of nasal calcitonin on vertebral BMD and vertebral fracture risk was small and inconsistent.",
"   </p>",
"   <p>",
"    Bone histology is normal in subjects with osteoporosis treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/9/28821?source=see_link\">",
"     calcitonin",
"    </a>",
"    for two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43173/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are conflicting data on the effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/9/28821?source=see_link\">",
"     calcitonin",
"    </a>",
"    on sites other than the spine. Two studies found that calcitonin had no beneficial effect outside the spine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43173/abstract/7,12\">",
"     7,12",
"    </a>",
"    ], but other studies have shown improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43173/abstract/9,13,15-17\">",
"     9,13,15-17",
"    </a>",
"    ]. The above studies were mostly conducted in postmenopausal women.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/9/28821?source=see_link\">",
"     Calcitonin",
"    </a>",
"    is less effective for the treatment of postmenopausal osteoporosis than bisphosphonates. As an example, in a placebo-controlled, randomized trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    (10 mg per day) versus intranasal calcitonin (200 int. units per day) for 12 months, BMD of the hip and spine increased significantly more in the alendronate group than in the calcitonin group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43173/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Bone pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/9/28821?source=see_link\">",
"     Calcitonin",
"    </a>",
"    has a beneficial short-term effect on acute pain relief in patients who have sustained a vertebral fracture, as illustrated by the findings of a meta-analysis of 10 trials comparing calcitonin (nasal or parenteral) with placebo in patients with acute (onset &lt;10 days) or chronic (&gt;3 months) pain due to an osteoporotic compression fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43173/abstract/19\">",
"     19",
"    </a>",
"    ]. After one week of treatment, there was a significant improvement in pain score at rest (three trials, 196 patients) and with activity (four trials, 228 patients) in patients receiving calcitonin for acute pain (mean difference for resting pain -3.39, 95% CI -4.02 to -2.76, using a visual analog scale from 0 to 10). There was also significant improvement in pain score two, three, and four weeks after starting treatment. In contrast, calcitonin was not effective for patients with chronic pain. The meta-analysis was limited by the small number of patients and heterogeneity of results. There was insufficient data to assess differences related to the route of calcitonin administration.",
"   </p>",
"   <p>",
"    The benefits of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/9/28821?source=see_link\">",
"     calcitonin",
"    </a>",
"    on bone pain have been noted with use of either parental or nasal calcitonin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43173/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. In one study, nasal calcitonin relieved pain more effectively than parenteral calcitonin (",
"    <a class=\"graphic graphic_figure graphicRef60350 \" href=\"mobipreview.htm?22/47/23293\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43173/abstract/21\">",
"     21",
"    </a>",
"    ], but this observation needs confirmation.",
"   </p>",
"   <p>",
"    The ability to relieve pain may represent a truly distinguishing feature from other drugs used in the treatment of osteoporosis. Thus,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/9/28821?source=see_link\">",
"     calcitonin",
"    </a>",
"    may be the antiresorptive agent of choice in patients with pain from an acute osteoporotic fracture. Why pain relief occurs is not well understood; one possibility is a rise in endorphin levels induced by calcitonin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43173/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CONCERNS ABOUT THE USE OF CALCITONIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main concern about treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/9/28821?source=see_link\">",
"     calcitonin",
"    </a>",
"    is that more effective drugs (eg, bisphosphonates) are available for the prevention of bone loss and reduction of fracture risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43173/abstract/18,24,25\">",
"     18,24,25",
"    </a>",
"    ]. For this reason, we typically do not use calcitonin to treat osteoporosis, unless pain from an acute osteoporotic fracture is a problem. In this setting, calcitonin could be used in the short-term (until the pain has abated), and then the patient should be switched to an osteoporosis therapy that more effectively prevents subsequent fracture. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another concern is that the long-term use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/9/28821?source=see_link\">",
"     calcitonin",
"    </a>",
"    for osteoporosis has been associated with an increase in cancer rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43173/abstract/26\">",
"     26",
"    </a>",
"    ]. The European Medicines Agency reviewed data provided by the companies who manufacture calcitonin-containing medications, post-marketing safety data, and randomized trials and reported that a higher proportion of patients treated with calcitonin-containing medications for long periods of time developed cancer (various types including basal cell carcinoma) than patients taking placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43173/abstract/26\">",
"     26",
"    </a>",
"    ]. The increases in cancer rates were small and ranged from 0.7 to 2.4 percent for oral and nasal formulations, respectively. Because calcitonin is a weak osteoporosis drug, and there are more effective drugs to prevent bone loss and fracture, the European Medicines Agency concluded that the benefits of calcitonin do not outweigh the risks for the treatment of osteoporosis. However, no formal action by the EMA has taken place.",
"   </p>",
"   <p>",
"    A US Food and Drug Administration advisory panel initiated an internal review of all",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/9/28821?source=see_link\">",
"     calcitonin",
"    </a>",
"    trials after a safety signal for prostate cancer was noted in clinical trials of oral calcitonin, a formulation under development. In a meta-analysis of 20 trials (17 nasal spray, 3 oral), the risk of malignancy was higher in the calcitonin treated group (4.2 verus 2.9 percent with placebo, OR 1.4, 95% CI 1.1-1.7) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43173/abstract/27\">",
"     27",
"    </a>",
"    ]. The meta-analysis was limited by heterogeneity and by high dropout rates in some of the trials, making it difficult to establish direct causality. Nevertheless, the FDA advisory panel similarly concluded that the potential risks of calcitonin do not outweigh its benefits as an osteoporosis drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43173/abstract/27\">",
"     27",
"    </a>",
"    ]. If there is a need for calcitonin, its use should be limited to &lt;6 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/9/28821?source=see_link\">",
"       Calcitonin",
"      </a>",
"      increases spine bone density and may decrease vertebral fracture risk. There are conflicting data on the effect of calcitonin on sites other than the spine. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Osteoporosis treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do",
"      <strong>",
"       not",
"      </strong>",
"      use",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/9/28821?source=see_link\">",
"       calcitonin",
"      </a>",
"      as first-line therapy because more effective drugs are available for prevention of bone loss and reduction of fracture risk. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link\">",
"       \"Overview of the management of osteoporosis in postmenopausal women\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/9/28821?source=see_link\">",
"       Calcitonin",
"      </a>",
"      has a beneficial short-term effect on acute pain relief in patients who have sustained a vertebral fracture. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Bone pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We occasionally administer",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/9/28821?source=see_link\">",
"       calcitonin",
"      </a>",
"      if pain from an acute osteoporotic fracture is a prominent problem, and then switch to other agents such as bisphosphonates once the pain has abated. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link\">",
"       \"Bisphosphonates in the management of osteoporosis in postmenopausal women\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43173/abstract/1\">",
"      Carstens JH Jr, Feinblatt JD. Future horizons for calcitonin: a U.S. perspective. Calcif Tissue Int 1991; 49 Suppl 2:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43173/abstract/2\">",
"      Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998; 338:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43173/abstract/3\">",
"      MacIntyre I, Stevenson JC, Whitehead MI, et al. Calcitonin for prevention of postmenopausal bone loss. Lancet 1988; 1:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43173/abstract/4\">",
"      Reginster JY, Meurmans L, Deroisy R, et al. A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium. Eur J Clin Invest 1994; 24:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43173/abstract/5\">",
"      Overgaard K, Riis BJ, Christiansen C, Hansen MA. Effect of salcatonin given intranasally on early postmenopausal bone loss. BMJ 1989; 299:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43173/abstract/6\">",
"      Gennari C, Agnusdei D, Montagnani M, et al. An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss. Calcif Tissue Int 1992; 50:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43173/abstract/7\">",
"      Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992; 305:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43173/abstract/8\">",
"      Overgaard K, Hansen MA, Nielsen VA, et al. Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment. Am J Med 1990; 89:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43173/abstract/9\">",
"      Overgaard K, Riis BJ, Christiansen C, et al. Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol (Oxf) 1989; 30:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43173/abstract/10\">",
"      Overgaard K, Agnusdei D, Hansen MA, et al. Dose-response bioactivity and bioavailability of salmon calcitonin in premenopausal and postmenopausal women. J Clin Endocrinol Metab 1991; 72:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43173/abstract/11\">",
"      Reginster JY, Franchimont P. Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection. Clin Exp Rheumatol 1985; 3:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43173/abstract/12\">",
"      Civitelli R, Gonnelli S, Zacchei F, et al. Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. J Clin Invest 1988; 82:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43173/abstract/13\">",
"      Rico H, Revilla M, Hern&aacute;ndez ER, et al. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study. Calcif Tissue Int 1995; 56:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43173/abstract/14\">",
"      Chesnut CH 3rd, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000; 109:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43173/abstract/15\">",
"      Gruber, HE, Ivey, JL, Baylink, DJ, et al. Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism 1984; 33:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43173/abstract/16\">",
"      Sileghem A, Geusens P, Dequeker J. Intranasal calcitonin for the prevention of bone erosion and bone loss in rheumatoid arthritis. Ann Rheum Dis 1992; 51:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43173/abstract/17\">",
"      Mazzuoli GF, Passeri M, Gennari C, et al. Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study. Calcif Tissue Int 1986; 38:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43173/abstract/18\">",
"      Downs RW Jr, Bell NH, Ettinger MP, et al. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab 2000; 85:1783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43173/abstract/19\">",
"      Knopp-Sihota JA, Newburn-Cook CV, Homik J, et al. Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: a systematic review and meta-analysis. Osteoporos Int 2012; 23:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43173/abstract/20\">",
"      Lyritis GP, Tsakalakos N, Magiasis B, et al. Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double-blind placebo-controlled clinical study. Calcif Tissue Int 1991; 49:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43173/abstract/21\">",
"      Gennari C, Agnusdei D, Camporeale A. Use of calcitonin in the treatment of bone pain associated with osteoporosis. Calcif Tissue Int 1991; 49 Suppl 2:S9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43173/abstract/22\">",
"      Lyritis GP, Ioannidis GV, Karachalios T, et al. Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study. Clin J Pain 1999; 15:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43173/abstract/23\">",
"      Lyritis GP, Paspati I, Karachalios T, et al. Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study. Acta Orthop Scand Suppl 1997; 275:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43173/abstract/24\">",
"      Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992; 117:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43173/abstract/25\">",
"      Watts, NB, Harris, ST, Genant, HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323:73.",
"     </a>",
"    </li>",
"    <li>",
"     European Medicines Agency recommends limiting long-term use of calcitonin medicines file://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2012/07/human_pha_detail_000065.jsp&amp;mid=WC0b01ac058001d126 (Accessed on October 17, 2012).",
"    </li>",
"    <li>",
"     Background Document for Meeting of Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee. file://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM341779.pdf (Accessed on March 06, 2013).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2025 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-043A92644E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_10_43173=[""].join("\n");
var outline_f42_10_43173=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREPARATIONS AND ROUTE OF ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6679777\">",
"      Osteoporosis prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Osteoporosis treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Bone pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CONCERNS ABOUT THE USE OF CALCITONIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2025\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2025|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/1/25629\" title=\"figure 1\">",
"      CT prevents osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/43/22205\" title=\"figure 2\">",
"      Prolonged benefit of nasal CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/36/19021\" title=\"figure 3\">",
"      CT treatment of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/55/25470\" title=\"figure 4\">",
"      Calcitonin BMD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/47/23293\" title=\"figure 5\">",
"      Nasal vs intramuscular calcitonin bone pain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=related_link\">",
"      Bisphosphonates in the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3929?source=related_link\">",
"      Pathogenesis of osteoporosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_10_43174="Carboplatin: Pediatric drug information";
var content_f42_10_43174=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Carboplatin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"    see \"Carboplatin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/18/40228?source=see_link\">",
"    see \"Carboplatin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F146189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Carboplatin Injection;",
"     </li>",
"     <li>",
"      Carboplatin Injection - LIQ IV",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1045745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Alkylating Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Platinum Analog",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1045738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"      see \"Carboplatin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V. (refer to individual protocols):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"     <b>",
"      Note:",
"     </b>",
"     Some protocols calculate dose on the basis of body weight rather than body surface area in infants and young children (&lt;3 years or &le;12 kg):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      BSA-directed dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Bone marrow transplant preparative regimen:",
"     </b>",
"     Children: 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 3 days (Gilheeney, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Glioma",
"     </b>",
"     (Packer, 1997): Infants &ge;3 months, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Induction: 175 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly for 4 weeks every 6 weeks (2-week recovery period between courses) in combination with vincristine for 2 cycles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance: 175 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     weekly for 4 weeks, with a 3-week recovery period between courses in combination with vincristine for &le;12 cycles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Sarcomas:",
"     </b>",
"     Ewing&rsquo;s sarcoma, osteosarcoma: Children and Adolescents: 400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 2 days every 21 days (in combination with ifosfamide and etoposide) (Van Winkle, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Alternative carboplatin dosing:",
"     </b>",
"     Some investigators calculate pediatric carboplatin doses using a modified Calvert formula: Dosing based on target AUC (modified Calvert formula for use in children): Total dose (mg) = [Target AUC (mg/mL/minute)] x [GFR (mL/minute) + (0.36 x body weight in kilograms)];",
"     <b>",
"      Note:",
"     </b>",
"     GFR in this equation is an exact measured value (eg, &ldquo;raw&rdquo; in mL/minute)",
"     <b>",
"      not",
"     </b>",
"     corrected for BSA (ie,",
"     <b>",
"      not",
"     </b>",
"     mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Calvert formula was based on using chromic edetate (",
"     <sup>",
"      51",
"     </sup>",
"     Cr-EDTA) plasma clearance to establish GFR. Some clinicians have recommended that methods for estimating Cl",
"     <sub>",
"      cr",
"     </sub>",
"     not be substituted for GFR since carboplatin dosing based on such estimates may not be predictive.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     The dose of carboplatin calculated is TOTAL mg DOSE not mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses for adults are commonly calculated by the target AUC using the Calvert formula, where",
"     <b>",
"      Total dose (mg) = Target AUC x (GFR + 25)",
"     </b>",
"     . If estimating glomerular filtration rate (GFR) instead of measuring GFR, the Food and Drug Administration (FDA) recommends considering capping estimated GFR at a maximum of 125 mL/minute to avoid potential toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Ovarian cancer, advanced:",
"     </b>",
"     I.V.: 360 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 4 weeks (as a single agent)",
"     <b>",
"      or",
"     </b>",
"     300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 4 weeks (in combination  with cyclophosphamide)",
"     <b>",
"      or",
"     </b>",
"     target AUC 4-6 (in previously treated patients)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for toxicity:",
"     </b>",
"     Platelets &lt;50,000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     or ANC &lt;500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Administer 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Dose determination with Calvert formula uses GFR and, therefore, inherently adjusts for renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     The manufacturer&rsquo;s labeling recommends the following dosage adjustment guidelines for single-agent therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Baseline Cl",
"     <sub>",
"      cr",
"     </sub>",
"     41-59 mL/minute: Initiate at 250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     and adjust subsequent doses based on bone marrow toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Baseline Cl",
"     <sub>",
"      cr",
"     </sub>",
"     16-40 mL/minute: Initiate at 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     and adjust subsequent doses based on bone marrow toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Baseline Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;15 mL/minute: No guidelines are available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     The following dosage adjustments have been used by some clinicians (for dosing based on mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Hemodialysis: Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Continuous ambulatory peritoneal dialysis (CAPD): Administer 25% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Dosage adjustments are not provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F146167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 10 mg/mL (5 mL, 15 mL, 45 mL, 60 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F146152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1045749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Administer by I.V. intermittent infusion over 15-60 minutes although some protocols may require infusions up to 24 hours; reconstituted carboplatin 10 mg/mL should be further diluted to a final concentration of 0.5-2 mg/mL with D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS for administration. When administered as sequential infusions, taxane derivatives (docetaxel, paclitaxel) should be administered before platinum derivatives to limit myelosuppression and to enhance efficacy. Needles or I.V. administration sets that contain aluminum should not be used in the preparation or administration of carboplatin; aluminum can react with carboplatin resulting in precipitate formation and loss of potency.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F146245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amifostine, anidulafungin, aztreonam, caspofungin, cefepime, cladribine, doripenem, doxorubicin liposomal, etoposide phosphate, filgrastim, fludarabine, gemcitabine, granisetron, linezolid, melphalan, micafungin, ondansetron, oxaliplatin, paclitaxel, palonosetron, pemetrexed, piperacillin/tazobactam, propofol, sargramostim, teniposide, thiotepa, topotecan, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1045741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store intact vials at room temperature of 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light. Further dilution to a concentration as low as 0.5 mg/mL is stable at room temperature (25&deg;C) for 8 hours in NS; stable at room temperature or under refrigeration for at least 9 days in D",
"     <sub>",
"      5",
"     </sub>",
"     W, although the manufacturer states to use within 8 hours due to lack of preservative.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Powder for reconstitution: Reconstituted to a final concentration of 10 mg/mL is stable for 5 days at room temperature (25&deg;C).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution for injection: Multidose vials are stable for up to 14 days after opening when stored at room temperature.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1045748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of advanced ovarian carcinoma (FDA approved in adults); has also been used in the treatment of bladder cancer, breast cancer (metastatic), central nervous system tumors, cervical cancer (recurrent or metastatic), endometrial cancer, esophageal cancer, head and neck cancer, Hodgkin lymphoma (relapsed or refractory), malignant pleural mesothelioma, melanoma (advanced or metastatic), Merkel cell carcinoma, neuroendocrine tumors (adrenal gland and carcinoid tumors), non-Hodgkin lymphomas (relapsed or refractory), nonsmall cell lung cancer, prostate cancer, sarcomas (Ewing&rsquo;s sarcoma, osteosarcoma), small cell lung cancer, testicular cancer, thymic malignancies, unknown primary adenocarcinoma, Wilm&rsquo;s tumor, and as a conditioning regimen prior to hematopoietic stem cell transplantation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F146248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       CARBOplatin may be confused with CISplatin, oxaliplatin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Paraplatin&reg; may be confused with Platinol&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F146244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Neurotoxicity, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, diarrhea, stomatitis/mucositis, nausea, taste dysgeusia, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, bleeding, hemorrhagic complications, leukopenia, myelosuppression (dose related and dose limiting; nadir at ~21 days with single-agent therapy), neutropenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, AST increased, bilirubin increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Peripheral neuropathy, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Visual disturbance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Ototoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased, creatinine clearance decreased, creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity/allergic reaction, infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylactic reaction, bronchospasm, cardiac failure, cerebrovascular accident, dehydration, embolism, erythema, hemolytic anemia (acute), hemolytic uremic syndrome (HUS), hyper-/hypotension, injection site reactions (pain, redness, swelling), limb ischemia (acute), necrosis (associated with extravasation), neutropenic fever, pruritus, rash, secondary malignancies, urticaria, vision loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1045752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to carboplatin, cisplatin, any component, other platinum-containing compounds, or mannitol; severe bone marrow suppression or excessive bleeding",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1045737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause severe, dose-limiting, dose-related bone marrow suppression",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; patients who have received prior myelosuppressive therapy and patients with renal dysfunction are at increased risk for bone marrow suppression; anemia may be cumulative and require transfusion; reduce dosage in patients with bone marrow suppression; cycles should be delayed until WBC and platelet counts have recovered. May cause severe vomiting",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; vomiting is dose-related and can be more severe in patients who previously received emetogenic therapy. High doses have resulted in severe abnormalities of liver function tests; reduce dosage in patients with impaired renal function (creatinine clearance values &lt;60 mL/minute). Clinically significant hearing loss has been reported to occur in pediatric patients when carboplatin was administered at higher than recommended doses in combination with other ototoxic agents (eg, aminoglycosides). Loss of vision (reversible) has been reported with higher than recommended doses. Peripheral neuropathy occurs infrequently; the incidence of peripheral neuropathy is increased in patients who have previously received cisplatin treatment. When administered as sequential infusions, taxane derivatives (docetaxel, paclitaxel) should be administered before the platinum derivatives (carboplatin, cisplatin) to limit myelosuppression and to enhance efficacy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     When calculating the carboplatin dose using the Calvert formula and an estimated glomerular filtration rate (GFR), the laboratory method used to measure serum creatinine may impact dosing. Compared to other methods, standardized Isotope Dilution Mass Spectrometry (IDMS) may underestimate serum creatinine values in patients with low creatinine values (eg, &le;0.7 mg/dL) and therefore may overestimate GFR in patients with normal renal function. This may result in higher calculated carboplatin doses and increased toxicities. If using IDMS, the Food and Drug Administration (FDA) recommends that clinicians consider capping estimated GFR at a maximum of 125 mL/minute to avoid potential toxicity.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Should be administered under the supervision of an experienced cancer chemotherapy physician",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1045736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . When carboplatin is dosed using AUC as the endpoint, note that the calculated dose is the dose administered, not the dose based on body surface area; anaphylactic-like reactions can occur within minutes of administration",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; risk for reaction increased in patients previously exposed to platinum therapy. Epinephrine, corticosteroids, and antihistamines have been used to treat symptoms. The risk of allergic reactions (including anaphylaxis) is increased in patients previously exposed to platinum therapy. Skin testing and desensitization protocols have been reported (Confina-Cohen, 2005; Lee, 2004; Markman, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F146161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: May enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bexarotene (Systemic): CARBOplatin may increase the serum concentration of Bexarotene (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: May enhance the adverse/toxic effect of CARBOplatin. Management: Concurrent sorafenib with carboplatin and paclitaxel in patients with squamous cell lung cancer is contraindicated.  Use in other settings is not specifically contraindicated but should be approached with added caution.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Taxane Derivatives: Platinum Derivatives may enhance the myelosuppressive effect of Taxane Derivatives. Administer Taxane derivative before Platinum derivative when given as sequential infusions to limit toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: Platinum Derivatives may enhance the adverse/toxic effect of Topotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F146163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10923584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Embryotoxicity and teratogenicity have been observed in animal reproduction studies. May cause fetal harm if administered during pregnancy. Women of childbearing potential should avoid becoming pregnant during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1045744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelet count, serum electrolytes, urinalysis, serum creatinine and BUN, creatinine clearance, liver function tests",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1045735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Platination of DNA results in possible cross-linking and interference with the function of DNA",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1045751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 16 L (based on a dose of 300-500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 0%; however, platinum (from carboplatin) is 30% protein bound",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Terminal: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;60 mL/minute: Carboplatin: 2.5-5.9 hours (based on a dose of 300-500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ); platinum (from carboplatin): &ge;5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (~70% as carboplatin within 24 hours; 3% to 5% as platinum within 1-4 days)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abramson DH, Frank CM, and Dunkel IJ, &ldquo;A Phase I/II Study of Subconjunctival Carboplatin for Intraocular Retinoblastoma,&rdquo;",
"      <i>",
"       Ophthalmology",
"      </i>",
"      , 1999, 106(10):1947-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/10/43174/abstract-text/10519590/pubmed\" id=\"10519590\" target=\"_blank\">",
"        10519590",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cairo MS, &ldquo;The Use of Ifosfamide, Carboplatin, and Etoposide in Children With Solid Tumors,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 1995, 22(3 Suppl 7):23-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/10/43174/abstract-text/7610395/pubmed\" id=\"7610395\" target=\"_blank\">",
"        7610395",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Calvert AH, Newell DR, Grumbell LA, et al, &ldquo;Carboplatin Dosage: Prospective Evaluation of a Simple Formula Based on Renal Function,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1989, 7(11):1748-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/10/43174/abstract-text/2681557/pubmed\" id=\"2681557\" target=\"_blank\">",
"        2681557",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cheung Y-W, Cradock JC, Vishnuvajjala BR, et al, \"Stability of Cisplatin, Iproplatin, Carboplatin, and Tetraplatin in Commonly Used Intravenous Solutions,\"",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1987, 44:124-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/10/43174/abstract-text/3548341/pubmed\" id=\"3548341\" target=\"_blank\">",
"        3548341",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Confino-Cohen R, Fishman A, Altaras M, et al, &ldquo;Successful Carboplatin Desensitization in Patients With Proven Carboplatin Allergy,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2005, 104(3):640-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/10/43174/abstract-text/15977213/pubmed\" id=\"15977213\" target=\"_blank\">",
"        15977213",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gilheeney SW, Khakoo Y, Souweidane M, et al, \"Thiotepa/Topotecan/Carboplatin With Autologous Stem Cell Rescue in Recurrent/Refractory/Poor Prognosis Pediatric Malignancies of the Central Nervous System,\"",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2010, 54(4):591-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/10/43174/abstract-text/19998470/pubmed\" id=\"19998470\" target=\"_blank\">",
"        19998470",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee CW, Matulonis UA, and Castells MC, &ldquo;Carboplatin Hypersensitivity: A 6-h 12-Step Protocol Effective in 35 Desensitizations in Patients With Gynecological Malignancies and Mast Cell/IgE-Mediated Reactions,&rdquo;",
"      <i>",
"       Gynecol Oncol",
"      </i>",
"      , 2004, 95(2):370-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/10/43174/abstract-text/15491759/pubmed\" id=\"15491759\" target=\"_blank\">",
"        15491759",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lovett D, Kelsen D, Eisenberger M, et al, &ldquo;A Phase II Trial of Carboplatin and Vinblastine in the Treatment of Advanced Squamous Cell Carcinoma of the Esophagus,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 1991, 67(2):354-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/10/43174/abstract-text/1985729/pubmed\" id=\"1985729\" target=\"_blank\">",
"        1985729",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Markman M, Zanotti K, Peterson G, et al, &ldquo;Expanded Experience With an Intradermal Skin Test to Predict for the Presence or Absence of Carboplatin Hypersensitivity,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2003, 21(24):4611-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/10/43174/abstract-text/14673050/pubmed\" id=\"14673050\" target=\"_blank\">",
"        14673050",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Newell DR, Pearson AD, Balmanno K, et al, &ldquo;Carboplatin Pharmacokinetics in Children: The Development of a Pediatric Dosing Formula. The United Kingdom Children's Cancer Study Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1993, 11(12):2314-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/10/43174/abstract-text/8246021/pubmed\" id=\"8246021\" target=\"_blank\">",
"        8246021",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Packer RJ, Ater J, Allen J, et al, &ldquo;Carboplatin and Vincristine Chemotherapy for Children With Newly Diagnosed Progressive Low-Grade Gliomas,&rdquo;",
"      <i>",
"       J Neurosurg",
"      </i>",
"      , 1997, 86(5):747-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/10/43174/abstract-text/9126887/pubmed\" id=\"9126887\" target=\"_blank\">",
"        9126887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pearson AD, Pinkerton CR, Lewis IJ, et al, \"High-Dose Rapid and Standard Induction Chemotherapy for Patients Aged Over 1 Year With Stage 4 Neuroblastoma: A Randomised Trial,\"",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2008, 9(3):247-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/10/43174/abstract-text/18308250/pubmed\" id=\"18308250\" target=\"_blank\">",
"        18308250",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Winkle P, Angiolillo A, Krailo M, et al, &ldquo;Ifosfamide, Carboplatin, and Etoposide (ICE) Reinduction Chemotherapy in a Large Cohort of Children and Adolescents With Recurrent/Refractory Sarcoma: The Children&rsquo;s Cancer Group (CCG) Experience,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2005, 44(4):338-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/10/43174/abstract-text/15503297/pubmed\" id=\"15503297\" target=\"_blank\">",
"        15503297",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zeltzer PM, Epport K, Nelson MD Jr, et al, &ldquo;Prolonged Response to Carboplatin in an Infant With Brain Stem Glioma,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 1991, 67(1):43-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/10/43174/abstract-text/1985722/pubmed\" id=\"1985722\" target=\"_blank\">",
"        1985722",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13117 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-13CD9D8202-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_10_43174=[""].join("\n");
var outline_f42_10_43174=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708661\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146189\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045745\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045738\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146167\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146152\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045749\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146245\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045741\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045748\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146248\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146244\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045752\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045737\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045736\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298973\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146161\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146163\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10923584\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045744\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045735\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045751\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13117\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13117|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=related_link\">",
"      Carboplatin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/18/40228?source=related_link\">",
"      Carboplatin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_10_43175="Fetal membranes: Anatomy and biochemistry";
var content_f42_10_43175=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fetal membranes: Anatomy and biochemistry",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/10/43175/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/10/43175/contributors\">",
"     Seth Guller, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/10/43175/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/10/43175/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/10/43175/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/10/43175/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/10/43175/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The membranous structure that surrounds the developing fetus and forms the amniotic cavity is derived from fetal tissue and is composed of two layers: the amnion (inner layer) and the chorion (outer layer). The amnion is a translucent structure adjacent to the amniotic fluid, which provides necessary nutrients to the amnion cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/1\">",
"     1",
"    </a>",
"    ]. The chorion is a more opaque membrane that is attached to the decidua (ie, maternal tissue that lines the uterus during pregnancy). The amnion and chorion are separated by the exocelomic cavity until approximately three months gestation, when they become fused. Intact, healthy fetal membranes are required for an optimal pregnancy outcome.",
"   </p>",
"   <p>",
"    Extracellular matrix (ECM) proteins synthesized by several cell types within the amnion and chorion confer both strength and elasticity to the fetal membranes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/2\">",
"     2",
"    </a>",
"    ]. During or just prior to labor, the breakdown of these proteins is regulated by matrix metalloproteinases (MMPs) and their inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/3\">",
"     3",
"    </a>",
"    ]. These biochemical changes in the fetal membranes reduce their integrity and elasticity, make them more vulnerable to rupture, and may contribute to the initiation of parturition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inspection of the fetal membranes following delivery reveals amnion that is mildly adherent to the fetal side of the chorion. Small amounts of maternal decidual tissue can be observed attached to the outer, maternal side of the chorion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cellular anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal membranes, as the name implies, are genetically identical to the fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/1\">",
"     1",
"    </a>",
"    ]. The membranes contain many cell types, but are avascular and without nerve cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/4\">",
"     4",
"    </a>",
"    ]. The cells appear columnar where the membranes are attached to the placenta, but become more flattened or cuboidal adjacent to the decidua [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Amnion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The amnion is loosely composed of three layers of cells:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The inner compact layer, which varies greatly in thickness, consists of epithelial cells attached to a basement membrane (",
"      <a class=\"graphic graphic_figure graphicRef65503 graphicRef75084 \" href=\"mobipreview.htm?18/40/19081\">",
"       figure 1A-B",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The mesenchymal cell layer, the thickest of the amnion layers, is comprised of dispersedly distributed fibroblasts.",
"     </li>",
"     <li>",
"      The outer intermediate layer, also known as the spongy layer or zona spongiosa, is adjacent to the chorion and can swell to facilitate sliding of the amnion across the chorion. In this way, the intermediate layer provides a cushioning mechanism to reduce stress applied to the fetal membranes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/2,3,5\">",
"       2,3,5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Chorion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chorion is composed of two layers: an outer reticular and an inner cytotrophoblast layer. The reticular layer is structurally similar to the amnionic mesenchyme, and is predominately made up of fibroblasts and macrophages (",
"    <a class=\"graphic graphic_figure graphicRef65503 graphicRef75084 \" href=\"mobipreview.htm?18/40/19081\">",
"     figure 1A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. A basal lamina or pseudobasement membrane separates the reticular layer from the underlying cytotrophoblast layer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/2,4\">",
"     2,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cytotrophoblast cells of the chorion, similar to all other trophoblasts found outside of the placental villus, are known as extravillous trophoblasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. They vary in appearance from small, round, proliferating cells to large, polygonal, well-differentiated cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. Although thicker than the amnion, the chorion plays only a minor role in maintaining the tensile strength of the fetal membranes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     BIOCHEMISTRY OF FETAL MEMBRANE STRENGTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal membrane strength is influenced by a number of proteins including extracellular membrane proteins, metalloproteinases, and tissue inhibitors of metalloproteinases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Extracellular membrane proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The strength and integrity of fetal membranes derive from extracellular membrane proteins including collagens, fibronectin, and laminins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Collagens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The collagens are a large family of triple helical ECM proteins that interact with other components of the extracellular matrix [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/6\">",
"     6",
"    </a>",
"    ]. Interstitial collagens (types I and III) located primarily in the compact layer of amnion play a critical role in maintaining the integrity of the fetal membranes and are the primary regulators of their tensile strength [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/2,3,5\">",
"     2,3,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cellular source of compact layer collagens is uncertain. In one report, mesenchymal cells expressed significantly higher levels of collagens I and III than did epithelial cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/7\">",
"     7",
"    </a>",
"    ]. However, another study using fetal membrane organ cultures found that both epithelial and mesenchymal cells produce interstitial collagens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/8\">",
"     8",
"    </a>",
"    ]. The epithelial cell contribution to collagen synthesis is likely to be dependent upon gestational age, as the density of mesenchymal cells in the amnion decreases in the third trimester [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/7\">",
"     7",
"    </a>",
"    ]. Thus, both epithelial and mesenchymal cells appear to contribute to the pool of interstitial collagens in the compact layer.",
"   </p>",
"   <p>",
"    Type IV and VII collagens also make important contributions to the integrity of the fetal membranes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type IV collagen, a basement membrane protein, is a product of both the epithelial cells of the amnion and the pseudobasement membrane of the chorion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/7\">",
"       7",
"      </a>",
"      ]. This collagen provides a scaffolding on which to attach and assemble other components of the basement membrane, such as laminin and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      sulfate proteoglycan [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Type VII collagen is made by epithelial cells of the amnion. It stabilizes the fetal membranes by creating anchoring fibrils that link the basal lamina of the amnion to the extracellular matrix components [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/10,11\">",
"       10,11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other compact layer collagens (eg, types V and VI) play a lesser role in maintaining fetal membrane strength [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Fibronectin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fibronectin that is present in basement membranes of the amnion and chorion is an oncofetal or fetal fibronectin (onfFN), a uniquely glycosylated molecule with a specific oncofetal epitope that is expressed by tumor cells and fetal tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. onfFN is thought to be a \"trophoblast glue\" that promotes cellular adhesion at uterine-placental and decidual-fetal membrane interfaces [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. It is released when the extracellular matrix of the",
"    <span class=\"nowrap\">",
"     chorionic/decidual",
"    </span>",
"    interface is disrupted prior to labor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinically, the determination of oncofetal fibronectin levels in the cervical and vaginal secretions of pregnant women may be a biochemical marker for the diagnosis and prediction of preterm labor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/51/15159?source=see_link\">",
"     \"Fetal fibronectin for prediction of preterm labor and delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Laminins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laminins interact with type VII collagen to stabilize fetal membranes. They anchor cells to the basement membrane and the basement membrane to the underlying layers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/10,11,18\">",
"     10,11,18",
"    </a>",
"    ]. Laminin 7, a novel laminin variant, has been found in fetal membranes associated with laminin 5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Matrix metalloproteinases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Matrix metalloproteases are a family of enzymes with varied substrate specificities that decrease membrane strength by increasing collagen degradation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/20\">",
"     20",
"    </a>",
"    ]. In situ hybridization and immunohistochemical analyses have identified MMP-2 (gelatinase A) and MMP-9 (gelatinase B) mRNA, protein, and activity in amnion epithelial cells and chorionic trophoblasts in fetal membranes after delivery and in explant cultures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. MMP-1 (collagenase-1) and MMP-8 (collagenase-2) hydrolyze triple helical regions of interstitial collagens (types I and III), which are subsequently degraded by MMP-9 and MMP-2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/3,20\">",
"     3,20",
"    </a>",
"    ]. MMP-2 and MMP-9 also degrade type IV collagen, proteoglycans, and fibronectin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Tissue inhibitors of metalloproteinases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissue inhibitors of MMPs (TIMPs) bind to matrix metalloproteinases and shut down proteolysis, thereby helping to maintain membrane integrity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/3,20\">",
"     3,20",
"    </a>",
"    ]. In vivo and in vitro studies demonstrated TIMPs in amnion and chorion layers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Thus, cells above and below compact layer collagens secrete both MMPs capable of hydrolyzing interstitial collagens as well as inhibitors that block this process",
"    <span class=\"nowrap\">",
"     (",
"     <a class=\"graphic graphic_figure graphicRef65503 graphicRef75084 \" href=\"mobipreview.htm?18/40/19081\">",
"      figure 1A-B",
"     </a>",
"     ).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Antimicrobial activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection/inflammation",
"    impacts survival of the cells comprising the fetal membranes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/28\">",
"     28",
"    </a>",
"    ]. There is some evidence that the fetal membranes have antimicrobial activity, which may help protect them from rupture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Pattern recognition receptors (PRRs) in tissue are thought to note the presence of microorganisms and initiate a protective host response. The toll-like receptors (toll-like receptor-2 and -4) are a type of PRRs that are expressed on the amnion, particularly during labor and with histologic chorioamnionitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/31\">",
"     31",
"    </a>",
"    ]. These receptors may play a role in the antimicrobial activity of fetal membranes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     BIOCHEMISTRY OF FETAL MEMBRANE ELASTICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal membranes must have elastic properties to accommodate enlargement of the uterus resulting from increases in fetal size and amniotic fluid as pregnancy progresses. Elastic fibers consist of fibrillin-containing microfibrils that are cross-linked to elastin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/32\">",
"     32",
"    </a>",
"    ]. These microfibrils are abundantly expressed in the mesenchymal and compact layers of the amnion and the reticular and cytotrophoblast layers of the chorion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. Elastin is also present and appears to contribute to the elasticity of fetal membranes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PATHOGENESIS OF RUPTURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fetal membranes normally remain undisturbed until late in gestation, most likely due to low MMP activity and high levels of TIMPs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/3,21,25-27\">",
"     3,21,25-27",
"    </a>",
"    ]. When contractions begin or the membranes rupture, MMP activity in the amnion and chorion increases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/21,25-27\">",
"     21,25-27",
"    </a>",
"    ] and levels of interstitial and basement membrane collagens decrease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/13,38-40\">",
"     13,38-40",
"    </a>",
"    ]. The specific changes that occur are illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In humans and in rat models, MMP-9, MMP-2, MMP-3 (stromelysin), and interstitial collagenase activities in fetal membranes and amniotic fluid rise near delivery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/21,25,41-44\">",
"       21,25,41-44",
"      </a>",
"      ]. In comparison, the level of TIMP-1 dramatically falls at these sites in association with labor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/25,27\">",
"       25,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An increase in MMP-9 activity has been noted in extracts of fetal membranes that overlie the cervix, but not in those obtained from the midzone of fetal membranes (midway between the placental edge and cervical region) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/45\">",
"       45",
"      </a>",
"      ]. This suggests that MMP activation at specific sites in fetal membranes may trigger their physiological rupture at term or pathological rupture prior to term. This limited zone of \"extreme altered morphology\" is characterized by cellular swelling and collagen breakdown in the compact, fibroblast, and spongy layers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/46\">",
"       46",
"      </a>",
"      ]. By comparison, activation of MMPs in rats is associated with generalized collagenolysis and a reduction in the strength and elasticity along the entire surface of the fetal membranes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/43,44\">",
"       43,44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Apoptosis (ie, programmed cell death) is induced in amnion epithelial and chorion trophoblast layers of fetal membranes late in gestation, in conjunction with or after activation of MMP and collagenolysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/44,47-49\">",
"       44,47-49",
"      </a>",
"      ]. Apoptosis is a form of cell death (as opposed to necrosis) in which isolated cells within a given region of a tissue are removed without activation of the immune system and inflammatory processes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/50\">",
"       50",
"      </a>",
"      ]. Higher rates of apoptosis have been detected in the region of fetal membranes overlying the cervix compared to midzone samples [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/49\">",
"       49",
"      </a>",
"      ]. Reduction of cellular adhesion is another trigger to apoptosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, regional activation of MMPs near delivery may trigger a cascade of events that reduce fetal membrane integrity and promote rupture at specific sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/52\">",
"     52",
"    </a>",
"    ]. In particular, in vitro studies suggest that the amnion and chorion separate prior to membrane rupture and the chorion ruptures before the stronger and more ductile amnion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the precise etiology of MMP activation prior to parturition is not known, several factors may play a role in this process:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compounds such as tumor necrosis factor-alpha, interleukin-1, prostaglandins E2 and F2 alpha appear to increase collagenase activity and activate inflammatory pathways in fetal membranes at parturition [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/55-58\">",
"       55-58",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/40/32393?source=see_link\">",
"       \"Pathogenesis of spontaneous preterm birth\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Relaxin, a hormone similar to insulin, may induce MMP-9 and MMP-3 activity in fetal membranes by antagonizing the suppressive actions of progesterone and estradiol&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Distension of the fetal membranes may initiate cellular events leading to periparturitional destabilization. Mechanical stretching of fetal membranes activates MMP-1 and MMP-3 and induces interleukin-8 expression in amnion and chorion cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/60,61\">",
"       60,61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The neuro- and placental peptides corticotropin releasing hormone (CRH) and urocortin (a member of the CRH family of peptides) may induce local MMP-9 activity in fetal membranes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Enhanced myoblast differentiation in fibroblast populations, particularly in the reticular layer of the chorion, correlates with the connective tissue changes, fetal membrane rupture, and labor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/63\">",
"     63",
"    </a>",
"    ]. This may be an additional mechanism that contributes to these events.",
"   </p>",
"   <p>",
"    Genetic or epigenetic factors that predispose women to membrane rupture and preterm delivery may be superimposed on these biochemical pathways. Preterm birth rates among blacks consistently exceed that of whites in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/64\">",
"     64",
"    </a>",
"    ]. It has been suggested that increased fetal membrane actions of the pro-inflammatory cytokine tumor necrosis factor (TNF)-a may, in part, be responsible for the racial disparity in preterm birth rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, a functional single nucleotide polymorphism (SNP) in the promoter of the SERPINH1 gene, which encodes heat-shock protein 47 gene, increases risk of preterm premature rupture of membranes in African Americans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/66\">",
"     66",
"    </a>",
"    ]. Since this protein is a chaperone which is essential for collagen synthesis, this suggests that the SNP results in decreased levels of heat-shock protein 47, thereby limiting collagen function, which ultimately promotes preterm rupture of fetal membranes.",
"   </p>",
"   <p>",
"    Stretch and shear forces from uterine contractions during labor probably contribute to membrane rupture, as well.",
"   </p>",
"   <p>",
"    Recently, proteomic profiling (large scale analysis of proteins) of amniotic fluid has been used to generate specific \"fingerprints\" that provide insight into the cellular mechanisms of idiopathic preterm birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43175/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fetal membranes are genetically identical to the fetus. The membranes have two layers, an amnion and a chorion, that contain many cell types, but are avascular and without nerve cells. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The tensile strength and elastic properties of fetal membranes allow them to accommodate the changing needs of the fetus across gestation. Tensile strength is conferred by collagens and other extracellular matrix proteins from the compact layer of the amnion; elasticity is derived from microfibrils and elastin. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Biochemistry of fetal membrane strength'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Biochemistry of fetal membrane elasticity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Throughout most of gestation, the structural integrity of fetal membranes is preserved. Prior to labor, a series of cellular events including activation of MMPs, hydrolysis of collagens, and apoptosis reduces the integrity of the membranes and may predispose them to rupture at specific sites. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Pathogenesis of rupture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cytokines, hormones, and mechanical stresses appear to play a role in the molecular cascade leading to the periparturitional changes in fetal membrane structure. These cascades are likely to be influenced by genetic or epigenetic factors that predispose women to preterm rupture of fetal membranes and preterm delivery. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Pathogenesis of rupture'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Benirschke K, Kaufmann P. Pathology of the Human Placenta, Springer-Verlag, New York 1995. p.268.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/2\">",
"      Bryant-Greenwood GD. The extracellular matrix of the human fetal membranes: structure and function. Placenta 1998; 19:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/3\">",
"      Parry S, Strauss JF 3rd. Premature rupture of the fetal membranes. N Engl J Med 1998; 338:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/4\">",
"      BOURNE GL. The microscopic anatomy of the human amnion and chorion. Am J Obstet Gynecol 1960; 79:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/5\">",
"      Behzad F, Dickinson MR, Charlton A, Aplin JD. Brief communication: sliding displacement of amnion and chorion following controlled laser wounding suggests a mechanism for short-term sealing of ruptured membranes. Placenta 1994; 15:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/6\">",
"      van der Rest M, Garrone R. Collagen family of proteins. FASEB J 1991; 5:2814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/7\">",
"      Casey ML, MacDonald PC. Interstitial collagen synthesis and processing in human amnion: a property of the mesenchymal cells. Biol Reprod 1996; 55:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/8\">",
"      Aplin JD, Campbell S, Donnai P, et al. Importance of vitamin C in maintenance of the normal amnion: an experimental study. Placenta 1986; 7:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/9\">",
"      Malak TM, Ockleford CD, Bell SC, et al. Confocal immunofluorescence localization of collagen types I, III, IV, V and VI and their ultrastructural organization in term human fetal membranes. Placenta 1993; 14:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/10\">",
"      Keene DR, Sakai LY, Lunstrum GP, et al. Type VII collagen forms an extended network of anchoring fibrils. J Cell Biol 1987; 104:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/11\">",
"      Rousselle P, Keene DR, Ruggiero F, et al. Laminin 5 binds the NC-1 domain of type VII collagen. J Cell Biol 1997; 138:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/12\">",
"      Burgeson RE, El Adli FA, Kaitila II, Hollister DW. Fetal membrane collagens: identification of two new collagen alpha chains. Proc Natl Acad Sci U S A 1976; 73:2579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/13\">",
"      Kanayama N, Terao T, Kawashima Y, et al. Collagen types in normal and prematurely ruptured amniotic membranes. Am J Obstet Gynecol 1985; 153:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/14\">",
"      Matsuura H, Hakomori S. The oncofetal domain of fibronectin defined by monoclonal antibody FDC-6: its presence in fibronectins from fetal and tumor tissues and its absence in those from normal adult tissues and plasma. Proc Natl Acad Sci U S A 1985; 82:6517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/15\">",
"      Matsuura H, Takio K, Titani K, et al. The oncofetal structure of human fibronectin defined by monoclonal antibody FDC-6. Unique structural requirement for the antigenic specificity provided by a glycosylhexapeptide. J Biol Chem 1988; 263:3314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/16\">",
"      Lockwood CJ, Senyei AE, Dische MR, et al. Fetal fibronectin in cervical and vaginal secretions as a predictor of preterm delivery. N Engl J Med 1991; 325:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/17\">",
"      Feinberg RF, Kliman HJ, Lockwood CJ. Is oncofetal fibronectin a trophoblast glue for human implantation? Am J Pathol 1991; 138:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/18\">",
"      Smith J, Ockleford CD. Laser scanning confocal examination and comparison of nidogen (entactin) with laminin in term human amniochorion. Placenta 1994; 15:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/19\">",
"      Champliaud MF, Lunstrum GP, Rousselle P, et al. Human amnion contains a novel laminin variant, laminin 7, which like laminin 6, covalently associates with laminin 5 to promote stable epithelial-stromal attachment. J Cell Biol 1996; 132:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/20\">",
"      Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 1995; 7:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/21\">",
"      Vadillo-Ortega F, Gonz&aacute;lez-Avila G, Furth EE, et al. 92-kd type IV collagenase (matrix metalloproteinase-9) activity in human amniochorion increases with labor. Am J Pathol 1995; 146:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/22\">",
"      Vettraino IM, Roby J, Tolley T, Parks WC. Collagenase-I, stromelysin-I, and matrilysin are expressed within the placenta during multiple stages of human pregnancy. Placenta 1996; 17:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/23\">",
"      Tsatas D, Baker MS, Rice GE. Differential expression of proteases in human gestational tissues before, during and after spontaneous-onset labour at term. J Reprod Fertil 1999; 116:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/24\">",
"      Fortunato SJ, Menon R, Lombardi SJ. Amniochorion gelatinase-gelatinase inhibitor imbalance in vitro: a possible infectious pathway to rupture. Obstet Gynecol 2000; 95:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/25\">",
"      Vadillo-Ortega F, Hernandez A, Gonzalez-Avila G, et al. Increased matrix metalloproteinase activity and reduced tissue inhibitor of metalloproteinases-1 levels in amniotic fluids from pregnancies complicated by premature rupture of membranes. Am J Obstet Gynecol 1996; 174:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/26\">",
"      Fortunato SJ, Menon R, Lombardi SJ. Presence of four tissue inhibitors of matrix metalloproteinases (TIMP-1, -2, -3 and -4) in human fetal membranes. Am J Reprod Immunol 1998; 40:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/27\">",
"      Riley SC, Leask R, Denison FC, et al. Secretion of tissue inhibitors of matrix metalloproteinases by human fetal membranes, decidua and placenta at parturition. J Endocrinol 1999; 162:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/28\">",
"      Murtha AP, Auten R, Herbert WN. Apoptosis in the chorion laeve of term patients with histologic chorioamnionitis. Infect Dis Obstet Gynecol 2002; 10:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/29\">",
"      Kjaergaard N, Hein M, Hyttel L, et al. Antibacterial properties of human amnion and chorion in vitro. Eur J Obstet Gynecol Reprod Biol 2001; 94:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/30\">",
"      Stock SJ, Kelly RW, Riley SC, Calder AA. Natural antimicrobial production by the amnion. Am J Obstet Gynecol 2007; 196:255.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/31\">",
"      Kim YM, Romero R, Chaiworapongsa T, et al. Toll-like receptor-2 and -4 in the chorioamniotic membranes in spontaneous labor at term and in preterm parturition that are associated with chorioamnionitis. Am J Obstet Gynecol 2004; 191:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/32\">",
"      Rosenbloom J, Abrams WR, Mecham R. Extracellular matrix 4: the elastic fiber. FASEB J 1993; 7:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/33\">",
"      Qian RQ, Glanville RW. Alignment of fibrillin molecules in elastic microfibrils is defined by transglutaminase-derived cross-links. Biochemistry 1997; 36:15841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/34\">",
"      Malak TM, Bell SC. Distribution of fibrillin-containing microfibrils and elastin in human fetal membranes: a novel molecular basis for membrane elasticity. Am J Obstet Gynecol 1994; 171:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/35\">",
"      Maddox BK, Sakai LY, Keene DR, Glanville RW. Connective tissue microfibrils. Isolation and characterization of three large pepsin-resistant domains of fibrillin. J Biol Chem 1989; 264:21381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/36\">",
"      Keene DR, Maddox BK, Kuo HJ, et al. Extraction of extendable beaded structures and their identification as fibrillin-containing extracellular matrix microfibrils. J Histochem Cytochem 1991; 39:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/37\">",
"      Hieber AD, Corcino D, Motosue J, et al. Detection of elastin in the human fetal membranes: proposed molecular basis for elasticity. Placenta 1997; 18:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/38\">",
"      Al-Zaid NS, Bou-Resli MN, Goldspink G. Bursting pressure and collagen content of fetal membranes and their relation to premature rupture of the membranes. Br J Obstet Gynaecol 1980; 87:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/39\">",
"      Skinner SJ, Campos GA, Liggins GC. Collagen content of human amniotic membranes: effect of gestation length and premature rupture. Obstet Gynecol 1981; 57:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/40\">",
"      Hampson V, Liu D, Billett E, Kirk S. Amniotic membrane collagen content and type distribution in women with preterm premature rupture of the membranes in pregnancy. Br J Obstet Gynaecol 1997; 104:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/41\">",
"      Bryant-Greenwood GD, Yamamoto SY. Control of peripartal collagenolysis in the human chorion-decidua. Am J Obstet Gynecol 1995; 172:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/42\">",
"      Draper D, McGregor J, Hall J, et al. Elevated protease activities in human amnion and chorion correlate with preterm premature rupture of membranes. Am J Obstet Gynecol 1995; 173:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/43\">",
"      Lei H, Vadillo-Ortega F, Paavola LG, Strauss JF 3rd. 92-kDa gelatinase (matrix metalloproteinase-9) is induced in rat amnion immediately prior to parturition. Biol Reprod 1995; 53:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/44\">",
"      Lei H, Furth EE, Kalluri R, et al. A program of cell death and extracellular matrix degradation is activated in the amnion before the onset of labor. J Clin Invest 1996; 98:1971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/45\">",
"      McLaren J, Taylor DJ, Bell SC. Increased concentration of pro-matrix metalloproteinase 9 in term fetal membranes overlying the cervix before labor: implications for membrane remodeling and rupture. Am J Obstet Gynecol 2000; 182:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/46\">",
"      Malak TM, Bell SC. Structural characteristics of term human fetal membranes: a novel zone of extreme morphological alteration within the rupture site. Br J Obstet Gynaecol 1994; 101:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/47\">",
"      Runi�� R, Lockwood CJ, LaChapelle L, et al. Apoptosis and Fas expression in human fetal membranes. J Clin Endocrinol Metab 1998; 83:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/48\">",
"      Ohyama K, Oka K, Emura A, et al. Suppression of apoptotic cell death progressed in vitro with incubation of the chorion laeve tissues of human fetal membrane by glucocorticoid. Biol Pharm Bull 1998; 21:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/49\">",
"      McLaren J, Taylor DJ, Bell SC. Increased incidence of apoptosis in non-labour-affected cytotrophoblast cells in term fetal membranes overlying the cervix. Hum Reprod 1999; 14:2895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/50\">",
"      Jacobson MD, Weil M, Raff MC. Programmed cell death in animal development. Cell 1997; 88:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/51\">",
"      Boudreau N, Sympson CJ, Werb Z, Bissell MJ. Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 1995; 267:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/52\">",
"      Maymon E, Romero R, Pacora P, et al. Human neutrophil collagenase (matrix metalloproteinase 8) in parturition, premature rupture of the membranes, and intrauterine infection. Am J Obstet Gynecol 2000; 183:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/53\">",
"      Arikat S, Novince RW, Mercer BM, et al. Separation of amnion from choriodecidua is an integral event to the rupture of normal term fetal membranes and constitutes a significant component of the work required. Am J Obstet Gynecol 2006; 194:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/54\">",
"      Oyen ML, Calvin SE, Landers DV. Premature rupture of the fetal membranes: is the amnion the major determinant? Am J Obstet Gynecol 2006; 195:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/55\">",
"      Katsura M, Ito A, Hirakawa S, Mori Y. Human recombinant interleukin-1 alpha increases biosynthesis of collagenase and hyaluronic acid in cultured human chorionic cells. FEBS Lett 1989; 244:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/56\">",
"      So T, Ito A, Sato T, et al. Tumor necrosis factor-alpha stimulates the biosynthesis of matrix metalloproteinases and plasminogen activator in cultured human chorionic cells. Biol Reprod 1992; 46:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/57\">",
"      Simpson KL, Keelan JA, Mitchell MD. Labour-associated changes in the regulation of production of immunomodulators in human amnion by glucocorticoids, bacterial lipopolysaccharide and pro-inflammatory cytokines. J Reprod Fertil 1999; 116:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/58\">",
"      Keelan JA, Sato TA, Gupta DK, et al. Prostanoid stimulation of cytokine production in an amnion-derived cell line: evidence of a feed-forward mechanism with implications for term and preterm labor. J Soc Gynecol Investig 2000; 7:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/59\">",
"      Qin X, Chua PK, Ohira RH, Bryant-Greenwood GD. An autocrine/paracrine role of human decidual relaxin. II. Stromelysin-1 (MMP-3) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1). Biol Reprod 1997; 56:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/60\">",
"      Maradny EE, Kanayama N, Halim A, et al. Stretching of fetal membranes increases the concentration of interleukin-8 and collagenase activity. Am J Obstet Gynecol 1996; 174:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/61\">",
"      Nemeth E, Tashima LS, Yu Z, Bryant-Greenwood GD. Fetal membrane distention: I. Differentially expressed genes regulated by acute distention in amniotic epithelial (WISH) cells. Am J Obstet Gynecol 2000; 182:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/62\">",
"      Li W, Challis JR. Corticotropin-releasing hormone and urocortin induce secretion of matrix metalloproteinase-9 (MMP-9) without change in tissue inhibitors of MMP-1 by cultured cells from human placenta and fetal membranes. J Clin Endocrinol Metab 2005; 90:6569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/63\">",
"      McParland PC, Taylor DJ, Bell SC. Myofibroblast differentiation in the connective tissues of the amnion and chorion of term human fetal membranes-implications for fetal membrane rupture and labour. Placenta 2000; 21:44.",
"     </a>",
"    </li>",
"    <li>",
"     Preterm Birth www.cdc.gov (Accessed on January 31, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/65\">",
"      Menon R, Thorsen P, Vogel I, et al. Increased bioavailability of TNF-alpha in African Americans during in vitro infection: predisposing evidence for immune imbalance. Placenta 2007; 28:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/66\">",
"      Wang H, Parry S, Macones G, et al. A functional SNP in the promoter of the SERPINH1 gene increases risk of preterm premature rupture of membranes in African Americans. Proc Natl Acad Sci U S A 2006; 103:13463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43175/abstract/67\">",
"      Buhimschi IA, Zhao G, Rosenberg VA, et al. Multidimensional proteomics analysis of amniotic fluid to provide insight into the mechanisms of idiopathic preterm birth. PLoS One 2008; 3:e2049.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2281 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-EF0CD76C64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_10_43175=[""].join("\n");
var outline_f42_10_43175=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cellular anatomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Amnion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Chorion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      BIOCHEMISTRY OF FETAL MEMBRANE STRENGTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Extracellular membrane proteins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Collagens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Fibronectin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Laminins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Matrix metalloproteinases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Tissue inhibitors of metalloproteinases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Antimicrobial activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      BIOCHEMISTRY OF FETAL MEMBRANE ELASTICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PATHOGENESIS OF RUPTURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/2281\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/2281|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/27/434\" title=\"figure 1A\">",
"      Diagram of fetal membranes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/19/39222\" title=\"figure 1B\">",
"      Layers of amnion chorion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/51/15159?source=related_link\">",
"      Fetal fibronectin for prediction of preterm labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/40/32393?source=related_link\">",
"      Pathogenesis of spontaneous preterm birth",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_10_43176="Bullous pemphigoid vulva";
var content_f42_10_43176=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78207%7EOBGYN%2F57255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78207%7EOBGYN%2F57255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bullous pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bullous pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_10_43176=[""].join("\n");
var outline_f42_10_43176=null;
var title_f42_10_43177="Stress urinary incontinence in women: Choosing a primary surgical procedure";
var content_f42_10_43177=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Stress urinary incontinence in women: Choosing a primary surgical procedure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/10/43177/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/10/43177/contributors\">",
"     J Eric Jelovsek, MD, MMEd, FACOG, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/10/43177/contributors\">",
"     Jhansi Reddy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/10/43177/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/10/43177/contributors\">",
"     Linda Brubaker, MD, FACS, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/10/43177/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/10/43177/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/10/43177/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress urinary incontinence (SUI), the involuntary leakage of urine on effort or exertion, or on sneezing or coughing, affects 4 to 35 percent of women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Conservative approaches to treatment of SUI include pelvic floor muscle training and incontinence pessaries. However, for women who decline or have insufficient improvement following conservative therapy, there are a variety of surgical treatments. The introduction of minimally invasive midurethral slings has changed the decision process for surgical treatment and is likely a factor in the increase in the rate of anti-incontinence surgery in the United States from",
"    <span class=\"nowrap\">",
"     0.8/1000",
"    </span>",
"    women in 1979 to",
"    <span class=\"nowrap\">",
"     1.0/1000",
"    </span>",
"    in 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The process of choosing a surgical procedure for women with SUI who have not had a prior anti-incontinence surgery will be reviewed here. Choosing a type midurethral sling, nonsurgical management of SUI, treatment of recurrent SUI, and diagnosis and treatment of other types of urinary incontinence are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/43/16055?source=see_link\">",
"     \"Stress urinary incontinence in women: Choosing a type of midurethral sling\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/4/32842?source=see_link\">",
"     \"Treatment of urinary incontinence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/23/44409?source=see_link\">",
"     \"Stress urinary incontinence in women: Persistent/recurrent symptoms after surgical treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29929?source=see_link\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Terminology used throughout this topic review is defined here:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stress urinary incontinence (SUI) &ndash; Involuntary leakage of urine on effort or exertion, or on sneezing or coughing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Suburethral sling &ndash; A suburethral sling is a sling that is inserted through a small vaginal incision and placed either at the bladder neck, midurethra or proximal urethra for the purpose of supporting the urethra in women with SUI. This category includes both bladder neck and midurethral slings.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Bladder neck sling &ndash; A suburethral sling that is placed at the level of the proximal urethra and bladder neck (",
"      <a class=\"graphic graphic_figure graphicRef76965 \" href=\"mobipreview.htm?15/42/16034\">",
"       figure 1",
"      </a>",
"      ). This procedure is usually performed using both a vaginal and abdominal incision. These slings can be made of either biologic materials (including the patient's own tissue) or synthetic mesh.",
"      <br/>",
"      <br/>",
"      Bladder neck slings are also referred to as proximal urethral slings. They are referred to as pubovaginal slings when the arms of the sling material are affixed to the anterior rectus fascia rather than the pubic bone or Cooper's ligament [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Midurethral sling &ndash; A suburethral sling that is inserted via a small vaginal incision and placed at the level of the midurethra in a tension free manner (eg, tension-free vaginal tape procedures). These slings are made of synthetic mesh.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retropubic colposuspension &mdash; Procedures performed through laparotomy or laparoscopy (Burch, Marshall-Marchetti-Krantz) in which the vaginal wall adjacent to the midurethra and bladder neck is suspended, using sutures, in a retropubic position (",
"      <a class=\"graphic graphic_figure graphicRef76932 graphicRef59261 graphicRef56969 \" href=\"mobipreview.htm?12/41/12954\">",
"       figure 2A-C",
"      </a>",
"      ). These procedures are also referred to as retropubic urethropexy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CANDIDATES FOR SURGICAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who are planning primary surgical treatment of SUI should undergo preoperative evaluation to reasonably exclude other etiologies of urinary incontinence and assess surgical risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/58/17319?source=see_link\">",
"     \"Stress urinary incontinence in women: Preoperative evaluation for a primary procedure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Women who decline or have persistent symptoms following conservative therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, a trial of conservative therapy is advisable prior to surgical treatment because of its low risk profile. Conservative therapy for SUI includes pelvic muscle exercises (PME) with or without biofeedback or incontinence pessaries. Pharmacologic treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    has been investigated, but its efficacy is very modest and drug availability is limited. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/4/32842?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of urinary incontinence\", section on 'Pelvic muscle exercises'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/7/17530?source=see_link&amp;anchor=H18#H18\">",
"     \"Vaginal pessary treatment of prolapse and incontinence\", section on 'Incontinence pessaries'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/4/32842?source=see_link\">",
"     \"Treatment of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Expert opinions suggest that a trial of drug therapy using anticholinergic medication in patients with mixed urinary incontinence is reasonable if urge symptoms are bothersome. Reduction of urge symptoms may help the patient enough to avoid surgery for the stress component. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Mixed incontinence'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/4/32842?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of urinary incontinence\", section on 'Pharmacologic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No studies have directly compared surgical versus nonsurgical treatment approaches for SUI. Surgical treatments have consistently been found to have a higher efficacy rate than conservative therapy (eg, approximately 40 percent for PME versus 70 to 80 percent for surgery) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]; however, surgery is associated with increased morbidity, postoperative voiding difficulty and development or worsening of urge incontinence. For some patients, stress incontinence symptoms may not be bothersome enough to justify a surgical procedure, although this judgment varies depending upon the patient's preference and the risks and success rate of the procedure offered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3793104\">",
"    <span class=\"h2\">",
"     Women with occult SUI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advanced pelvic organ prolapse and SUI commonly co-exist; however, in many women, the SUI may become apparent only when the prolapse has been corrected. This phenomenon is known as occult SUI and is not reliably predicted by preoperative urodynamic testing with prolapse reduction. Concomitant anti-incontinence surgery is warranted in some women who are undergoing repair of advanced pelvic organ prolapse. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/32/1546?source=see_link&amp;anchor=H15#H15\">",
"     \"Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment\", section on 'POP with no symptoms of SUI'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Women finished with childbearing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since pelvic support may be disrupted during pregnancy, and particularly following a vaginal birth, most physicians recommend delaying surgical management of SUI until childbearing has been completed.",
"   </p>",
"   <p>",
"    The best choice for mode of delivery is uncertain in women who have undergone prior anti-incontinence surgery. A review of case reports suggested that vaginal delivery was associated with a higher risk of recurrent incontinence than cesarean delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/11\">",
"     11",
"    </a>",
"    ], but no significant difference was found in a survey of physicians who had performed 3400 retropubic or transobturator midurethral sling procedures (vaginal delivery: 20 percent; cesarean: 13 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/12\">",
"     12",
"    </a>",
"    ]. Women of childbearing age who elect surgical treatment should be counseled on the lack of data regarding the preferred mode of delivery and the risk of recurrent incontinence following delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/11-14\">",
"     11-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TYPES OF PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevailing evidence supports using a vaginal approach for anti-incontinence procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Vaginal approach",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Midurethral sling",
"     </li>",
"     <li>",
"      Bladder neck sling",
"     </li>",
"     <li>",
"      Injection of urethral bulking agents",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Currently, bladder neck slings are mainly reserved for women in whom midurethral slings are contraindicated or were unsuccessful. This is largely due to the decrease in morbidity and less voiding dysfunction associated with performing midurethral slings (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Midurethral slings versus other procedures'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The use of urethral injectable agents is often reserved for women who are unable to tolerate, or wish to defer, surgery. In addition, these agents are used in some patients with recurrent or refractory incontinence after a prior incontinence procedure (see",
"    <a class=\"local\" href=\"#H24\">",
"     'Lack of urethral hypermobility and intrinsic sphincter deficiency'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H28\">",
"     'Women who are elderly or infirm'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Abdominal approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The modified Burch retropubic colposuspension (described by Tanagho, also referred to as Burch or retropubic urethropexy) can be performed via laparotomy, conventional laparoscopy, or robot-assisted laparoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Procedures no longer recommended",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical treatment of SUI has evolved, particularly since the introduction of midurethral slings. Several procedures that were once widely used are now no longer recommended since there are more effective alternatives. Data regarding these procedures will be reviewed in this section. Choosing among procedures that are currently in use is discussed below (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Choosing a procedure'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Retropubic colposuspension has generally been used as the reference standard for these procedures. This is because the procedures in this section precede the widespread use of suburethral slings, particularly midurethral slings. Thus, they can be compared with slings only indirectly, using data that show that the efficacy of midurethral sling placement is comparable to colposuspension (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Midurethral slings versus other procedures'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Anterior colporrhaphy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior colporrhaphy (even with Kelly-Kennedy plication) is not an effective approach to surgical treatment of SUI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. A meta-analysis of eight randomized trials found that the SUI treatment failure rate within one to five years was significantly higher after anterior repair compared with retropubic colposuspension (38 versus 17 percent; RR 2.3, 95% CI 1.7-3.1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/18\">",
"     18",
"    </a>",
"    ]. No difference was found in perioperative complications between the two procedure types.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Paravaginal repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transabdominal paravaginal repair is also ineffective as a treatment for SUI. There are few high quality data regarding use of paravaginal repair for women with SUI. A small randomized trial (n = 36) found that the success rate at one to three years was significantly lower following paravaginal repair compared with Burch colposuspension (72 versus 100 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/19\">",
"     19",
"    </a>",
"    ]. No difference was found in perioperative complications between the two procedures. In addition, observational studies have reported that paravaginal repair for treatment of SUI was associated with a 20 to 57 percent failure rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Transvaginal needle suspensions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transvaginal needle suspensions (eg, Raz, Stamey, or Gittes procedures) have largely been replaced by other procedures. These procedures are also referred to as needle urethropexy and consist of transvaginal placement of permanent sutures to attach the suburethral endopelvic fascia to the rectus fascia or pubic bone. A meta-analysis of 10 trials demonstrated a significantly higher SUI treatment failure rate at one-year postoperatively for needle suspension compared with retropubic colposuspension (29 versus 16 percent; RR 2.0, 95% CI 1.5-2.7) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/22\">",
"     22",
"    </a>",
"    ]. No difference was found in the rate of perioperative complications between the two procedure types.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Marshall-Marchetti-Krantz",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Marshall-Marchetti-Krantz (MMK) procedure, a type of retropubic colposuspension that has generally been an alternative to Burch colposuspension, is rarely used. The two procedures vary by the site of attachment of the endopelvic fascia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Burch procedure, the endopelvic fascia adjacent to the mid and proximal urethra at the bladder neck is attached to the pectineal (Cooper's) ligaments on the posterior surface of the superior pubic ramus (",
"      <a class=\"graphic graphic_figure graphicRef76932 graphicRef59261 graphicRef56969 \" href=\"mobipreview.htm?12/41/12954\">",
"       figure 2A-C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In the MMK procedure, the endopelvic fascia next to the bladder neck is attached to the periosteum of the posterior pubic symphysis (",
"      <a class=\"graphic graphic_figure graphicRef80731 \" href=\"mobipreview.htm?38/23/39283\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Burch appears to be more effective than MMK and also has a lower procedural morbidity. A meta-analysis of four randomized trials found that, at one- to five-year follow-up, the SUI treatment failure rate was lower for Burch compared with MMK (23 versus 34 percent; RR 0.72; 95% CI 0.52-0.99) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/23\">",
"     23",
"    </a>",
"    ]. This result had a wide confidence interval, and therefore does not strongly support the superiority of the Burch procedure. However, Burch has additional advantages compared with MMK, including: (1) duration of postoperative bladder catheterization is an average of six days shorter with Burch; (2) osteitis pubis occurs after 1 percent of MMK procedures, but not after Burch; (3) the pectineal ligament is a stronger supporting structure than the pubic periosteum; and (4) Burch corrects small anterior wall support defects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/22,24,25\">",
"     22,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CHOOSING A PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the introduction of midurethral slings in the 1990s, these procedures have become the procedure of choice for primary surgical treatment of SUI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Midurethral slings are as effective as retropubic colposuspension and bladder neck slings, but have a shorter operative duration and a lower risk of certain postoperative complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are few clinical contexts in which other procedures are preferred over midurethral slings, including women with the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Apical pelvic organ prolapse with repair planned via laparotomy",
"     </li>",
"     <li>",
"      Decline surgery or are not able to tolerate surgery",
"     </li>",
"     <li>",
"      Recurrent SUI",
"     </li>",
"     <li>",
"      Concomitant urethral diverticulum repair",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The common teaching is that women with pelvic organ prolapse who require an abdominal approach for prolapse repair should have an incontinence procedure that can be performed through the same incision, since it is generally preferred to avoid both abdominal and vaginal incisions. This applies primarily to women with apical prolapse repaired using abdominal sacrocolpopexy. However, even in this population, many surgeons perform midurethral sling procedures, especially when using laparoscopic or robotically-assisted laparoscopic techniques (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Apical prolapse'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Women who cannot tolerate surgery and who have persistent bothersome symptoms following conservative SUI therapy should be offered treatment with injection of periurethral bulking agents (see",
"    <a class=\"local\" href=\"#H28\">",
"     'Women who are elderly or infirm'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Urethral diverticulum and management of women with recurrent SUI after surgery are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/15/26873?source=see_link\">",
"     \"Urethral diverticulum in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/23/44409?source=see_link\">",
"     \"Stress urinary incontinence in women: Persistent/recurrent symptoms after surgical treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Preoperative counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient and surgeon satisfaction with treatment can be optimized by having a discussion during the planning phase for the surgery about the individual patient's goals and expectations for her treatment and awareness of potential adverse events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. One study found that increasing age, body mass index, and fascial sling rather than midurethral sling were associated with decreased satisfaction following surgical treatment of SUI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Evaluating SUI procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;In evaluating SUI treatments, earlier investigations in pelvic reconstructive surgery focused on the objective cure rate (evaluation with office or urodynamic testing) as the primary outcome. Many experts now consider the subjective cure rate (based upon the patient's report of cure or improvement) to be the primary outcome since it is the most important to patients. In general, objective cure rates are often higher than subjective cure rates, and thus, may lead to different conclusions. In the following sections, we will report subjective rather than objective cure rates whenever possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Midurethral slings versus other procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Midurethral slings are as effective as other surgical treatments for SUI, but with a shorter operative duration and a lower risk of certain postoperative complications.",
"   </p>",
"   <p>",
"    This was demonstrated in a meta-analysis of 62 randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/10\">",
"     10",
"    </a>",
"    ]. Regarding short-term effectiveness (within 12 months postoperatively), the subjective cure rate of SUI among women who underwent placement of midurethral slings was comparable to other procedures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Midurethral sling versus bladder neck sling (73 versus 71 percent, RR 1.0, 95% CI 0.9-1.1).",
"     </li>",
"     <li>",
"      Midurethral sling versus open retropubic colposuspension (79 versus 82 percent, RR 1.0, 95% CI 0.9-1.0)",
"     </li>",
"     <li>",
"      Midurethral sling versus laparoscopic colposuspension (82 versus 74 percent, RR 1.1, 95% CI 1.0-1.2)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Long-term effectiveness of midurethral slings was comparable to open colposuspension in one randomized trial (63 versus 70 percent) and to laparoscopic colposuspension in another randomized trial (92 versus 89 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. In addition, two prospective cohort studies that followed women for 7 to 11 years after tension-free vaginal tape procedures (the first midurethral sling that was introduced) reported subjective cure rates of 77 to 85 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The meta-analysis also noted the following findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The operative duration was significantly shorter for midurethral sling procedures by an average of 71, 15, and 25 minutes compared to bladder neck slings, open colposuspension, and laparoscopic colposuspension, respectively.",
"     </li>",
"     <li>",
"      The rate of most perioperative complications did not differ significantly across the procedures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/10\">",
"       10",
"      </a>",
"      ]. The notable exception was perforation of the bladder or urethra, which occurred more frequently during midurethral sling surgery compared with open or laparoscopic colposuspension (4.7 versus 1.1 percent and 4.9 versus 1.7 percent); these data reflect mainly bladder perforation since urethral perforation is rare [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/35\">",
"       35",
"      </a>",
"      ]. However, this finding does not greatly impact the choice of procedure, since bladder perforations associated with midurethral slings add little to patient recovery time (they are managed with a bladder catheter for a few days) and do not appear to have serious sequelae or affect SUI cure rates. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/49/33562?source=see_link&amp;anchor=H4700528#H4700528\">",
"       \"Stress urinary incontinence in women: Retropubic midurethral slings\", section on 'Bladder injury'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Adverse effects on bladder function occurred with less or similar frequency in women who underwent midurethral sling procedures. As an example, de novo urinary urgency or urge incontinence was significantly less frequent with midurethral slings than bladder neck slings and laparoscopic colposuspension (6 versus 17 and 4 versus 13 percent), but not open colposuspension (9 versus 12 percent).",
"     </li>",
"     <li>",
"      The rate of voiding dysfunction (eg, urinary retention) following midurethral sling surgery did not differ significantly from bladder neck slings (10 versus 13 percent), open colposuspension (6 versus 9 percent), or laparoscopic colposuspension (4 versus 6 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hospital stay was significantly shorter for midurethral slings compared with bladder neck slings (0.5 days shorter), open colposuspension (four days), and laparoscopic colposuspension (one day). Data regarding return to normal activity were available only for midurethral slings compared with laparoscopic colposuspension (six days shorter). The difference is probably greater between midurethral slings and open colposuspension, since an open incision typically requires a longer recovery time than laparoscopic incisions.",
"     </li>",
"     <li>",
"      Midurethral slings appear to be more cost-effective than other procedures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/36,37\">",
"       36,37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, midurethral slings have comparable efficacy to other procedures, but a shorter operative duration and recovery time. While most complication rates are similar across procedures, midurethral slings have a lower rate of de novo urinary urgency symptoms. The main disadvantage of midurethral slings is the risk of bladder perforation, but this complication is easily managed. Thus, we recommend midurethral sling placement for most healthy women with SUI who desire surgical treatment.",
"   </p>",
"   <p>",
"    Women with apical prolapse are an exception to this general conclusion. Thus, for women who are undergoing open abdominal sacrocolpopexy, we suggest Burch colposuspension rather than midurethral sling placement (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Apical prolapse'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Choosing between retropubic, transobturator, and single incision slings is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/43/16055?source=see_link\">",
"     \"Stress urinary incontinence in women: Choosing a type of midurethral sling\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     COEXISTENT SUI AND PELVIC ORGAN PROLAPSE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Apical prolapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with apical prolapse can undergo repair via an abdominal route (abdominal sacrocolpopexy) or a vaginal route (sacrospinous ligament suspension or uterosacral vaginal vault suspension). The merit of a vaginal versus an open abdominal approach for the treatment of apical prolapse remains a topic of debate among experts. Although data from randomized clinical trials show abdominal repairs to be more durable, vaginal repairs are associated with fewer complications and a faster recovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/4/35914?source=see_link&amp;anchor=H21188326#H21188326\">",
"     \"Pelvic organ prolapse in women: Surgical repair of apical prolapse (uterine or vaginal vault prolapse)\", section on 'Vaginal versus abdominal approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For women undergoing surgical treatment of both SUI and apical prolapse, combining open abdominal sacrocolpopexy with Burch colposuspension allows for the use of a single abdominal incision. Furthermore, an abdominal procedure avoids additional incisions and additional foreign body near the urinary tract.",
"   </p>",
"   <p>",
"    Midurethral sling placement is preferable to Burch for most women, as discussed above. This has led some surgeons to perform an abdominal sacrocolpopexy combined with midurethral sling placement. Unfortunately, this combination of procedures limits some of the advantages of midurethral slings. Women who undergo this combination of procedures will not benefit from the usual shorter recovery period following transvaginal sling surgery. On the other hand, the midurethral sling vaginal incisions are minimal and unlikely to increase postoperative discomfort. Wound infection is rare following midurethral sling procedures (8 per 1000 procedures in one series) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/40\">",
"     40",
"    </a>",
"    ]. The remaining potential advantage of this approach is the finding in a meta-analysis of randomized trials that there may be a lower risk developing of urinary urge symptoms after a midurethral sling compared with Burch (9 versus 12 percent), but this difference was not statistically significant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/10\">",
"     10",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H17\">",
"     'Midurethral slings versus other procedures'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    There are no high quality data regarding the best combination of procedures for women with apical prolapse and SUI. Based on the available evidence, we suggest Burch colposuspension rather than midurethral sling placement in women with SUI who are undergoing open abdominal sacrocolpopexy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Open versus laparoscopic Burch",
"    </span>",
"    &nbsp;&mdash;&nbsp;When Burch colposuspension is chosen as the SUI treatment procedure, the decision must be made regarding whether it will be performed through laparotomy or with laparoscopy. There is no difference in efficacy between the two approaches, but laparoscopic procedures have somewhat lower complication rates. Routine use of laparoscopic Burch colposuspension is limited because significant laparoscopic experience and technical skill are required. Thus, we suggest performing open Burch colposuspension. Laparoscopic Burch is a reasonable alternative for surgeons with the appropriate surgical skills.",
"   </p>",
"   <p>",
"    Open and laparoscopic Burch colposuspension were compared in a meta-analysis of 10 randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/41\">",
"     41",
"    </a>",
"    ]. Short-term subjective cure rates for laparoscopic compared with open Burch colposuspension were similar (at 18-month follow-up: 78 versus 83 percent, RR 1.0, 95% CI 0.9-1.0) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/41\">",
"     41",
"    </a>",
"    ]. The lower rate of perioperative complications (eg, infection, hemorrhage) for laparoscopic procedures just reached statistical significance (15 versus 18 percent, RR 0.74, 95% CI 0.58-0.96). Laparoscopic procedures were an average of 14 minutes longer. The main advantages of the laparoscopic approach were a shorter hospital stay (an average of one day) and a faster return to normal activity (10 days sooner). The long-term effectiveness of open Burch colposuspension ranges from 70 to 90 percent at 5 to 10 years following surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/42-44\">",
"     42-44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Advanced prolapse and occult SUI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advanced pelvic organ prolapse and SUI commonly co-exist; however, in many women, the SUI may become apparent only when the prolapse has been corrected. This phenomenon is known as occult SUI and is not reliably predicted by preoperative urodynamic testing with prolapse reduction. Concomitant anti-incontinence surgery in women with advanced pelvic organ prolapse is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/32/1546?source=see_link&amp;anchor=H15#H15\">",
"     \"Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment\", section on 'POP with no symptoms of SUI'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     URINARY FUNCTION ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Lack of urethral hypermobility and intrinsic sphincter deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been a debate among experts regarding whether management should differ for women with SUI and urethral hypermobility versus those who lack urethral hypermobility and may have intrinsic sphincter deficiency (ISD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/10,45\">",
"     10,45",
"    </a>",
"    ]. ISD is defined as a maximal urethral closure pressure &lt;20 cm H2O",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a Valsalva leak-point pressure &lt;60 cm H2O. These cut-offs are highly arbitrary and have been found to have limited predictive value in determining postoperative outcomes for primary SUI treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/46\">",
"     46",
"    </a>",
"    ]. Studies have found that lack of urethral hypermobility and ISD are not necessarily a unified clinical entity since these issues co-exist in many, but not all, women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. The current understanding is that urethral sphincter function is compromised to some degree in all women with SUI.",
"   </p>",
"   <p>",
"    In our practice, we no longer routinely test for urethral hypermobility (ie, with a cotton swab test) since the results do not impact the choice of a primary anti-incontinence procedure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/58/17319?source=see_link&amp;anchor=H1568119#H1568119\">",
"     \"Stress urinary incontinence in women: Preoperative evaluation for a primary procedure\", section on 'Assessing urethral mobility'",
"    </a>",
"    .) Further, since ISD is a urodynamic diagnosis and the clinical utility of routine urodynamic testing in women with uncomplicated SUI remains unknown, there is no rationale to support its routine assessment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/58/17319?source=see_link&amp;anchor=H13#H13\">",
"     \"Stress urinary incontinence in women: Preoperative evaluation for a primary procedure\", section on 'Urodynamic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women without urethral hypermobility",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    with ISD may be successfully treated with a midurethral sling. There are few data regarding colposuspension in this population. Data are inconsistent regarding whether women with both ISD and a fixed urethra have a higher failure rate than women with ISD alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/49\">",
"     49",
"    </a>",
"    ]. Some studies have reported that midurethral slings are less effective in women without urethral hypermobility",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    with ISD, but in general, observational studies have found high success rates (approximately 70 to 80 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/45,49-59\">",
"     45,49-59",
"    </a>",
"    ]. This appears comparable to long-term studies of midurethral slings, which have reported success rates of 77 to 85 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. As noted above, whether retropubic slings are more effective in women with ISD than transobturator slings is under investigation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/23/44409?source=see_link\">",
"     \"Stress urinary incontinence in women: Persistent/recurrent symptoms after surgical treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/43/16055?source=see_link&amp;anchor=H2822326#H2822326\">",
"     \"Stress urinary incontinence in women: Choosing a type of midurethral sling\", section on 'Transobturator versus retropubic midurethral slings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical dilemma in women with a lack of urethral hypermobility",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ISD is whether it is possible to identify which women are likely to fail treatment with a sling or colposuspension. There are no comparative studies regarding outcomes of bulking agents and other anti-incontinence procedures. The reported success rate of periurethral bulking agents varies from 48 to 75 percent, which is similar to the success rates for midurethral slings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/4,45\">",
"     4,45",
"    </a>",
"    ]. However, symptomatic relief is short-lived following bulking agent injection, and injections typically need to be repeated every one to two years.",
"   </p>",
"   <p>",
"    Further study is needed to address treatment of women with a lack of urethral hypermobility",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ISD. Based on the available data, we suggest that these women be treated in the same manner as other women with SUI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Mixed incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with mixed incontinence (urge incontinence and SUI) derive some, but as expected, not complete, relief of incontinence from procedures designed to treat SUI. The presence of mixed incontinence does not influence the choice of surgical procedure.",
"   </p>",
"   <p>",
"    These women should have a trial of an anticholinergic drug prior to anti-incontinence surgery if urge symptoms are most bothersome. Reduction of urge symptoms may help the patient enough to avoid the need for surgical therapy of the stress component. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/4/32842?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of urinary incontinence\", section on 'Pharmacologic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Comparative data show that midurethral sling placement in women with mixed incontinence compared with SUI alone results in a similar cure rate of SUI symptoms, but a lower overall incontinence cure rate (68 versus 88 percent in a retrospective study of 1225 women) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/60-66\">",
"     60-66",
"    </a>",
"    ]. There are few data regarding the use of Burch colposuspension in women with mixed incontinence. In one prospective study of 40 women who underwent Burch (some controls had pubovaginal sling surgery), women with mixed incontinence versus SUI alone had no significant difference at six-month follow-up in the overall incontinence cure rate (87 versus 80 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/67\">",
"     67",
"    </a>",
"    ]. In a follow-up study of surgery for stress predominant urinary incontinence, among women with a history of preoperative urge incontinence, 29 percent in the Burch colposuspension group and 41 percent in the rectus fascial group had persistent urge incontinence postoperatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     OTHER PATIENT CHARACTERISTICS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Obese women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity is a known risk factor for urinary incontinence and weight loss has been associated with a significant reduction in the number of incontinence episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/69-71\">",
"     69-71",
"    </a>",
"    ]. There are no randomized trials that suggest superiority of one surgical procedure over another in the obese population for the primary treatment of SUI. Midurethral slings appear to be effective in obese women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. A case-control study of women who had undergone TVT&trade; matched obese (BMI&gt;40",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    to non-obese patients (BMI&lt;30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     );",
"    </span>",
"    there was no significant difference between groups in continence rates at 18-month follow-up (87 versus 92 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/75\">",
"     75",
"    </a>",
"    ]. In addition, in a randomized trial of Burch colposuspension versus rectus fascial sling for the primary treatment of stress predominant urinary incontinence, BMI was not a significant risk factor for treatment failure at 24 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Women who are elderly or infirm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many elderly women are candidates for midurethral sling surgery; therefore, the decision to avoid anti-incontinence surgery should be made based upon medical status rather than age. This was illustrated in a prospective cohort study of TVT&trade; placement in women aged &ge;70 years (mean 76 years) compared with &lt;70 years (mean 54 years); both groups had significant improvements in quality of life following surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/77\">",
"     77",
"    </a>",
"    ]. The rate of improvement in SUI symptoms was lower in the older group (80 versus 91 percent), but no test of significance was reported.",
"   </p>",
"   <p>",
"    Women with SUI who cannot tolerate, or decline, surgery and have failed conservative therapy are candidates for injection of periurethral bulking agents. The overall reported success rate of periurethral bulking agents is 48 to 75 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/10/43177/abstract/4,45\">",
"     4,45",
"    </a>",
"    ]. Periurethral injection is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/23/44409?source=see_link\">",
"     \"Stress urinary incontinence in women: Persistent/recurrent symptoms after surgical treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Assessment of surgical risk is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41735?source=see_link\">",
"     \"Overview of the principles of medical consultation and perioperative medicine\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/8/22658?source=see_link\">",
"       \"Patient information: Urinary incontinence (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/56/35714?source=see_link\">",
"       \"Patient information: Surgery to treat stress urinary incontinence in women (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/19/19764?source=see_link\">",
"       \"Patient information: Urinary incontinence treatments for women (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stress urinary incontinence (SUI) is the involuntary leakage of urine on effort or exertion, or on sneezing or coughing. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical treatment of SUI is best avoided in women who plan future childbearing. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Women finished with childbearing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A vaginal or abdominal approach can be used for surgical treatment of SUI. Vaginal procedures include: midurethral sling, bladder neck sling, or injection of urethral bulking agents. Burch retropubic colposuspension is an abdominal procedure for SUI. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Types of procedures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most healthy women with SUI who desire surgical treatment, we recommend midurethral sling placement rather than Burch colposuspension or bladder neck sling (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Procedures that are clearly less effective than midurethral slings are: anterior colporrhaphy (even with Kelly-Kennedy plication), transabdominal paravaginal repair, and transvaginal needle suspension. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Midurethral slings versus other procedures'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Procedures no longer recommended'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with SUI who are undergoing abdominal sacrocolpopexy, we suggest retropubic colposuspension rather than midurethral sling placement (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For women undergoing retropubic colposuspension, we suggest the Burch rather than Marshall-Marchetti-Krantz procedure (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Apical prolapse'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Procedures no longer recommended'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women undergoing Burch colposuspension, we suggest an open rather than a laparoscopic approach (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Laparoscopic Burch is a reasonable alternative for surgeons with the appropriate surgical skills. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Open versus laparoscopic Burch'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who decline or cannot tolerate surgery, but have failed conservative therapy, we suggest injection of periurethral bulking agents (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Women who are elderly or infirm'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/1\">",
"      Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010; 29:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/2\">",
"      Luber KM. The definition, prevalence, and risk factors for stress urinary incontinence. Rev Urol 2004; 6 Suppl 3:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/3\">",
"      Kane AR, Nager CW. Midurethral slings for stress urinary incontinence. Clin Obstet Gynecol 2008; 51:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/4\">",
"      Dmochowski RR, Blaivas JM, Gormley EA, et al. Update of AUA guideline on the surgical management of female stress urinary incontinence. J Urol 2010; 183:1906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/5\">",
"      Oliphant SS, Jones KA, Wang L, et al. Trends over time with commonly performed obstetric and gynecologic inpatient procedures. Obstet Gynecol 2010; 116:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/6\">",
"      Jonsson Funk M, Levin PJ, Wu JM. Trends in the surgical management of stress urinary incontinence. Obstet Gynecol 2012; 119:845.",
"     </a>",
"    </li>",
"    <li>",
"     Walters, MD, Karram, MM. Sling procedures for stress urinary incontinence. In: Urogynecology and Reconstructive Pelvic Surgery, 3rd ed, Mosby Elsevier, Philadelphia 2007. p. 197.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/8\">",
"      B&oslash; K, Talseth T, Holme I. Single blind, randomised controlled trial of pelvic floor exercises, electrical stimulation, vaginal cones, and no treatment in management of genuine stress incontinence in women. BMJ 1999; 318:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/9\">",
"      Shamliyan TA, Kane RL, Wyman J, Wilt TJ. Systematic review: randomized, controlled trials of nonsurgical treatments for urinary incontinence in women. Ann Intern Med 2008; 148:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/10\">",
"      Ogah J, Cody JD, Rogerson L. Minimally invasive synthetic suburethral sling operations for stress urinary incontinence in women. Cochrane Database Syst Rev 2009; :CD006375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/11\">",
"      Groenen R, Vos MC, Willekes C, Vervest HA. Pregnancy and delivery after mid-urethral sling procedures for stress urinary incontinence: case reports and a review of literature. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/12\">",
"      Panel L, Triopon G, Courtieu C, et al. How to advise a woman who wants to get pregnant after a sub-urethral tape placement? Int Urogynecol J Pelvic Floor Dysfunct 2008; 19:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/13\">",
"      Dainer M, Hall CD, Choe J, Bhatia N. Pregnancy following incontinence surgery. Int Urogynecol J Pelvic Floor Dysfunct 1998; 9:385.",
"     </a>",
"    </li>",
"    <li>",
"     Kohorst, F, et al. Pregnancy and delivery after tension-free vaginal tape (TVT) procedure: literature review and case report. Eur J Obstet Gynecol 2010; :. [Epub ahead of print].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/15\">",
"      Tanagho EA. Colpocystourethropexy: the way we do it. J Urol 1976; 116:751.",
"     </a>",
"    </li>",
"    <li>",
"     Smith, ARB, Dmochowski, R, Hilton, P et al. Surgery for Urinary Incontinence. In: Incontinence, Abrams, P, Cardozo, L, Khoury, S, Wein, A (Eds), Health Publication Ltd, Plymouth, UK 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/17\">",
"      Thaweekul Y, Bunyavejchevin S, Wisawasukmongchol W, Santingamkun A. Long term results of anterior colporrhaphy with Kelly plication for the treatment of stress urinary incontinence. J Med Assoc Thai 2004; 87:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/18\">",
"      Glazener CM, Cooper K. Anterior vaginal repair for urinary incontinence in women. Cochrane Database Syst Rev 2001; :CD001755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/19\">",
"      Colombo M, Milani R, Vitobello D, Maggioni A. A randomized comparison of Burch colposuspension and abdominal paravaginal defect repair for female stress urinary incontinence. Am J Obstet Gynecol 1996; 175:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/20\">",
"      Demirci F, Ozdemir I, Somunkiran A, et al. Abdominal paravaginal defect repair in the treatment of paravaginal defect and urodynamic stress incontinence. J Obstet Gynaecol 2007; 27:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/21\">",
"      Mallipeddi PK, Steele AC, Kohli N, Karram MM. Anatomic and functional outcome of vaginal paravaginal repair in the correction of anterior vaginal wall prolapse. Int Urogynecol J Pelvic Floor Dysfunct 2001; 12:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/22\">",
"      Glazener CM, Cooper K. Bladder neck needle suspension for urinary incontinence in women. Cochrane Database Syst Rev 2004; :CD003636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/23\">",
"      Lapitan MC, Cody JD, Grant A. Open retropubic colposuspension for urinary incontinence in women. Cochrane Database Syst Rev 2009; :CD002912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/24\">",
"      Colombo M, Scalambrino S, Maggioni A, Milani R. Burch colposuspension versus modified Marshall-Marchetti-Krantz urethropexy for primary genuine stress urinary incontinence: a prospective, randomized clinical trial. Am J Obstet Gynecol 1994; 171:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/25\">",
"      Kammerer-Doak DN, Cornella JL, Magrina JF, et al. Osteitis pubis after Marshall-Marchetti-Krantz urethropexy: a pubic osteomyelitis. Am J Obstet Gynecol 1998; 179:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/26\">",
"      Leach GE, Dmochowski RR, Appell RA, et al. Female Stress Urinary Incontinence Clinical Guidelines Panel summary report on surgical management of female stress urinary incontinence. The American Urological Association. J Urol 1997; 158:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/27\">",
"      Anger JT, Weinberg AE, Albo ME, et al. Trends in surgical management of stress urinary incontinence among female Medicare beneficiaries. Urology 2009; 74:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/28\">",
"      Elkadry EA, Kenton KS, FitzGerald MP, et al. Patient-selected goals: a new perspective on surgical outcome. Am J Obstet Gynecol 2003; 189:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/29\">",
"      Mahajan ST, Elkadry EA, Kenton KS, et al. Patient-centered surgical outcomes: the impact of goal achievement and urge incontinence on patient satisfaction one year after surgery. Am J Obstet Gynecol 2006; 194:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/30\">",
"      Trabuco EC, Klingele CJ, Weaver AL, et al. Preoperative and postoperative predictors of satisfaction after surgical treatment of stress urinary incontinence. Am J Obstet Gynecol 2011; 204:444.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/31\">",
"      Ward KL, Hilton P, UK and Ireland TVT Trial Group. Tension-free vaginal tape versus colposuspension for primary urodynamic stress incontinence: 5-year follow up. BJOG 2008; 115:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/32\">",
"      Jelovsek JE, Barber MD, Karram MM, et al. Randomised trial of laparoscopic Burch colposuspension versus tension-free vaginal tape: long-term follow up. BJOG 2008; 115:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/33\">",
"      Nilsson CG, Palva K, Rezapour M, Falconer C. Eleven years prospective follow-up of the tension-free vaginal tape procedure for treatment of stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/34\">",
"      Liapis A, Bakas P, Creatsas G. Long-term efficacy of tension-free vaginal tape in the management of stress urinary incontinence in women: efficacy at 5- and 7-year follow-up. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/35\">",
"      Morton HC, Hilton P. Urethral injury associated with minimally invasive mid-urethral sling procedures for the treatment of stress urinary incontinence: a case series and systematic literature search. BJOG 2009; 116:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/36\">",
"      Kilonzo M, Vale L, Stearns SC, et al. Cost effectiveness of tension-free vaginal tape for the surgical management of female stress incontinence. Int J Technol Assess Health Care 2004; 20:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/37\">",
"      Cody J, Wyness L, Wallace S, et al. Systematic review of the clinical effectiveness and cost-effectiveness of tension-free vaginal tape for treatment of urinary stress incontinence. Health Technol Assess 2003; 7:iii, 1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/38\">",
"      Maher CF, Qatawneh AM, Dwyer PL, et al. Abdominal sacral colpopexy or vaginal sacrospinous colpopexy for vaginal vault prolapse: a prospective randomized study. Am J Obstet Gynecol 2004; 190:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/39\">",
"      Benson JT, Lucente V, McClellan E. Vaginal versus abdominal reconstructive surgery for the treatment of pelvic support defects: a prospective randomized study with long-term outcome evaluation. Am J Obstet Gynecol 1996; 175:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/40\">",
"      Kuuva N, Nilsson CG. A nationwide analysis of complications associated with the tension-free vaginal tape (TVT) procedure. Acta Obstet Gynecol Scand 2002; 81:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/41\">",
"      Dean NM, Ellis G, Wilson PD, Herbison GP. Laparoscopic colposuspension for urinary incontinence in women. Cochrane Database Syst Rev 2006; :CD002239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/42\">",
"      Bergman A, Elia G. Three surgical procedures for genuine stress incontinence: five-year follow-up of a prospective randomized study. Am J Obstet Gynecol 1995; 173:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/43\">",
"      Alcalay M, Monga A, Stanton SL. Burch colposuspension: a 10-20 year follow up. Br J Obstet Gynaecol 1995; 102:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/44\">",
"      Eriksen BC, Hagen B, Eik-Nes SH, et al. Long-term effectiveness of the Burch colposuspension in female urinary stress incontinence. Acta Obstet Gynecol Scand 1990; 69:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/45\">",
"      Nygaard IE, Heit M. Stress urinary incontinence. Obstet Gynecol 2004; 104:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/46\">",
"      Nager CW, Schulz JA, Stanton SL, Monga A. Correlation of urethral closure pressure, leak-point pressure and incontinence severity measures. Int Urogynecol J Pelvic Floor Dysfunct 2001; 12:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/47\">",
"      Rardin CR, Kohli N, Rosenblatt PL, et al. Tension-free vaginal tape: outcomes among women with primary versus recurrent stress urinary incontinence. Obstet Gynecol 2002; 100:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/48\">",
"      Lemack GE, Xu Y, Brubaker L, et al. Clinical and demographic factors associated with valsalva leak point pressure among women undergoing burch bladder neck suspension or autologous rectus fascial sling procedures. Neurourol Urodyn 2007; 26:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/49\">",
"      Lim YN, Dwyer PL. Effectiveness of midurethral slings in intrinsic sphincteric-related stress urinary incontinence. Curr Opin Obstet Gynecol 2009; 21:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/50\">",
"      Sand PK, Bowen LW, Panganiban R, Ostergard DR. The low pressure urethra as a factor in failed retropubic urethropexy. Obstet Gynecol 1987; 69:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/51\">",
"      Daneshgari F, Moore C, Frinjari H, Babineau D. Patient related risk factors for recurrent stress urinary incontinence surgery in women treated at a tertiary care center. J Urol 2006; 176:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/52\">",
"      Bai SW, Jung YH, Jeon MJ, et al. Treatment outcome of tension-free vaginal tape in stress urinary incontinence: comparison of intrinsic sphincter deficiency and nonintrinsic sphincter deficiency patients. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/53\">",
"      Paick JS, Ku JH, Shin JW, et al. Tension-free vaginal tape procedure for urinary incontinence with low Valsalva leak point pressure. J Urol 2004; 172:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/54\">",
"      Meschia M, Pifarotti P, Buonaguidi A, et al. Tension-free vaginal tape (TVT) for treatment of stress urinary incontinence in women with low-pressure urethra. Eur J Obstet Gynecol Reprod Biol 2005; 122:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/55\">",
"      Mutone, N, Brizendine, E, Hale, D. Clinical outcome of tension-free vaginal tape procedure for stress urinary incontinence without preoperative urethral hypermobility. J Pelvic Med Surg 2003; 9:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/56\">",
"      Segal JL, Vassallo BJ, Kleeman SD, et al. The efficacy of the tension-free vaginal tape in the treatment of five subtypes of stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/57\">",
"      Clemons JL, LaSala CA. The tension-free vaginal tape in women with a non-hypermobile urethra and low maximum urethral closure pressure. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/58\">",
"      Liapis A, Bakas P, Salamalekis E, et al. Tension-free vaginal tape (TVT) in women with low urethral closure pressure. Eur J Obstet Gynecol Reprod Biol 2004; 116:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/59\">",
"      Goktolga U, Atay V, Tahmaz L, et al. Tension-free vaginal tape for surgical relief of intrinsic sphincter deficiency: results of 5-year follow-up. J Minim Invasive Gynecol 2008; 15:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/60\">",
"      Gamble TL, Botros SM, Beaumont JL, et al. Predictors of persistent detrusor overactivity after transvaginal sling procedures. Am J Obstet Gynecol 2008; 199:696.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/61\">",
"      Duckett JR, Tamilselvi A. Effect of tension-free vaginal tape in women with a urodynamic diagnosis of idiopathic detrusor overactivity and stress incontinence. BJOG 2006; 113:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/62\">",
"      Sinha D, Blackwell A, Moran PA. Outcome measures after TVT for mixed urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/63\">",
"      Rezapour M, Ulmsten U. Tension-Free vaginal tape (TVT) in women with mixed urinary incontinence--a long-term follow-up. Int Urogynecol J Pelvic Floor Dysfunct 2001; 12 Suppl 2:S15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/64\">",
"      Paick JS, Ku JH, Kim SW, et al. Tension-free vaginal tape procedure for the treatment of mixed urinary incontinence: significance of maximal urethral closure pressure. J Urol 2004; 172:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/65\">",
"      Lim HS, Kim JM, Song PH, et al. Impact of the midurethral sling procedure on quality of life in women with urinary incontinence. Korean J Urol 2010; 51:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/66\">",
"      Stav K, Dwyer PL, Rosamilia A, et al. Risk factors of treatment failure of midurethral sling procedures for women with urinary stress incontinence. Int Urogynecol J 2010; 21:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/67\">",
"      Osman T. Stress incontinence surgery for patients presenting with mixed incontinence and a normal cystometrogram. BJU Int 2003; 92:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/68\">",
"      Kenton K, Richter H, Litman H, et al. Risk factors associated with urge incontinence after continence surgery. J Urol 2009; 182:2805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/69\">",
"      Cummings JM, Rodning CB. Urinary stress incontinence among obese women: review of pathophysiology therapy. Int Urogynecol J Pelvic Floor Dysfunct 2000; 11:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/70\">",
"      Richter HE, Kenton K, Huang L, et al. The impact of obesity on urinary incontinence symptoms, severity, urodynamic characteristics and quality of life. J Urol 2010; 183:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/71\">",
"      Subak LL, Wing R, West DS, et al. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med 2009; 360:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/72\">",
"      Rechberger T, Futyma K, Jankiewicz K, et al. Body mass index does not influence the outcome of anti-incontinence surgery among women whereas menopausal status and ageing do: a randomised trial. Int Urogynecol J 2010; 21:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/73\">",
"      Mukherjee K, Constantine G. Urinary stress incontinence in obese women: tension-free vaginal tape is the answer. BJU Int 2001; 88:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/74\">",
"      Killingsworth LB, Wheeler TL 2nd, Burgio KL, et al. One-year outcomes of tension-free vaginal tape (TVT) mid-urethral slings in overweight and obese women. Int Urogynecol J Pelvic Floor Dysfunct 2009; 20:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/75\">",
"      Skriapas K, Poulakis V, Dillenburg W, et al. Tension-free vaginal tape (TVT) in morbidly obese patients with severe urodynamic stress incontinence as last option treatment. Eur Urol 2006; 49:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/76\">",
"      Richter HE, Diokno A, Kenton K, et al. Predictors of treatment failure 24 months after surgery for stress urinary incontinence. J Urol 2008; 179:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/10/43177/abstract/77\">",
"      Walsh K, Generao SE, White MJ, et al. The influence of age on quality of life outcome in women following a tension-free vaginal tape procedure. J Urol 2004; 171:1185.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8070 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-3E1552308A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_10_43177=[""].join("\n");
var outline_f42_10_43177=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CANDIDATES FOR SURGICAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Women who decline or have persistent symptoms following conservative therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3793104\">",
"      Women with occult SUI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Women finished with childbearing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TYPES OF PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Vaginal approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Abdominal approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Procedures no longer recommended",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Anterior colporrhaphy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Paravaginal repair",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Transvaginal needle suspensions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Marshall-Marchetti-Krantz",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CHOOSING A PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Preoperative counseling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Evaluating SUI procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Midurethral slings versus other procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      COEXISTENT SUI AND PELVIC ORGAN PROLAPSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Apical prolapse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Open versus laparoscopic Burch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Advanced prolapse and occult SUI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      URINARY FUNCTION ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Lack of urethral hypermobility and intrinsic sphincter deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Mixed incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      OTHER PATIENT CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Obese women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Women who are elderly or infirm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/8070\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/8070|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/42/16034\" title=\"figure 1\">",
"      Sling placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/12/37058\" title=\"figure 2A\">",
"      Burch medial displace bladder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/26/20899\" title=\"figure 2B\">",
"      Suture placement Coopers ligmnt",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/20/16707\" title=\"figure 2C\">",
"      Burch suture placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/23/39283\" title=\"figure 3\">",
"      Marshall Marchetti Krantz",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29929?source=related_link\">",
"      Clinical presentation and diagnosis of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41735?source=related_link\">",
"      Overview of the principles of medical consultation and perioperative medicine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/56/35714?source=related_link\">",
"      Patient information: Surgery to treat stress urinary incontinence in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/8/22658?source=related_link\">",
"      Patient information: Urinary incontinence (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/19/19764?source=related_link\">",
"      Patient information: Urinary incontinence treatments for women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/32/1546?source=related_link\">",
"      Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/4/35914?source=related_link\">",
"      Pelvic organ prolapse in women: Surgical repair of apical prolapse (uterine or vaginal vault prolapse)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/43/16055?source=related_link\">",
"      Stress urinary incontinence in women: Choosing a type of midurethral sling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/23/44409?source=related_link\">",
"      Stress urinary incontinence in women: Persistent/recurrent symptoms after surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/58/17319?source=related_link\">",
"      Stress urinary incontinence in women: Preoperative evaluation for a primary procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/49/33562?source=related_link\">",
"      Stress urinary incontinence in women: Retropubic midurethral slings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/4/32842?source=related_link\">",
"      Treatment of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/15/26873?source=related_link\">",
"      Urethral diverticulum in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/7/17530?source=related_link\">",
"      Vaginal pessary treatment of prolapse and incontinence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_10_43178="12 lead WPW";
var content_f42_10_43178=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67181%7ECARD%2F57442&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67181%7ECARD%2F57442&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1272px;\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    ECG in Wolff-Parkinson-White",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 365px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The 12 lead ECG shows the typical features of Wolff-Parkinson-White; the PR interval is short (*) and the QRS duration prolonged as a result of a delta wave (arrow), indicating ventricular preexcitation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Martin Burke, DO.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Normal ECG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 594px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75&deg;.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Sinus rhythm radiofrequency ablation of accessory pathway",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The 12 lead ECG of a patient with Wolff-Parkinson-White who underwent a successful radiofrequency ablation of an accessory pathway shows a normal PR interval (*), no delta wave, and QRS complexes that are normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Martin Burke, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_10_43178=[""].join("\n");
var outline_f42_10_43178=null;
var title_f42_10_43179="Treatment of osteomyelitis";
var content_f42_10_43179=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antibiotic therapy for osteomyelitis in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Infectious agent",
"      </td>",
"      <td class=\"subtitle1\">",
"       Antibiotic",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dosing",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       MSSA",
"      </td>",
"      <td>",
"       Nafcillin",
"      </td>",
"      <td>",
"       1-2 g intravenously every 6 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Oxacillin",
"      </td>",
"      <td>",
"       1-2 g intravenously every 6 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cefazolin",
"      </td>",
"      <td>",
"       1 g intravenously every 8 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       MRSA*",
"      </td>",
"      <td>",
"       Vancomycin",
"      </td>",
"      <td>",
"       30 mg/kg intravenously every 24 hours in 2 equally divided doses; not to exceed 2 g/24 hours unless concentrations in serum are inappropriately low",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Coagulase negative staphylococci",
"      </td>",
"      <td>",
"       Vancomycin",
"      </td>",
"      <td>",
"       30 mg/kg intravenously every 24 hours in 2 equally divided doses; not to exceed 2 g/24 hours unless concentrations in serum are inappropriately low",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       Gram negative organisms (including Pseudomonas)",
"      </td>",
"      <td>",
"       Ciprofloxacin",
"      </td>",
"      <td>",
"       750 mg orally twice daily",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Levofloxacin",
"      </td>",
"      <td>",
"       750 mg orally once daily",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ceftazidime",
"      </td>",
"      <td>",
"       2 g intravenously every 8 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cefepime",
"      </td>",
"      <td>",
"       2 g intravenously every 12 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Empiric therapy",
"      </td>",
"      <td colspan=\"2\">",
"       Vancomycin PLUS an agent with activity against gram negative organisms",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MSSA: Methicillin-susceptible Staphylococcus aureus; MRSA: Methicillin-resistant Staphylococcus aureus.",
"     <br>",
"      * For alternative agents with activity against MRSA, see \"Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults\".",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_10_43179=[""].join("\n");
var outline_f42_10_43179=null;
var title_f42_10_43180="Adding calories to formula";
var content_f42_10_43180=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Methods of increasing caloric density of infant formula",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        For concentrated formula (40 kcal/oz)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Caloric density (kcal/oz)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Volume concentrate (oz)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Volume water (oz)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        20",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        22",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        10.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        24",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        8.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        For powdered formula (40 kcal/scoop)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Caloric density (kcal/oz)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Volume powder (scoops)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Volume water (oz)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        20",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        22",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        24",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle2\">",
"        Kcal/unit",
"       </td>",
"       <td class=\"subtitle2\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Polycose powder (glucose polymer)",
"       </td>",
"       <td>",
"        8 kcal per teaspoon",
"       </td>",
"       <td>",
"        Increases osmolality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Polycose liquid (glucose polymer)",
"       </td>",
"       <td>",
"        2 kcal/mL",
"       </td>",
"       <td>",
"        Increases osmolality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Corn syrup",
"       </td>",
"       <td>",
"        3.8 kcal/mL",
"       </td>",
"       <td>",
"        Increases osmolality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"3\">",
"        Fat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Medium chain triglyceride oil (MCT oil)",
"       </td>",
"       <td>",
"        7.7 kcal/mL",
"       </td>",
"       <td>",
"        Nonemulsified",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Corn oil",
"       </td>",
"       <td>",
"        8.4 kcal/mL",
"       </td>",
"       <td>",
"        Nonemulsified",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Safflower oil",
"       </td>",
"       <td>",
"        8.4 kcal/mL",
"       </td>",
"       <td>",
"        Nonemulsified",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Based on the calculation: ((a x b)/c) - a = y.",
"     <br>",
"      a = volume of formula to be diluted (ie, 13 oz), b = caloric density of formula (40 kcal/oz), c = desired caloric density (kcal/oz), and y = amount of water needed.",
"      <br>",
"       &bull; Based on the calculation (a/b) = x.",
"       <br>",
"        a = kcal/scoop (ie, 40 kcal/scoop), b = desired concentration of formula mixture (kcal/oz), and x = amount of water to use per scoop.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Singla S, Olsson JM. Enteral nutrition. In: Pediatric Hospital Medicine. Textbook of inpatient Managment, Perkin RM, Swift JD, Newton DA (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2003. p. 812.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_10_43180=[""].join("\n");
var outline_f42_10_43180=null;
var title_f42_10_43181="Treatment AL amyloidosis transplant eligible";
var content_f42_10_43181=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F88825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F88825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Approach to therapy in patients with AL amyloidosis eligible for hematopoietic cell transplantation (HCT)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 308px; background-image: url(data:image/gif;base64,R0lGODlhdgE0AcQAAP///wAAAIiIiLu7u0RERCIiIjMzM2ZmZt3d3ZmZmczMzO7u7hEREVVVVXd3d6qqqs/Pzz8/P5+fn9/f339/f19fXw8PD+/v77+/vwAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAB2ATQBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/byYG8fs/v+/+AgYKDhIWGh4iJiouMjY13LAGQk5QmkpUnl5ibdpqcIp6fom6hnKWjqGinmKuprmKtlLEwA7MjAgRLBAJKAQMtvl+4O8EruyTDKrZ3oQQBvAjFLLUuw8dH1yQGAQgiBwc90iPUJOIo5izJPOoq7OcD5CXWvLe5yqnNBdzRvy3xK+6MZBMxgIEBet/C9VuBLkdAHA9NRCy3MMXAiaDwlSBwgAABfgAa5DGwwEEDZAao/xXgtYDBA2R6ch3TF6CAAgACYgIgsC0AOAQ9HQBIwCAPL5EBSIbUQ2/EgQYJCngDZyKBHnACaBro+YDoApwGAARzFoDAAmpA9fwia1ZBz5O+3OY5qSJangO4ctpNejZpAAYKFpBlsLMn1lwH9CQofHcvVRE5a970hbanL2uGceYaQHNxOY0kONbKOUCA0oMPCHcMKYBa1KFSRygINo9EAQezX1rbzK3BSQUMBhAQCvm0gKzdBrZ80PJXwhRWFyCPxmt1gcXXxZYusGDBQWoN7F3m7v142BGXz5dI7BOZvawVoz2otfZAra8iCPwOoIDdgbAeAVALAu4Ad5NJ2oF33v9lMu3XXy4MLJZaCct0shE4SA3A3l0LBPDAcEQpQE1zBngmwmua7STAAhsegGJt0SCQ3U4JDLANAQps6NNzA1l1FQDPlZCAZQSK98swuDwQmy/PCWCfJDMySZWTCIhUonZVJmViCskkowBZAdR4SUIO/MXLNWEiWVRNKgIQozs+5iEVZVB6xmCbYiWAy155dIMeaCNw5GYepSk1QgMRAkcYOaYRRsJsN4WnYnQAGHAApCHJBE1v+y3UAF6G4kTeSqERd1+Qtgn1ADfJ0JZLSweBsl13K4HXaVa0NpWVdrfE1s55yfwHQIdiTiUbN8esWqR8ADgg1TFvqieCgRTZCsD/bKVpCoCyw0R4DqD5UZXYL0iFiRMDX1kq4CUdNuXUSJqmVRM47BWgbYzyCkWWTUvlkYB3f5EqQjQ3ibCSjgtFpk+RsqbYLLoNs9XXtfpss1YeZkVm7mWKsQCcT8kUVFOY5HxTy107MZXivs9uisDHj+H0I50Uj5xtykalyJmcFIKrQ0H42fDpGAOlUTQRs/lJQ4V1MP2CAcTRQJYBSn+xatBqHA3Eyc/c4PQcX78idhVhx1H22Gg/cfYba6ftdhJttxH323QPMfcad9etdzj4OOL334AHLvjghBde+N6IA5P44oz/kHfjkC/+eOSU1z155ZijfXnmnPvc+eeMTwBB/0YAQDAB6KgjfkEAEUgQgAQRBHBB6rTXXQEfFdSuu9sQ8DH67sCLHXseEQRvvCuu5yHB8cyPYkEAFjQvPScUBEDB9NhTMkEAp2fvvR0YfC/++OSXb/75RRiu/vqEoL/35nDA7z7bess/v9z130+3/fjr7zb/bACg/84gQBRojRan+McJDpiCAg4QDxcaWDDkUhONqWUF1LgGA12gQILMYoOZeKDmIjioASCAAVOiC0YWSA8QTiOBH3SX4kQotmZQhR+mOUFAYnUoB9QiTgngCcpCQxMC6IMB3VCYiCSRlaKQpBbbAAyQOjYTOU2mJ1sSCw1ruBE+lCZm9TABggQFmP8MtpA3VQuQVX6xEmqZhBq4WkCtxhIzYQ3kNmLhxa4+s0VX2FCC29GhPUiQGj0ZYEJmzI/LQsMLcuwiTjWBoz1EMyasrKllLJrZL1D0pz76TFAlPKEKVThIEjAAiQJgwEkySBxocYOR61IktTyYohMWC0gHYJazJhWAdIEjGJwknSdH8ccSCqgnPHyIpIgVSx8FcZGBauQljqGxJ8lsLrHEJc4K0DJ5FeCXm/SVMIf5CQcKYYU5MCc5taBOIKATB+1c5xXiCUF5miJ/9twEPcewz3xGoZ9hAKg/nSDQLxR0oEtgn0IXugeEju+gDkUfRCNqvolSlHwWvaj4MqpR73H/tKPY+yhIpSfSkTKvpCaFG0NXytKWEi6lnYTpOE2KUtrVFHQ3RV1OO7fTz/U0cz/lXFArN1TMFXVxoiOd6UCaVC2WrnsUXV3rXhe72XVUqq6Dnew6ers95G6kXdXDVzXauz38DqRl1cNZNTo81sG0rcUbafJeB9O5Ls+kz4ueTPMK0+pdT6Z+hen2oJrSwco0fDIVAWITy9jGOpanLo0sQ8Eg2cqyzwtHtcJPM0s2zAKVsp/tAmepsNnQcmG0UyitUT27WoOadguofSERVCuHDvpgp7FAwC/yBZmRYE0ItpVtJPrRkHu4lgW8vWaohhBcDC6jGMVtIGtNoABEkesk/zJ6AKagZoTmqsC76KlIDGh7Ih4eCrsF0C5/KhU15pYNvA1b2nTHwZOmGIAuDXBADh3mwW3wS4l5+ubOniEvcAixPTQRZ5i+WWAB0UQSqwFAdjQGJpBIDIp/KVhMRUvdxFxKBPcVQX73yw4M/9eKAbYPTQTQ4AODI8HliEouMzNgCNtjwjHRg4Ux1pcoanimWQiFVcA4YAbo9z3irEWkGuBGuNCFAU0Z2gm/hMYOBgC/PwEMlGMZ4etgK7yyiuN36Niz4y6wPUU+MmSSvF7fNFksT45ylqm8Lt2W4soinvOWqdHlBHw5vuPpzpjrU+bTmkA45jWleSBTSkZdZw9z2v/tKw22h2cOys6W6MeDw/RKPt84AcGEroamZE1t8nG+0/Lwj0UAZRI3+hJZgWSkLz2CTVs6RlbWdKU7bWODgVrBxB01ZEqNKqca+gTVDU5o0LXd9pLDUrOM75bzDEtc95JC/RjaCLacE1EJKFHS8FCYR9WaShaawyQYkgwDxez1cnccl4C2FMEMgGmHJGautPNvi6FtVuuRiVIpiJ/D/RLtxHGOxjo1bOsi6aQULDLL5RrVrtmeYoiMwETKN8CAPTAi+WgbbqqYtzSWoz6NhcclAyN5h8KHn4zk4b4lgcSTqEmCrInFGXfZxinScR1/XBIySsrI9VBybpy8LBMz9Yb/2dkD+NLPzD+LrQxw23Spjxe0PHA6KVANuZV3neuN83rYwT6Dd0a9s1C3gdlzoPUjUN0i60aBNfbAmS1prAFVK0Fz2y5zcbpJ2fkZIsR/e+5jGzDugsQZoWbU27nkXeat4Ps4/H7ChZBlSjGXLrohIpOYMd5ZN0EAAcQL+RRIniDijEw/cHVC9d7k3d9Kew2s4XkTgd5Nozd95N+bekKteQGtb7ZxDc9CsWBRHjoBpa+3XXAT7IUkMJ68HliOMlIt59B+51VIWrlo/oZQ9rD0i7lggrGd1J75KHi+HHkm/TxQH8EscQn2My1i7rt6+AuHex69fawjyUQnjDdpKSAf/x20Z54QHa8RTBLGB01RDBqEF0iGf8RnAsfQNXs0La6ieLkQgI9XAgRYCgaYbr2UgH63aV0TXw/YJdmncEynf8AkTi/SebZhIt6CbGBySyMQI81EJCSSRahHf9unSPeneWSnSLwSTDFofjO4bT44LTeoQDroGjwYHFcyf9hWf0IILKVkCUXYJi/4KG0mg7VmewWwW7nnDWFBLPdRAtwGJarySo2CApwBhKznEsJHhJtXfF94LJEihssnAs5ihgshLGp4bYomMxL2hklkAI5ihTwnKsBnh+7WXlyYhxTIC3v4Lknhhws4fS2iNCKjD//iXyLoF9e0MMNygo5IcVRxef+Nt1yV2IUVGE7rAS9KWGsN9YnjUBSiuHMj8HOn+ErtIoe9N0SuqFyEx4JB1gZA0wtYtwbNCDddOAawhwRiZwbV6HbT+D7PSDlvR1TdGDnf6I3h+HWWaI7biE8TiI7nOHaiZVnw+FIGFY/0CDg81VhWp44ylY+Wg4+JxY/6SFP+uI8DCVMAmTZNdQlLNVIHiTZYRVVbxZAyFVZ5MFZpU48YGY96k1Z5sFYj9FB7A1f9CJJ6Y1cjuVGIw1cn+T0NCQSBtZIehTiGBZPZ05JAsFhok5AisJDMo5NP9Vg88JBaZVXMI5RVBZQ8QJEBYJHMo5RMKTcZyQdvwJEB4JHHQ5X/VhlAWNCQIpk9XWk2WwkHJpk9YwmW8xQHKuk9aWmWmhUHL+k9b8mWaPcGM+k9dSmXpCUHOOk9exk/YYmU98gCLkQDiVEAeWeTgOmMtZgzeNIDs5EHlGhRUQkIUDmZjkBQJXB7BXEmiHcDjxkAkZmX+Yc3/cMEoSB/xcEY7UEUOYMUT+QLYeIoOeSaX1GYhymaLUiaWtkEngASJ/IsDjIct2AcozEs3hIhppEunWls/7SOBFSaCcWGzZdDaFIjN1J0dxEPSSIVOgJGhac2zmkG/AhQoXAA/LKZbaIshwIqQRMP0UAqyTlDUnBT4wmdikkCG9JCKrMvkaIY/3AAENMv/+MXe/NZA6dHb+PgncyZBvITXfKwhcNFoNF5lqlFQvxgW06HDtIAFB1BAFlUnyQgGHmwZYN5hS0wEUdTXOT5lwUaGjcUXQcaX7hIeiA6Ag5wHkHUmC/goO4xXqQHZNbIos3pooBUGWqBYfPmQT8UF2+hHd6Bd5ZiAB76nc9JAjeqNEC0IYvhYm5iGSakB6/5QxQGeT+0CxQEFwPwpFSqjRTaooHiRQoiK/Rxix5ED+lRDg9gXhryfbo5AiziRFsqQ3aERpKifYMyH13zZSV2gruwX6CQp+u2om06pIHyovBQJ3JqbvAWXllyJX8hLXjIoNDRS9eQSjyTb1EyAF/in/+XkISbqkiduhifyqcJZZnuV6FEWkLWgi0pV3oyuithIqWRYJ8NQA9eIZy61DKX5hvXwiRpSDKXgCmFSktGuGZ5IqxrWj7FdKGSoAD6oA+XmnDUanAd4wveAYvZWk+9Iieb5C8s0yYx4q1+AQ+8CK2aiK3j2qjlmqZbgTWIKaoxkDRs2qdq8K+q8AJcs5y3ZZ8Hqz/0ybBVej8Pu5sE6z4TW7ENK7HhWQY1Oj8XW7AQW1G2KpUBNLKMQJDampgLm7IqywMGW44tawMvC34xK18sW7PwVFE4m046u7Ne07M+WwMzm45BG6riabJIezg3m7EsCbRMG5NLG7FNG7XiiVH/Tiu1UGu1IEuSWlsGPsmTx/O1hBVSZ2CUEVmUrJNVRzm1ZuCU2OO2KHkGWIk9cxu3Z/CV04O3WWsGZTk9fbu3ZrCW2CO4gFsGcYk9h1u4ZHCX2MO4iksGfYk9kVuTRTtQQ1u5cpA3SbtS/7S5C+VHOnC5EsqbxAS6PCsKByW6tIq6oVu6UKC6sei6Ocu6ryu7tiuzt2uauXtPp1tOlMq7qKC5N2BC70cbmUcEa6eME4oDkHQkxzsEybt0vtu7MjAkExdMd4i8ECqfmBkDHZFF2DuJRhC9QKpPrSsDpnGG76dHWogMBeBEX0Gb9JEmRDdgW2oYjnF1tVu9iHIA+BEn/+zLaO4Lv/0SpvSbByLSGaqZSz8CA7A7ukIrA4nRhCz3INbaK7kSn2PGC39WbxJCGAEyIOS7oLortANawSrovhlMnIkqDd4yISHMKts7rJ5jszGQvj96p96XDBzRneTASXyCLC4zwqk7AwnQv4Snw+zAw9+wB6UGxHwgekM8wwxhurNrxFvRDVAxFO32eu01DLYUn9TawTVohNEyA0XsvVNKAlvsFdlbS8gZKuRAxluSb47qwFb8szZAvJFRg4NHfngmoDhIcgOmrPFaFAoqgSUMAzpiLn3sGX98C3qAX6wqyQhcyPDKDTCjv8F7vkgwwkKQxp9MxYu8u2isBKAcBP+ifASpDAQPvLoRTLvgKcumPHW1HKS0nMuxHAMlWgS9DMHLCwO/PATDHLu6bMPCrLAOE708Gk1cUxbBtADlEpr7y8vK3CWknAk/ykLP7KHiJM16QM2dTL0v4EKtXM7lhqXi1K/HlK4Dm8zpkM06sAsD8ovrrBQ24s6TILzuoRe0KaAs9oUDVk1I8nILjG1Iumrlks72fCzJWL7S2M+9EXMLDRKvMdBXUdAOd9DV4hdJKmJMUc+/6dBGC7x63CtHYhzIoSIWLRX2hs2YshoxXDV0Qmi9khzlphacNIclfZ9rltLKudK70NL1pivvgSPrJdNo1NE2vWY4/cwDsNMrKL3/Jo27PTpFV8EjAR1OOijAmoEic5hvHS2upkbPAshJAgvMPu0w3anVLd3Vy+zNPyjW4dWrTtGKDD3SGNiBEF0J/BxGYBE0B4eJW+rSuqKF0novApggmvp7cpTXsKENE5fPyrvWXRIqg50nO2HYw8loiZ3JNB2uSgeJjy3SkT0CWdzOlc0KnuzVggwwDACfIxFwNwczGm0AN0HXmUrWsD1HWLoHLDYY4ty9gP3aUSTbSUHbRmHbuQBxuQ1Nuz3avQ3ZkBTcIzrcx3zK2R3R0zvOV1zVpWy+Nazd3U3c4H3e5I3e3K3eft3a4j3L5b3dnMze7/zet4zH8l3frD3eU+e5/wrVuf69PnmMtZRLtRzbtVz7tAWO4AROtgaurmyb4A0+Pa88BWI7BhfePBkuPWZLlGDQ4RyethDp4c0Dt2Ng4iWOO95Tt2PA4s3j4nmrB3FVBnrbPDUuPX8rBjnOPDsuPYQ7Bj/ePEEuPYk7BkXePEcuPY6L4dwjPksuuWswudIj5Zhb5VZ+5WQT4J/7PyP7NhWuz/GNqxc54Fw0qWPz5avt3XP5kWp+5kLq5vzd5mLO5mSzzTGqd6GA5orspnSueBOnAsVsDJho53ejQHre09Xc54LSEgob6MBA6GyX517eAo7OArYJ5lUtKFOmXJMRFZVmv3ySALyVFSPBFV54fP+Q5183kWCBMRgO5i+vfqtUTeb5Wa2OGc6Ybt9+PnA3sRqBfA0v3IjJyazAsR0IQB1Aoi0WSBidoWQhQRcG40OG6MHbQhghmOa3q5kkqswz8JnYXeaV2lt7NIcOuCl70A3/8RUz4qGt4n9e+AumnU240iLNYiZBHIWS/j/S2dlcyppdI7+wSRSp+c+Xju25DEqp9NkOSBxlnOzn1aw3wyu1EQy75KuWQinqstcN34a5vt+A1ND60axfEjUaXG7xtxhxrJx7PuBggmMbXQzOVMjPjHOQ6TAZWIHsiucjcew9IWA/gsnAaPDxjZpggSckc50+rAnbidVDpNZxLguTjp//57nt2yKAnyLG2TQo8ImusPwKh07CXm8Cta54Z4Ji5YKDQBKgZ7/yT7/PUd+W+t72Yc7ncB4E54zLY27m4L4OR02zch/Mdc/3rr2xck73e68DjpEVFRO/vjW/cfKaqu4VRb+yF9nlcd8DKogALWFIylmcOeghzs6s2cF4LovlMMt5Xn0dSe+ElextS+84pu/3ate+Esb5r0qI9lop4AAr3J7esZ+bPMDcy3f25BCK0LrzgBiglP/7wF8FHVTpNMz8zU8FCnQ1qiz9o3nf2A/f2r/9pPv33r/Wcx/+iZ7f5F+rWn5Z57/+7N/+7v/+8B//8j//9F//9n//+J//+o86AiEAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     dFLC: difference between involved and uninvolved serum free light chain levels.",
"     <br/>",
"     * High risk: Mayo stage III (cTnT &gt;0.035 mcg/L and NT-proBNP &gt;332 ng/L).",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Start alternate therapy if organ progression at any time.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: mSMART (",
"     <a href=\"file://msmart.org/\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"      msmart.org",
"     </a>",
"     ).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_10_43181=[""].join("\n");
var outline_f42_10_43181=null;
var title_f42_10_43182="Left and right axis deviation";
var content_f42_10_43182=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57151&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57151&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Left and right axis deviation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 241px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the QRS complex in leads I and II in left and right axis deviation. The net QRS area is normally positive in leads I and II. An axis more negative than -30&ordm; is referred to as left axis deviation, which produces a negative net area in lead II with a positive QRS area in lead I. In comparison, an axis more positive than +100&ordm; is referred to as right axis deviation, which produces a negative net area in lead I (a left-right lead) with a positive QRS area in lead II.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_10_43182=[""].join("\n");
var outline_f42_10_43182=null;
var title_f42_10_43183="AC joint tenderness";
var content_f42_10_43183=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55667&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55667&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    AC joint local tenderness",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 391px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The anterior, lateral, and posterior edges of the acromion are marked with a pen. In this photograph, the examiner's finger is located at the articulation between the acromion and the distal clavicle (AC joint). The subacromial space is palpated just under the lateral edge of the acromion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_10_43183=[""].join("\n");
var outline_f42_10_43183=null;
